CN117597327A - 药物制剂 - Google Patents
药物制剂 Download PDFInfo
- Publication number
- CN117597327A CN117597327A CN202080088987.0A CN202080088987A CN117597327A CN 117597327 A CN117597327 A CN 117597327A CN 202080088987 A CN202080088987 A CN 202080088987A CN 117597327 A CN117597327 A CN 117597327A
- Authority
- CN
- China
- Prior art keywords
- compound
- μιη
- particle size
- size distribution
- niclosamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 239000002245 particle Substances 0.000 claims abstract description 281
- 229960001920 niclosamide Drugs 0.000 claims abstract description 213
- 238000009826 distribution Methods 0.000 claims abstract description 189
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical class OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims abstract description 130
- 239000013078 crystal Substances 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 63
- 239000000126 substance Substances 0.000 claims abstract description 57
- 239000002552 dosage form Substances 0.000 claims abstract description 34
- -1 niclosamide compound Chemical class 0.000 claims description 441
- 150000001875 compounds Chemical class 0.000 claims description 240
- 230000002829 reductive effect Effects 0.000 claims description 41
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 39
- 239000003112 inhibitor Substances 0.000 claims description 36
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 35
- LOCWBQIWHWIRGN-UHFFFAOYSA-N 2-chloro-4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1Cl LOCWBQIWHWIRGN-UHFFFAOYSA-N 0.000 claims description 29
- NKBASRXWGAGQDP-UHFFFAOYSA-N 5-chlorosalicylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1O NKBASRXWGAGQDP-UHFFFAOYSA-N 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 206010009887 colitis Diseases 0.000 claims description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229940092705 beclomethasone Drugs 0.000 claims description 18
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 17
- 229960004436 budesonide Drugs 0.000 claims description 17
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 17
- 229960004963 mesalazine Drugs 0.000 claims description 17
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 15
- 208000011231 Crohn disease Diseases 0.000 claims description 14
- 210000001072 colon Anatomy 0.000 claims description 14
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 13
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 13
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
- 108010024121 Janus Kinases Proteins 0.000 claims description 12
- 102000015617 Janus Kinases Human genes 0.000 claims description 12
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
- 230000001363 autoimmune Effects 0.000 claims description 12
- 238000002288 cocrystallisation Methods 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 11
- 102000002689 Toll-like receptor Human genes 0.000 claims description 10
- 108020000411 Toll-like receptor Proteins 0.000 claims description 10
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 9
- 239000004012 Tofacitinib Substances 0.000 claims description 9
- 229960001164 apremilast Drugs 0.000 claims description 9
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229960001350 tofacitinib Drugs 0.000 claims description 9
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 claims description 8
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 claims description 8
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 229940010849 brepocitinib Drugs 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- 229950008141 ozanimod Drugs 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 7
- DADAEARVGOQWHV-OSYLJGHBSA-N CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 Chemical compound CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 DADAEARVGOQWHV-OSYLJGHBSA-N 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 230000000642 iatrogenic effect Effects 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 5
- 101100034357 Arabidopsis thaliana RIPK gene Proteins 0.000 claims description 5
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 claims description 5
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 5
- 108010041012 Integrin alpha4 Proteins 0.000 claims description 5
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 5
- 206010061309 Neoplasm progression Diseases 0.000 claims description 5
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 5
- 108010010057 TYK2 Kinase Proteins 0.000 claims description 5
- 108010009978 Tec protein-tyrosine kinase Proteins 0.000 claims description 5
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 5
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 210000004921 distal colon Anatomy 0.000 claims description 5
- 108010044426 integrins Proteins 0.000 claims description 5
- 102000006495 integrins Human genes 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 108010079437 lanthionine synthase Proteins 0.000 claims description 5
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 210000003384 transverse colon Anatomy 0.000 claims description 5
- 230000005751 tumor progression Effects 0.000 claims description 5
- KSELABKNBIUMGG-YGBAREPYSA-N (2z,3ar,4r,5r,6as)-3,3-difluoro-4-[(e,3r,4r)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2h-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3ah-cyclopenta[b]furan-5-ol Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1(F)F)/C=C/[C@@H](O)[C@H](C)C=2C=C(C)C=CC=2)\C1=C/CCCC=1N=NNN=1 KSELABKNBIUMGG-YGBAREPYSA-N 0.000 claims description 4
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 claims description 4
- BZZKEPGENYLQSC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical group C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NN(C=N1)C)OC BZZKEPGENYLQSC-FIBGUPNXSA-N 0.000 claims description 4
- VFGSKBLZRDRHOI-ZAGPDIDGSA-N 6-[[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]amino]-8-chloro-4-(2,2-dimethylpropylamino)quinoline-3-carbonitrile Chemical compound C12(CC(C1)C2)N1N=NC(=C1)[C@H](C1=C2C=CN(C(C2=CC=C1)=O)C)NC=1C=C2C(=C(C=NC2=C(C=1)Cl)C#N)NCC(C)(C)C VFGSKBLZRDRHOI-ZAGPDIDGSA-N 0.000 claims description 4
- 229940124282 BMS-986165 Drugs 0.000 claims description 4
- XPLZTJWZDBFWDE-OYOVHJISSA-N CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N Chemical compound CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N XPLZTJWZDBFWDE-OYOVHJISSA-N 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 4
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 4
- 229940124281 PF-06826647 Drugs 0.000 claims description 4
- 210000001815 ascending colon Anatomy 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- 229950006663 filgotinib Drugs 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 229950007217 tremelimumab Drugs 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 230000007115 recruitment Effects 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 2
- 229940125565 BMS-986016 Drugs 0.000 claims description 2
- 102100025429 Butyrophilin-like protein 2 Human genes 0.000 claims description 2
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 claims description 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 2
- 102000007563 Galectins Human genes 0.000 claims description 2
- 108010046569 Galectins Proteins 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 2
- 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 claims description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 2
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 claims description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 2
- 101150069255 KLRC1 gene Proteins 0.000 claims description 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102000007295 Mucin-3 Human genes 0.000 claims description 2
- 108010008701 Mucin-3 Proteins 0.000 claims description 2
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 101150012848 PVR gene Proteins 0.000 claims description 2
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 2
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims description 2
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229950007213 spartalizumab Drugs 0.000 claims description 2
- 229950005972 urelumab Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 102000015774 TYK2 Kinase Human genes 0.000 claims 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims 1
- 102000002111 Neuropilin Human genes 0.000 claims 1
- 108050009450 Neuropilin Proteins 0.000 claims 1
- 101700026522 SMAD7 Proteins 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000001174 ascending effect Effects 0.000 claims 1
- 238000010579 first pass effect Methods 0.000 claims 1
- ABASMUXUCSQFKC-PKEKLUKKSA-N mongersen Chemical compound CC1=CN([C@H]2C[C@H](OP(=S)(O)OC[C@H]3O[C@H](C[C@@H]3OP(=S)(O)OC[C@H]4O[C@H](C[C@@H]4OP(=S)(O)OC[C@H]5O[C@H](C[C@@H]5OP(=S)(O)OC[C@H]6O[C@H](C[C@@H]6OP(=S)(O)OC[C@H]7O[C@H](C[C@@H]7O)N8C=CC(=NC8=O)N)n9cnc%10C(=O)NC(=Nc9%10)N)n%11cnc%12c(N)ncnc%11%12)N%13C=CC(=NC%13=O)N)n%14cnc%15C(=O)NC(=Nc%14%15)N)[C@@H](COP(=S)(O)O[C@H]%16C[C@@H](O[C@@H]%16COP(=S)(O)O[C@H]%17C[C@@H](O[C@@H]%17COP(=S)(O)O[C@H]%18C[C@@H](O[C@@H]%18COP(=S)(O)O[C@H]%19C[C@@H](O[C@@H]%19COP(=S)(O)O[C@H]%20C[C@@H](O[C@@H]%20COP(=S)(O)O[C@H]%21C[C@@H](O[C@@H]%21COP(=S)(O)O[C@H]%22C[C@@H](O[C@@H]%22COP(=S)(O)O[C@H]%23C[C@@H](O[C@@H]%23COP(=S)(O)O[C@H]%24C[C@@H](O[C@@H]%24COP(=S)(O)O[C@H]%25C[C@@H](O[C@@H]%25COP(=S)(O)O[C@H]%26C[C@@H](O[C@@H]%26COP(=S)(O)O[C@H]%27C[C@@H](O[C@@H]%27COP(=S)(O)O[C@H]%28C[C@@H](O[C@@H]%28COP(=S)(O)O[C@H]%29C[C@@H](O[C@@H]%29COP(=S)(O)O[C@H]%30C[C@@H](O[C@@H]%30CO)n%31cnc%32C(=O)NC(=Nc%31%32)N)N%33C=C(C)C(=O)NC%33=O)N%34C=C(C)C(=NC%34=O)N)n%35cnc%36C(=O)NC(=Nc%35%36)N)N%37C=CC(=NC%37=O)N)N%38C=CC(=NC%38=O)N)N%39C=CC(=NC%39=O)N)N%40C=CC(=NC%40=O)N)N%41C=C(C)C(=O)NC%41=O)N%42C=C(C)C(=O)NC%42=O)N%43C=CC(=NC%43=O)N)N%44C=C(C)C(=O)NC%44=O)N%45C=CC(=NC%45=O)N)N%46C=CC(=NC%46=O)N)N%47C=CC(=NC%47=O)N)O2)C(=O)N=C1N ABASMUXUCSQFKC-PKEKLUKKSA-N 0.000 claims 1
- 229950002917 mongersen Drugs 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 45
- 229940124597 therapeutic agent Drugs 0.000 description 33
- 239000002253 acid Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 16
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 229910052708 sodium Inorganic materials 0.000 description 16
- 229940083542 sodium Drugs 0.000 description 16
- 235000015424 sodium Nutrition 0.000 description 16
- 239000003246 corticosteroid Substances 0.000 description 15
- 229960001334 corticosteroids Drugs 0.000 description 15
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- 150000005829 chemical entities Chemical class 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 12
- 229960004618 prednisone Drugs 0.000 description 12
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- 235000021355 Stearic acid Nutrition 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 10
- 239000008117 stearic acid Substances 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229960002170 azathioprine Drugs 0.000 description 9
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 9
- 229960000598 infliximab Drugs 0.000 description 9
- 229960005205 prednisolone Drugs 0.000 description 9
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229960005069 calcium Drugs 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 8
- 229960001571 loperamide Drugs 0.000 description 8
- 229960001428 mercaptopurine Drugs 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- 235000001465 calcium Nutrition 0.000 description 7
- 229940082500 cetostearyl alcohol Drugs 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 229960000448 lactic acid Drugs 0.000 description 7
- 229960001940 sulfasalazine Drugs 0.000 description 7
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 7
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229960002964 adalimumab Drugs 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 6
- 229960004166 diltiazem Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 229960004914 vedolizumab Drugs 0.000 description 6
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 5
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 5
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 5
- 239000005760 Difenoconazole Substances 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
- 229960000396 atropine Drugs 0.000 description 5
- 229960000830 captopril Drugs 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 229940106164 cephalexin Drugs 0.000 description 5
- 229960003291 chlorphenamine Drugs 0.000 description 5
- BQYJATMQXGBDHF-UHFFFAOYSA-N difenoconazole Chemical compound O1C(C)COC1(C=1C(=CC(OC=2C=CC(Cl)=CC=2)=CC=1)Cl)CN1N=CN=C1 BQYJATMQXGBDHF-UHFFFAOYSA-N 0.000 description 5
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 5
- 229960004192 diphenoxylate Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 229940099690 malic acid Drugs 0.000 description 5
- 239000001630 malic acid Substances 0.000 description 5
- 235000011090 malic acid Nutrition 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- QBWLKDFBINPHFT-UHFFFAOYSA-L 1,3,2$l^{2}-benzodioxabismin-4-one;hydrate Chemical compound O.C1=CC=C2C(=O)O[Bi]OC2=C1 QBWLKDFBINPHFT-UHFFFAOYSA-L 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 240000007551 Boswellia serrata Species 0.000 description 4
- 235000012035 Boswellia serrata Nutrition 0.000 description 4
- 229920002911 Colestipol Polymers 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 4
- 101710116149 Histone acetyltransferase KAT5 Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229940025084 amphetamine Drugs 0.000 description 4
- 229960002274 atenolol Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960002903 benzyl benzoate Drugs 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 229960000782 bismuth subsalicylate Drugs 0.000 description 4
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 4
- 229960000603 cefalotin Drugs 0.000 description 4
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 4
- 229960001139 cefazolin Drugs 0.000 description 4
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 4
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 229960002604 colestipol Drugs 0.000 description 4
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 4
- 229960005227 delapril Drugs 0.000 description 4
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 4
- 229960002768 dipyridamole Drugs 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229960003592 fexofenadine Drugs 0.000 description 4
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 229960001743 golimumab Drugs 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229960001361 ipratropium bromide Drugs 0.000 description 4
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 4
- 229960003350 isoniazid Drugs 0.000 description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 4
- 229960001252 methamphetamine Drugs 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 229960005027 natalizumab Drugs 0.000 description 4
- 229960000482 pethidine Drugs 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229960003040 rifaximin Drugs 0.000 description 4
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229940037001 sodium edetate Drugs 0.000 description 4
- 239000012453 solvate Chemical group 0.000 description 4
- 229960003433 thalidomide Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 3
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 3
- 239000005885 Buprofezin Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 108010020326 Caspofungin Proteins 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- 239000005499 Clomazone Substances 0.000 description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 3
- 108010061435 Enalapril Proteins 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 3
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 108010007859 Lisinopril Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229960004530 benazepril Drugs 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 3
- 229960002781 bisoprolol Drugs 0.000 description 3
- PRLVTUNWOQKEAI-VKAVYKQESA-N buprofezin Chemical compound O=C1N(C(C)C)\C(=N\C(C)(C)C)SCN1C1=CC=CC=C1 PRLVTUNWOQKEAI-VKAVYKQESA-N 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 3
- 229960003034 caspofungin Drugs 0.000 description 3
- 229960004682 cefoperazone Drugs 0.000 description 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 3
- 229960003115 certolizumab pegol Drugs 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 229940001468 citrate Drugs 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 229960002842 clobetasol Drugs 0.000 description 3
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 3
- KIEDNEWSYUYDSN-UHFFFAOYSA-N clomazone Chemical compound O=C1C(C)(C)CON1CC1=CC=CC=C1Cl KIEDNEWSYUYDSN-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 229960005319 delavirdine Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 229960003914 desipramine Drugs 0.000 description 3
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 3
- 229960004976 desogestrel Drugs 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 229960000385 dyclonine Drugs 0.000 description 3
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- 229960000873 enalapril Drugs 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 229940031098 ethanolamine Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229960004979 fampridine Drugs 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 229960002598 fumaric acid Drugs 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 3
- 229950010864 guselkumab Drugs 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229960002394 lisinopril Drugs 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 229940098895 maleic acid Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229960004023 minocycline Drugs 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229950004354 phosphorylcholine Drugs 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 229940095050 propylene Drugs 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- SSEBTPPFLLCUMN-CYBMUJFWSA-N (1r)-2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol Chemical compound CCC1=CC=CC2=C1OC([C@H](O)CNC(C)(C)C)=C2 SSEBTPPFLLCUMN-CYBMUJFWSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
- YLFZHHDVRSYTKT-NRFANRHFSA-N (2s)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid Chemical compound COC1=CC(COCC)=CC(OC)=C1C(C=C1)=CC=C1C[C@@H](C(O)=O)NC(=O)C1=C(F)C=CC=C1F YLFZHHDVRSYTKT-NRFANRHFSA-N 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- LATZVDXOTDYECD-UFTFXDLESA-N 2,3-dihydroxybutanedioic acid (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide tetrahydrate Chemical compound O.O.O.O.OC(C(O)C(O)=O)C(O)=O.CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F LATZVDXOTDYECD-UFTFXDLESA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 description 2
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 2
- XPRDUGXOWVXZLL-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C(O)=O)=CC=2)=C1 XPRDUGXOWVXZLL-UHFFFAOYSA-N 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- DQTMTQZSOJMZSF-UHFFFAOYSA-N 3-pentadecylcatechol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 2
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 239000005500 Clopyralid Substances 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 2
- FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 2
- YASYVMFAVPKPKE-UHFFFAOYSA-N acephate Chemical compound COP(=O)(SC)NC(C)=O YASYVMFAVPKPKE-UHFFFAOYSA-N 0.000 description 2
- 229960001413 acetanilide Drugs 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 2
- 229960001171 acetohydroxamic acid Drugs 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 2
- 229950010221 alexidine Drugs 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 229960002535 alfacalcidol Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 2
- 229960005174 ambroxol Drugs 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 229960002587 amitraz Drugs 0.000 description 2
- QXAITBQSYVNQDR-ZIOPAAQOSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1/N=C/N(C)\C=N\C1=CC=C(C)C=C1C QXAITBQSYVNQDR-ZIOPAAQOSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
- 229960001830 amprenavir Drugs 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 229940124339 anthelmintic agent Drugs 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 description 2
- 229960002970 artemotil Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 229960004168 balsalazide Drugs 0.000 description 2
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- 229940023842 benzyl nicotinamide Drugs 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 2
- 229940036358 bismuth subcarbonate Drugs 0.000 description 2
- 229960000199 bismuth subgallate Drugs 0.000 description 2
- XXCBNHDMGIZPQF-UHFFFAOYSA-L bismuth(2+);5-carboxy-3-hydroxybenzene-1,2-diolate;hydrate Chemical compound O.OC1=CC(C(=O)O)=CC2=C1O[Bi]O2 XXCBNHDMGIZPQF-UHFFFAOYSA-L 0.000 description 2
- 229960001169 brivudine Drugs 0.000 description 2
- 229950005228 bromoform Drugs 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 229950005341 bucindolol Drugs 0.000 description 2
- 229960004111 buformin Drugs 0.000 description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 2
- 229950006886 bufuralol Drugs 0.000 description 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 2
- 229960004064 bumetanide Drugs 0.000 description 2
- 229960002467 bunazosin Drugs 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 2
- 229960004205 carbidopa Drugs 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- 229960003585 cefmetazole Drugs 0.000 description 2
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 2
- 229960004489 cefonicid Drugs 0.000 description 2
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 229960001991 ceftizoxime Drugs 0.000 description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005443 chloroxylenol Drugs 0.000 description 2
- ISZNZKHCRKXXAU-UHFFFAOYSA-N chlorproguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C(Cl)=C1 ISZNZKHCRKXXAU-UHFFFAOYSA-N 0.000 description 2
- 229950000764 chlorproguanil Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 229960001523 chlortalidone Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 2
- 229950002020 clemizole Drugs 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- HUBANNPOLNYSAD-UHFFFAOYSA-N clopyralid Chemical compound OC(=O)C1=NC(Cl)=CC=C1Cl HUBANNPOLNYSAD-UHFFFAOYSA-N 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229930003836 cresol Natural products 0.000 description 2
- 229930184833 crotamide Natural products 0.000 description 2
- MZZBPDKVEFVLFF-UHFFFAOYSA-N cyanazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)(C)C#N)=N1 MZZBPDKVEFVLFF-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 2
- 239000011615 dehydroascorbic acid Substances 0.000 description 2
- 229960002997 dehydrocholic acid Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 2
- 229960003309 dienogest Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 229960003933 dorzolamide Drugs 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 229960005178 doxylamine Drugs 0.000 description 2
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
- 229960004913 dydrogesterone Drugs 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 2
- 229960002694 emetine Drugs 0.000 description 2
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- 229960003745 esmolol Drugs 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229940009626 etidronate Drugs 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229940069604 etrasimod Drugs 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 229960003667 flupirtine Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- 229960005352 gestodene Drugs 0.000 description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960003258 hexylresorcinol Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- LJOQGZACKSYWCH-WZBLMQSHSA-N hydroquinine Chemical compound C1=C(OC)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-WZBLMQSHSA-N 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960004187 indoprofen Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 229960001888 ipratropium Drugs 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 2
- 229960004577 laquinimod Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- CSFWPUWCSPOLJW-UHFFFAOYSA-N lawsone Chemical compound C1=CC=C2C(=O)C(O)=CC(=O)C2=C1 CSFWPUWCSPOLJW-UHFFFAOYSA-N 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 2
- 229960000692 levosimendan Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229960002422 lomefloxacin Drugs 0.000 description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 229960001786 megestrol Drugs 0.000 description 2
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960005192 methoxamine Drugs 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 2
- 229960001512 miglustat Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229950009792 mirikizumab Drugs 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- KKBOOQDFOWZSDC-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCN(CC)CC KKBOOQDFOWZSDC-UHFFFAOYSA-N 0.000 description 2
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960005385 proguanil Drugs 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229940095574 propionic acid Drugs 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- ZLVSYODPTJZFMK-UHFFFAOYSA-M sodium 4-hydroxybenzoate Chemical compound [Na+].OC1=CC=C(C([O-])=O)C=C1 ZLVSYODPTJZFMK-UHFFFAOYSA-M 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- 229940046307 sodium thioglycolate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005256 sulbactam Drugs 0.000 description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 229940099368 (+/-)- limonene Drugs 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- YLJXZSWHZFXCDY-RQJHMYQMSA-N (1r,3s)-3-amino-n-(3-amino-3-iminopropyl)cyclopentane-1-carboxamide Chemical compound N[C@H]1CC[C@@H](C(=O)NCCC(N)=N)C1 YLJXZSWHZFXCDY-RQJHMYQMSA-N 0.000 description 1
- XXZAOMJCZBZKPV-WEDXCCLWSA-N (1r,3s,4r)-3-chloro-4,7,7-trimethylbicyclo[2.2.1]heptane Chemical compound C1C[C@@]2(C)[C@@H](Cl)C[C@@H]1C2(C)C XXZAOMJCZBZKPV-WEDXCCLWSA-N 0.000 description 1
- JKFZMIQMKFWJAY-RQJQXFIZSA-N (1r,3s,5z)-5-[(2e)-2-[(3as,7as)-1-[(2r)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C JKFZMIQMKFWJAY-RQJQXFIZSA-N 0.000 description 1
- AXMKZEOEXSKFJI-XSSZXYGBSA-N (1s,2r,4r)-2-hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1C[C@@]2(C)C(=O)[C@H](O)[C@@H]1C2(C)C AXMKZEOEXSKFJI-XSSZXYGBSA-N 0.000 description 1
- NJQADTYRAYFBJN-FWWHASMVSA-N (1s,2s,4r)-2-bromo-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1C[C@@]2(C)C(=O)[C@@H](Br)[C@@H]1C2(C)C NJQADTYRAYFBJN-FWWHASMVSA-N 0.000 description 1
- FHNKBSDJERHDHZ-UHFFFAOYSA-N (2,4-dimethylphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=C(C)C=C1C FHNKBSDJERHDHZ-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LQIPDFIUPOYMPR-BKYURJJWSA-N (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide Chemical compound O1[C@@H]([C@@H](O)CO)[C@H](NC(=O)CNC(=O)/C=C/C=C/CCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1NC=N2 LQIPDFIUPOYMPR-BKYURJJWSA-N 0.000 description 1
- JMPZTWDLOGTBPM-OUQSKUGOSA-N (2e,4e,6e)-7-(3,5-ditert-butylphenyl)-3-methylocta-2,4,6-trienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 JMPZTWDLOGTBPM-OUQSKUGOSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- YAGBSNMZQKEFCO-SNVBAGLBSA-N (2r)-n-ethyl-1-phenylpropan-2-amine Chemical compound CCN[C@H](C)CC1=CC=CC=C1 YAGBSNMZQKEFCO-SNVBAGLBSA-N 0.000 description 1
- CIDUJQMULVCIBT-MQDUPKMGSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N CIDUJQMULVCIBT-MQDUPKMGSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WNDUPUMWHYAJOR-SADXPQEKSA-K (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WNDUPUMWHYAJOR-SADXPQEKSA-K 0.000 description 1
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FOPALECPEUVCTL-QMMMGPOBSA-N (2s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid Chemical compound CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O FOPALECPEUVCTL-QMMMGPOBSA-N 0.000 description 1
- KZBKRARRXDZOII-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;2-hydroxybenzoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)C1=CC=CC=C1O KZBKRARRXDZOII-ZSCHJXSPSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- JMWOGOGGXYCJQC-YYQZADIYSA-N (2s)-2-[[(2s)-2-aminohexanoyl]amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4h-imidazol-4-yl)-1-oxo Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(N)=O)C1C=NC=N1 JMWOGOGGXYCJQC-YYQZADIYSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- NAFSYPCVPLWHFY-HNNXBMFYSA-N (2s)-3,3,3-trifluoro-2-hydroxy-2-methyl-n-(5,5,10-trioxo-4h-thieno[3,2-c][1]benzothiepin-9-yl)propanamide Chemical compound FC(F)(F)[C@](O)(C)C(=O)NC1=CC=CC(S(C2)(=O)=O)=C1C(=O)C1=C2C=CS1 NAFSYPCVPLWHFY-HNNXBMFYSA-N 0.000 description 1
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
- KCEHUPIXDRDKQS-VKHMYHEASA-N (2s)-5-amino-2-hydrazinyl-5-oxopentanoic acid Chemical compound NN[C@H](C(O)=O)CCC(N)=O KCEHUPIXDRDKQS-VKHMYHEASA-N 0.000 description 1
- NOYZWUQUALADDO-VWLOTQADSA-N (2s)-n-(4-amino-1-methyl-2,6-dioxo-3-phenylpyrimidin-5-yl)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O=C([C@@]1(C)OC=2C(C)=C(C(=C(C)C=2CC1)O)C)NC(C(N(C)C1=O)=O)=C(N)N1C1=CC=CC=C1 NOYZWUQUALADDO-VWLOTQADSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- XLPLFRLIWKRQFT-XUJYDZMUSA-N (3,3-dimethyl-2-oxobutyl) (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound CC(C)(C)C(=O)COC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XLPLFRLIWKRQFT-XUJYDZMUSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- MBRMDGSBOOLIGQ-QYJZNYBASA-N (3S,5S,6R,7R,8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,6,7-triol Chemical compound C([C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC/C(=C/C)[C@@]2(C)CC1 MBRMDGSBOOLIGQ-QYJZNYBASA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- LDVVMCZRFWMZSG-OLQVQODUSA-N (3ar,7as)-2-(trichloromethylsulfanyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)Cl)C(=O)[C@H]21 LDVVMCZRFWMZSG-OLQVQODUSA-N 0.000 description 1
- CZURVZMARWUXMH-KBYGAXRISA-N (3r)-1-(4-chlorophenyl)-3-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]pyrrolidin-2-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(CCOC)CCN1C[C@@H]1C(=O)N(C=2C=CC(Cl)=CC=2)CC1 CZURVZMARWUXMH-KBYGAXRISA-N 0.000 description 1
- QCVNMNYRNIMDKV-QGZVFWFLSA-N (3r)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone Chemical compound FC1=CC(Br)=CC=C1CN1C(=O)[C@@]2(C(NC(=O)C2)=O)N2C=CC=C2C1=O QCVNMNYRNIMDKV-QGZVFWFLSA-N 0.000 description 1
- IPRJDKMLMDPMBH-XFULWGLBSA-N (3r)-n-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2C(C2)=C1CN[C@H]2C(=O)NCC1=CC=C(OCO2)C2=C1 IPRJDKMLMDPMBH-XFULWGLBSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- LYBWGROBJJXCJJ-BBRMVZONSA-N (3s)-5-fluoro-3-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 LYBWGROBJJXCJJ-BBRMVZONSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- JSLISSGEILAIOU-UHFFFAOYSA-N (4-chloro-2-iodophenyl)hydrazine Chemical compound NNC1=CC=C(Cl)C=C1I JSLISSGEILAIOU-UHFFFAOYSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- WRVJTXDJDKITNK-XNGFCKKMSA-N (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-3-[(3s,5s)-5-[(r)-hydroxy-[(3r)-pyrrolidin-3-yl]methyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.C([C@H]1[C@@H](O)[C@H]2NC[C@H](C2)SC=2[C@H](C)[C@@H]3[C@H](C(N3C=2C(O)=O)=O)[C@H](O)C)CNC1 WRVJTXDJDKITNK-XNGFCKKMSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- KZSSWXACMCYLBM-RMWNCEGRSA-N (5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 KZSSWXACMCYLBM-RMWNCEGRSA-N 0.000 description 1
- XZPSYCOYKJRHKE-MRXNPFEDSA-N (5s)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC([N+]([O-])=O)=C(O)C=C2[C@H]1C1=CC=CC2=C1OCC2 XZPSYCOYKJRHKE-MRXNPFEDSA-N 0.000 description 1
- IUHMIOAKWHUFKU-YINIXLNUSA-N (5s,6r,7r)-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-[(2s)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-5h-cyclopenta[b]pyridine-6-carboxylic acid Chemical compound C1([C@H]2[C@@H]([C@H](C3=CC=C(N=C32)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1C[C@H](C)C(O)=O IUHMIOAKWHUFKU-YINIXLNUSA-N 0.000 description 1
- VKSIBVBEGLEBSB-ATVHPVEESA-N (5z)-5-hydroxyimino-6h-benzo[b][1]benzazepine-11-carboxamide Chemical compound C1\C(=N\O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 VKSIBVBEGLEBSB-ATVHPVEESA-N 0.000 description 1
- DMJWENQHWZZWDF-PKOBYXMFSA-N (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2[C@H]2C3=CC=CC=C3CC[C@H]12 DMJWENQHWZZWDF-PKOBYXMFSA-N 0.000 description 1
- DZUOQMBJJSBONO-CQSZACIVSA-N (6ar)-10-methoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-11-ol Chemical compound CN1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(OC)C(O)=C13 DZUOQMBJJSBONO-CQSZACIVSA-N 0.000 description 1
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- ZYACKOKSHZQYDS-NTVGDFDMSA-N (6ar,10ar)-9-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline Chemical compound C1=CC([C@@H]2[C@H](NCC(C2)C)C2)=C3C2=CNC3=C1 ZYACKOKSHZQYDS-NTVGDFDMSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 1
- HKHRWODVCOCCIC-UCZFRPJKSA-N (6s)-3-[[(2-amino-2-oxoethyl)-methylamino]methyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S1C(CN(C)CC(N)=O)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)C21 HKHRWODVCOCCIC-UCZFRPJKSA-N 0.000 description 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
- BSRQHWFOFMAZRL-BODGVHBXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C BSRQHWFOFMAZRL-BODGVHBXSA-N 0.000 description 1
- MXAZMWGALDAMFV-JBBJNLNBSA-N (8R,9S,13S,14S)-15-ethyl-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@]4(C)C(O)CC(CC)[C@H]4[C@@H]3CCC2=C1 MXAZMWGALDAMFV-JBBJNLNBSA-N 0.000 description 1
- MCKJPJYRCPANCC-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 MCKJPJYRCPANCC-XLXYOEISSA-N 0.000 description 1
- KKVPWYXKKAIBTN-FDIQSBBYSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1-fluoro-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC(F)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 KKVPWYXKKAIBTN-FDIQSBBYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-INIZCTEOSA-N (S)-fluoxetine Chemical compound O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-INIZCTEOSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- UEJJHQNACJXSKW-VIFPVBQESA-N (S)-thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H]1CCC(=O)NC1=O UEJJHQNACJXSKW-VIFPVBQESA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 description 1
- ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 1
- ZWLMLVIUWRUDBD-BTJKTKAUSA-N (z)-but-2-enedioate;3-(2-methoxy-10h-phenothiazin-10-ium-10-yl)propyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2N(CCCN(C)C)C3=CC(OC)=CC=C3SC2=C1 ZWLMLVIUWRUDBD-BTJKTKAUSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- KETQAJRQOHHATG-UHFFFAOYSA-N 1,2-naphthoquinone Chemical compound C1=CC=C2C(=O)C(=O)C=CC2=C1 KETQAJRQOHHATG-UHFFFAOYSA-N 0.000 description 1
- 229940105324 1,2-naphthoquinone Drugs 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- BYXCFUMGEBZDDI-UHFFFAOYSA-N 1,3,7-trimethyluric acid Chemical compound CN1C(=O)N(C)C(=O)C2=C1NC(=O)N2C BYXCFUMGEBZDDI-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- FXCYGAGBPZQRJE-ZHACJKMWSA-N 1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1,6-heptadien-3-one Chemical compound CC1=CCCC(C)(C)C1\C=C\C(=O)CCC=C FXCYGAGBPZQRJE-ZHACJKMWSA-N 0.000 description 1
- MRFOLGFFTUGAEB-UHFFFAOYSA-N 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone Chemical compound [O-][N+](=O)C1=C(O)C(O)=CC(C(=O)CC=2C=CC=CC=2)=C1 MRFOLGFFTUGAEB-UHFFFAOYSA-N 0.000 description 1
- SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 1
- SQZCAOHYQSOZCE-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N=C(N)N=C(N)N SQZCAOHYQSOZCE-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- KPQFKCWYCKXXIP-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylamino)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(NC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 KPQFKCWYCKXXIP-XLPZGREQSA-N 0.000 description 1
- FMBVHKPWDJQLNO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC(F)=C1 FMBVHKPWDJQLNO-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- MBGVUMXBUGIIBQ-LEWJYISDSA-N 1-[(3r,4r)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one Chemical compound C([C@H]([C@@H](C1)CO)N2C3=CC=CC=C3N(C2=O)CC)CN1CC1CCCCCCC1 MBGVUMXBUGIIBQ-LEWJYISDSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- UDDPPYHULIXFDV-UHFFFAOYSA-N 1-[(6-chloro-2-methoxyacridin-9-yl)amino]-3-(diethylamino)propan-2-ol Chemical compound C1=C(OC)C=C2C(NCC(O)CN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 UDDPPYHULIXFDV-UHFFFAOYSA-N 0.000 description 1
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- JTUQXGZRVLWBCR-UHFFFAOYSA-N 1-[1-[2-(phenylmethyl)phenoxy]propan-2-yl]piperidine Chemical compound C1CCCCN1C(C)COC1=CC=CC=C1CC1=CC=CC=C1 JTUQXGZRVLWBCR-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- USMXIXZBRZZOQH-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;dihydrate;octahydrochloride Chemical compound O.O.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 USMXIXZBRZZOQH-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- LHJGNHRBQMBUDD-UHFFFAOYSA-N 1-acetylsulfonylethanone Chemical compound CC(=O)S(=O)(=O)C(C)=O LHJGNHRBQMBUDD-UHFFFAOYSA-N 0.000 description 1
- RRQGZMDHLIAOLY-UHFFFAOYSA-N 1-bromopiperidine Chemical compound BrN1CCCCC1 RRQGZMDHLIAOLY-UHFFFAOYSA-N 0.000 description 1
- RPOUGULCGNMIBX-UHFFFAOYSA-N 1-chlorophenazine Chemical compound C1=CC=C2N=C3C(Cl)=CC=CC3=NC2=C1 RPOUGULCGNMIBX-UHFFFAOYSA-N 0.000 description 1
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 description 1
- BJQHLKABXJIVAM-BGYRXZFFSA-N 1-o-[(2r)-2-ethylhexyl] 2-o-[(2s)-2-ethylhexyl] benzene-1,2-dicarboxylate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@H](CC)CCCC BJQHLKABXJIVAM-BGYRXZFFSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HWRLUCKYMWCCLN-UHFFFAOYSA-N 1-phenazin-1-ylethanone Chemical compound C1=CC=C2N=C3C(C(=O)C)=CC=CC3=NC2=C1 HWRLUCKYMWCCLN-UHFFFAOYSA-N 0.000 description 1
- KLCDQSGLLRINHY-UHFFFAOYSA-N 1-phenyldiazenylnaphthalen-2-amine Chemical compound NC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1 KLCDQSGLLRINHY-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QVEPWCHFXPHWJG-GNAFDRTKSA-N 11-[[(2r)-1-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]-6h-benzo[c][1,5]benzoxazepine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CCN1[C@@H](CN2C3=CC=CC=C3OCC3=CC=CC=C32)CCC1 QVEPWCHFXPHWJG-GNAFDRTKSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- UDACROBZRRPQHG-UHFFFAOYSA-N 1h-indol-3-ylmethylhydrazine Chemical compound C1=CC=C2C(CNN)=CNC2=C1 UDACROBZRRPQHG-UHFFFAOYSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- ZNOVVAJWYUBFMI-JIFFNSBPSA-N 2,2-dimethylpropanoyloxymethyl (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3r)-5-oxopyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)S[C@H]1CNC(=O)C1 ZNOVVAJWYUBFMI-JIFFNSBPSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- NRJAVPSFFCBXDT-UHFFFAOYSA-N 2,3-di(octadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-UHFFFAOYSA-N 0.000 description 1
- QSWMUPMIFOJNFO-UHFFFAOYSA-N 2,3-dichloro-2H-phenazin-1-one Chemical compound ClC=1C(C(C2=NC3=CC=CC=C3N=C2C=1)=O)Cl QSWMUPMIFOJNFO-UHFFFAOYSA-N 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical compound OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- QPTLSCXVCHENDU-UHFFFAOYSA-N 2,3-dimethoxy-2-phenylpropanoic acid Chemical compound COCC(OC)(C(O)=O)C1=CC=CC=C1 QPTLSCXVCHENDU-UHFFFAOYSA-N 0.000 description 1
- VAPDZNUFNKUROY-UHFFFAOYSA-N 2,4,6-triiodophenol Chemical compound OC1=C(I)C=C(I)C=C1I VAPDZNUFNKUROY-UHFFFAOYSA-N 0.000 description 1
- NAZQXTHWEFCOOX-UHFFFAOYSA-N 2,4-dimethyl-6-prop-2-enyl-7,8-dihydropurino[7,8-a]imidazole-1,3-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N1CCN(CC=C)C1=N2 NAZQXTHWEFCOOX-UHFFFAOYSA-N 0.000 description 1
- HGDVHRITTGWMJK-UHFFFAOYSA-N 2,6-dimethylheptan-2-ol Chemical compound CC(C)CCCC(C)(C)O HGDVHRITTGWMJK-UHFFFAOYSA-N 0.000 description 1
- ZGSFWANJADAZQC-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[4-[2-(4-chlorophenyl)-2-hydroxyethyl]piperazin-1-yl]methyl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CN2CCN(CC(O)C=3C=CC(Cl)=CC=3)CC2)=C1 ZGSFWANJADAZQC-UHFFFAOYSA-N 0.000 description 1
- WEBILLRFBZTUIX-BTJKTKAUSA-N 2-(1-adamantyl)ethyl 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetate;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OCC(O)CNC(C)C)=CC=C1CC(=O)OCCC1(C2)CC(C3)CC2CC3C1 WEBILLRFBZTUIX-BTJKTKAUSA-N 0.000 description 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- YCTSCXLOPJCPDH-UHFFFAOYSA-N 2-(3,7-dimethyl-2,6-dioxopurin-1-yl)acetic acid Chemical compound CN1C(=O)N(CC(O)=O)C(=O)C2=C1N=CN2C YCTSCXLOPJCPDH-UHFFFAOYSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- JMEVHYCNAPFOAB-UHFFFAOYSA-L 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [O-]c1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=[NH+]c2ccc(cc2C1=O)S([O-])(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-L 0.000 description 1
- FNLNSQHJKVQCBP-UHFFFAOYSA-N 2-(3-sulfanylpropyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCCS FNLNSQHJKVQCBP-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- OYLIEVIKIUHKTG-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)phenol Chemical compound OC1=CC=CC=C1CN1CCOCC1 OYLIEVIKIUHKTG-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- OLIKCJUMYWSDIV-UHFFFAOYSA-N 2-[2,6-diiodo-4-[(2-methyl-1-benzofuran-3-yl)methyl]phenoxy]acetic acid Chemical compound CC=1OC2=CC=CC=C2C=1CC1=CC(I)=C(OCC(O)=O)C(I)=C1 OLIKCJUMYWSDIV-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- CQOZJDNCADWEKH-UHFFFAOYSA-N 2-[3,3-bis(2-hydroxyphenyl)propyl]phenol Chemical compound OC1=CC=CC=C1CCC(C=1C(=CC=CC=1)O)C1=CC=CC=C1O CQOZJDNCADWEKH-UHFFFAOYSA-N 0.000 description 1
- XNGGRURGYIXOBY-UHFFFAOYSA-N 2-[3-[1-(4-fluorobenzoyl)piperidin-4-yl]phenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC(C2CCN(CC2)C(=O)C=2C=CC(F)=CC=2)=C1 XNGGRURGYIXOBY-UHFFFAOYSA-N 0.000 description 1
- FJNRJBQUOQLUNQ-CYBMUJFWSA-N 2-[3-[[(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]propyl]pyridazin-3-one Chemical compound O=C1C=CC=NN1CCCNC[C@H]1OC2=CC=CC=C2OC1 FJNRJBQUOQLUNQ-CYBMUJFWSA-N 0.000 description 1
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 description 1
- OUEKLNJUMVZULZ-UHFFFAOYSA-N 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-n-[3-(3,4-dimethylphenyl)propyl]acetamide;hydron;chloride Chemical compound Cl.C1=C(OCCN)C(OC)=CC(CC(=O)NCCCC=2C=C(C)C(C)=CC=2)=C1 OUEKLNJUMVZULZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFDKCZMYQOSTJG-UHFFFAOYSA-N 2-[4-(trifluoromethylsulfanyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(SC(F)(F)F)C=C1 BFDKCZMYQOSTJG-UHFFFAOYSA-N 0.000 description 1
- KKXPBQQLKHBRDA-DJJJIMSYSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(OCC(O)=O)C=C1 KKXPBQQLKHBRDA-DJJJIMSYSA-N 0.000 description 1
- LYXKFNHUJJDTIA-UHFFFAOYSA-N 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound O=C1C2=CC=CC=C2S(=O)(=O)N1CCCCN(CC1)CCN1C1=CC(Cl)=CC2=C1OCCO2 LYXKFNHUJJDTIA-UHFFFAOYSA-N 0.000 description 1
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 description 1
- ZSDLYSDDELEVDD-UFTMZEDQSA-K 2-[[(2r)-2-[bis(carboxylatomethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron Chemical compound [H+].[H+].[H+].[Gd+3].C1CC(OP([O-])(=O)OC[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC(=O)[O-])N(CC([O-])=O)CC([O-])=O)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 ZSDLYSDDELEVDD-UFTMZEDQSA-K 0.000 description 1
- USPVLEIQIUNQGE-DBFLIVQGSA-N 2-[[(2s)-2-benzyl-3-[(3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid;dihydrate Chemical compound O.O.C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 USPVLEIQIUNQGE-DBFLIVQGSA-N 0.000 description 1
- FHEYFIGWYQJVDR-ACJLOTCBSA-N 2-[[3-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1h-indol-7-yl]oxy]acetic acid Chemical compound C1([C@@H](O)CN[C@@H](CC=2C3=CC=CC(OCC(O)=O)=C3NC=2)C)=CC=CC(Cl)=C1 FHEYFIGWYQJVDR-ACJLOTCBSA-N 0.000 description 1
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 description 1
- IKHFJPZQZVMLRH-RNFRBKRXSA-N 2-[[[(3r,5r)-3,6-diamino-5-hydroxyhexanoyl]amino]-methylamino]acetic acid Chemical compound OC(=O)CN(C)NC(=O)C[C@H](N)C[C@@H](O)CN IKHFJPZQZVMLRH-RNFRBKRXSA-N 0.000 description 1
- HRHYOXZFPZQNTD-UHFFFAOYSA-K 2-[bis(carboxymethylsulfanyl)stibanylsulfanyl]acetic acid Chemical compound OC(=O)CS[Sb](SCC(O)=O)SCC(O)=O HRHYOXZFPZQNTD-UHFFFAOYSA-K 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 1
- RTJUXLYUUDBAJN-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](F)[C@@H](CO)O1 RTJUXLYUUDBAJN-KVQBGUIXSA-N 0.000 description 1
- JLYSZBQNRJVPEP-KGFZYKRKSA-N 2-amino-9-[[(1s,2r)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C[C@]1(CO)C[C@H]1CO JLYSZBQNRJVPEP-KGFZYKRKSA-N 0.000 description 1
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- UZRUKLJLGXLGDM-UHFFFAOYSA-N 2-aminopentanamide Chemical compound CCCC(N)C(N)=O UZRUKLJLGXLGDM-UHFFFAOYSA-N 0.000 description 1
- KWIPUXXIFQQMKN-UHFFFAOYSA-N 2-azaniumyl-3-(4-cyanophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-UHFFFAOYSA-N 0.000 description 1
- BURBNIPKSRJAIQ-UHFFFAOYSA-N 2-azaniumyl-3-[3-(trifluoromethyl)phenyl]propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(C(F)(F)F)=C1 BURBNIPKSRJAIQ-UHFFFAOYSA-N 0.000 description 1
- QKJAZPHKNWSXDF-UHFFFAOYSA-N 2-bromoquinoline Chemical compound C1=CC=CC2=NC(Br)=CC=C21 QKJAZPHKNWSXDF-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-butanol Substances CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- XCHHJFVNQPPLJK-UHFFFAOYSA-N 2-carboxyphenolate;1h-imidazol-1-ium Chemical class C1=CNC=N1.OC(=O)C1=CC=CC=C1O XCHHJFVNQPPLJK-UHFFFAOYSA-N 0.000 description 1
- HTIZLJISEUYGSA-UHFFFAOYSA-N 2-chloro-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(Cl)=CC=C21 HTIZLJISEUYGSA-UHFFFAOYSA-N 0.000 description 1
- BRBDUWYAQKYQNI-UHFFFAOYSA-N 2-chloro-4,5-dihydro-1,3-oxazole Chemical compound ClC1=NCCO1 BRBDUWYAQKYQNI-UHFFFAOYSA-N 0.000 description 1
- GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- BYVQIEDYUFEJJI-UHFFFAOYSA-N 2-ethoxy-6-[2-[(3-ethoxy-2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound C(C)OC1=C(C(C=NCCN=CC=2C(O)=C(C=CC=2)OCC)=CC=C1)O BYVQIEDYUFEJJI-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical compound CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- AEXIQPQOFKQACC-UHFFFAOYSA-N 2-ethoxypyrimidine Chemical compound CCOC1=NC=CC=N1 AEXIQPQOFKQACC-UHFFFAOYSA-N 0.000 description 1
- LHJPKLWGGMAUAN-UHFFFAOYSA-N 2-ethyl-2-methyl-butanoic acid Chemical compound CCC(C)(CC)C(O)=O LHJPKLWGGMAUAN-UHFFFAOYSA-N 0.000 description 1
- AJKXDPSHWRTFOZ-UHFFFAOYSA-N 2-ethylhexane-1,6-diol Chemical compound CCC(CO)CCCCO AJKXDPSHWRTFOZ-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- FRWYFWZENXDZMU-UHFFFAOYSA-N 2-iodoquinoline Chemical compound C1=CC=CC2=NC(I)=CC=C21 FRWYFWZENXDZMU-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 1
- ZRLFRWNYFMYZEG-UHFFFAOYSA-N 2-methylhexanamide Chemical compound CCCCC(C)C(N)=O ZRLFRWNYFMYZEG-UHFFFAOYSA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- NUPGPJBRKLLVNK-UHFFFAOYSA-N 2-n-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-1,3,5-triazine-2,4-diamine Chemical compound CC1=CC=C(Cl)C=C1C1=NC(N)=NC(NC=2C=CC(Br)=CC=2)=N1 NUPGPJBRKLLVNK-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- FBVDVFULNXWYRF-UHFFFAOYSA-N 3-(6-oxo-3h-purin-9-yl)-n-[3-(2-oxopyrrolidin-1-yl)propyl]propanamide Chemical compound C1=NC(C(NC=N2)=O)=C2N1CCC(=O)NCCCN1CCCC1=O FBVDVFULNXWYRF-UHFFFAOYSA-N 0.000 description 1
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- WAWDOEHEAULMGC-UHFFFAOYSA-N 3-[(6-butoxypyridin-3-yl)diazenyl]pyridine-2,6-diamine Chemical compound C1=NC(OCCCC)=CC=C1N=NC1=CC=C(N)N=C1N WAWDOEHEAULMGC-UHFFFAOYSA-N 0.000 description 1
- LZXRQLIIMYJZDA-UETOGOEVSA-N 3-[(r)-[(2s,5r)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-n-(3-fluorophenyl)-n-methylbenzamide Chemical compound C[C@H]1CN(CC=C)[C@H](C)CN1[C@H](C=1C=C(C=CC=1)C(=O)N(C)C=1C=C(F)C=CC=1)C1=CC=CC(O)=C1 LZXRQLIIMYJZDA-UETOGOEVSA-N 0.000 description 1
- MQNWWJVIEQBJJO-UHFFFAOYSA-N 3-[2-(1-hydroxyethyl)-3-methyl-1-benzofuran-5-yl]-2h-furan-5-one Chemical compound C1=C2C(C)=C(C(O)C)OC2=CC=C1C1=CC(=O)OC1 MQNWWJVIEQBJJO-UHFFFAOYSA-N 0.000 description 1
- XDJCLCLBSGGNKS-UHFFFAOYSA-N 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole Chemical compound C=1C=CC(C=2C3=CC(=CC=C3NN=2)C=2NN=CN=2)=CC=1OCCN1CCCCC1 XDJCLCLBSGGNKS-UHFFFAOYSA-N 0.000 description 1
- LZVBMKDVEPGGFK-DQEYMECFSA-N 3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2s,5s)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea Chemical compound COC1=CC([C@H]2O[C@@H](CC2)C=2C=C(OC)C(OC)=C(OC)C=2)=CC(CNC(=O)N(C)O)=C1OCCSC1=CC=C(Cl)C=C1 LZVBMKDVEPGGFK-DQEYMECFSA-N 0.000 description 1
- RTKMFQOHBDVEBC-UHFFFAOYSA-N 3-bromo-3-buten-1-ol Chemical compound OCCC(Br)=C RTKMFQOHBDVEBC-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- MBWWSIMPQZRRGR-UHFFFAOYSA-N 3-bromopyran-2-imine Chemical compound BrC=1C(OC=CC=1)=N MBWWSIMPQZRRGR-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- UXKKFPGAZIINBX-UHFFFAOYSA-N 3-chloro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(Cl)=CC2=C1 UXKKFPGAZIINBX-UHFFFAOYSA-N 0.000 description 1
- BZFKSWOGZQMOMO-UHFFFAOYSA-N 3-chloropropan-1-amine Chemical compound NCCCCl BZFKSWOGZQMOMO-UHFFFAOYSA-N 0.000 description 1
- YDHTUVFGGJLMJB-UHFFFAOYSA-N 3-ethyl-2H-thiazine Chemical compound C(C)C=1NSC=CC1 YDHTUVFGGJLMJB-UHFFFAOYSA-N 0.000 description 1
- HNPVERUJGFNNRV-UHFFFAOYSA-N 3-iodophthalic acid Chemical compound OC(=O)C1=CC=CC(I)=C1C(O)=O HNPVERUJGFNNRV-UHFFFAOYSA-N 0.000 description 1
- LFHSNLRTGGKKRT-UHFFFAOYSA-N 3-iodopyran-2-one Chemical compound IC1=CC=COC1=O LFHSNLRTGGKKRT-UHFFFAOYSA-N 0.000 description 1
- PSUFQBRCUSJTDO-UHFFFAOYSA-N 3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl-n-pentan-3-ylpyrazin-2-amine Chemical compound N1=C(OC)C(NC(CC)CC)=NC(C)=C1C1=CC=C(OC(F)(F)F)C=C1OC PSUFQBRCUSJTDO-UHFFFAOYSA-N 0.000 description 1
- PPWROHYRENWVPC-UHFFFAOYSA-N 3-methylsulfanylhex-3-ene Chemical compound C(C)C(=CCC)SC PPWROHYRENWVPC-UHFFFAOYSA-N 0.000 description 1
- CLUWOWRTHNNBBU-UHFFFAOYSA-N 3-methylthiopropanal Chemical compound CSCCC=O CLUWOWRTHNNBBU-UHFFFAOYSA-N 0.000 description 1
- YTCVPEZECJYZRK-UHFFFAOYSA-N 3-nitrochromen-2-one Chemical compound C1=CC=C2OC(=O)C([N+](=O)[O-])=CC2=C1 YTCVPEZECJYZRK-UHFFFAOYSA-N 0.000 description 1
- TZZGHGKTHXIOMN-UHFFFAOYSA-N 3-trimethoxysilyl-n-(3-trimethoxysilylpropyl)propan-1-amine Chemical compound CO[Si](OC)(OC)CCCNCCC[Si](OC)(OC)OC TZZGHGKTHXIOMN-UHFFFAOYSA-N 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- UNTNRNUQVKDIPV-UHFFFAOYSA-N 3h-dithiazole Chemical compound N1SSC=C1 UNTNRNUQVKDIPV-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FXRYWOJYVGJZLE-UHFFFAOYSA-N 4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine Chemical compound C1=CC=C2C(C)(C)CN[Se]C2=C1 FXRYWOJYVGJZLE-UHFFFAOYSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- AGURKSYKTJQPNA-UHFFFAOYSA-N 4,6-ditert-butyl-2,2-dipentyl-3h-1-benzofuran-5-ol Chemical compound C1=C(C(C)(C)C)C(O)=C(C(C)(C)C)C2=C1OC(CCCCC)(CCCCC)C2 AGURKSYKTJQPNA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- 239000004101 4-Hexylresorcinol Substances 0.000 description 1
- BDBMLMBYCXNVMC-UHFFFAOYSA-O 4-[(2e)-2-[(2e,4e,6z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS(O)(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C BDBMLMBYCXNVMC-UHFFFAOYSA-O 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
- HAQOEWGSBVQDHB-UHFFFAOYSA-N 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CN)SC=2)=C1 HAQOEWGSBVQDHB-UHFFFAOYSA-N 0.000 description 1
- LHUPKWKWYWOMSK-UHFFFAOYSA-N 4-[2-[4-(4-ethylphenyl)-2,2-dimethylthiochromen-6-yl]ethynyl]benzoic acid Chemical compound C1=CC(CC)=CC=C1C1=CC(C)(C)SC2=CC=C(C#CC=3C=CC(=CC=3)C(O)=O)C=C12 LHUPKWKWYWOMSK-UHFFFAOYSA-N 0.000 description 1
- VPTONMHDLLMOOV-UHFFFAOYSA-N 4-[3-[4-(2-methylimidazol-1-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide Chemical compound CC1=NC=CN1C(C=C1)=CC=C1SC1=CC=CC(C2(CCOCC2)C(N)=O)=C1 VPTONMHDLLMOOV-UHFFFAOYSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- XBVOXAWRUIZEMG-UHFFFAOYSA-N 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1NC1=NC(N)=NC=C1C#CC1=CC=C(Cl)C=C1 XBVOXAWRUIZEMG-UHFFFAOYSA-N 0.000 description 1
- DJKNRCWSXSZACF-UHFFFAOYSA-N 4-acetamido-n-tert-butylbenzamide Chemical compound CC(=O)NC1=CC=C(C(=O)NC(C)(C)C)C=C1 DJKNRCWSXSZACF-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- HRXVBNZDZKAOCI-UHFFFAOYSA-N 4-acetyl-3H-1,3-oxazol-2-one Chemical compound CC(=O)C1=COC(O)=N1 HRXVBNZDZKAOCI-UHFFFAOYSA-N 0.000 description 1
- JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2r,3r,4s,5r)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- GIYAQDDTCWHPPL-UHFFFAOYSA-N 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC GIYAQDDTCWHPPL-UHFFFAOYSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- HSBKFSPNDWWPSL-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1C=C[C@@H](CO)O1 HSBKFSPNDWWPSL-CAHLUQPWSA-N 0.000 description 1
- QGMGHALXLXKCBD-UHFFFAOYSA-N 4-amino-n-(2-aminophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=CC=C1N QGMGHALXLXKCBD-UHFFFAOYSA-N 0.000 description 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
- XYCDHXSQODHSLG-UHFFFAOYSA-N 4-chloro-2-[(2-chloro-4-nitrophenyl)carbamoyl]phenolate;2-hydroxyethylazanium Chemical compound NCCO.OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl XYCDHXSQODHSLG-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 235000019360 4-hexylresorcinol Nutrition 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- NMXIZJLIYYDNJG-UHFFFAOYSA-N 4-nitrooxybutyl 5-amino-2-hydroxybenzoate Chemical compound NC1=CC=C(O)C(C(=O)OCCCCO[N+]([O-])=O)=C1 NMXIZJLIYYDNJG-UHFFFAOYSA-N 0.000 description 1
- BLFGQHDZMHMURV-UHFFFAOYSA-N 4-oxo-2-phenylchromene-3-carboxylic acid Chemical class O1C2=CC=CC=C2C(=O)C(C(=O)O)=C1C1=CC=CC=C1 BLFGQHDZMHMURV-UHFFFAOYSA-N 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- SPLHPRPQTCQRGZ-UHFFFAOYSA-N 5-(2-amino-6-chloropurin-9-yl)pentylboronic acid Chemical compound NC1=NC(Cl)=C2N=CN(CCCCCB(O)O)C2=N1 SPLHPRPQTCQRGZ-UHFFFAOYSA-N 0.000 description 1
- YVQVOQKFMFRVGR-VGOFMYFVSA-N 5-(morpholin-4-ylmethyl)-3-[(e)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OC(CN2CCOCC2)C1 YVQVOQKFMFRVGR-VGOFMYFVSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- QEYBPFUVEMVIQD-WUHRBBMRSA-N 5-amino-7-[(3r,4s)-3-(1-aminocyclopropyl)-4-fluoropyrrolidin-1-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound NC1([C@@H]2[C@H](F)CN(C2)C2=C(C3=C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)C(N)=C2F)C)CC1 QEYBPFUVEMVIQD-WUHRBBMRSA-N 0.000 description 1
- RHTIMXFFOVWNLX-UHFFFAOYSA-N 5-bromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC=C1O RHTIMXFFOVWNLX-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- ZBXRPLQCPHTHLM-UHFFFAOYSA-N 5-chloro-n-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide;hydrate Chemical compound O.OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl ZBXRPLQCPHTHLM-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- DCDFLGVJWQIRGH-UHFFFAOYSA-N 5-methyl-2-piperazin-4-ium-1-ylbenzenesulfonate Chemical compound OS(=O)(=O)C1=CC(C)=CC=C1N1CCNCC1 DCDFLGVJWQIRGH-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- USPYDUPOCUYHQL-VEVMSBRDSA-N 5beta-dihydrodeoxycorticosterone Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 USPYDUPOCUYHQL-VEVMSBRDSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- VGLGVJVUHYTIIU-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC=C)NS2(=O)=O VGLGVJVUHYTIIU-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- JYRHGXXQSIPDDP-IACUBPJLSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C12([C@H](N)CN(C1)C1=C(C3=C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)C=C1F)OC)CC2 JYRHGXXQSIPDDP-IACUBPJLSA-N 0.000 description 1
- FVNFBBAOMBJTST-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FVNFBBAOMBJTST-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- JPIQZRAYPNKFEI-UHFFFAOYSA-N 8-cyclohexyl-1,3-bis(prop-2-enyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC=C)C(=O)N(CC=C)C=2N=C1C1CCCCC1 JPIQZRAYPNKFEI-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- VDBGPMJFHCJMOL-UHFFFAOYSA-N 9-[2-[bis(2,2,2-trifluoroethoxy)phosphorylmethoxy]ethyl]-6-(4-methoxyphenyl)sulfanylpurin-2-amine Chemical compound C1=CC(OC)=CC=C1SC1=NC(N)=NC2=C1N=CN2CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F VDBGPMJFHCJMOL-UHFFFAOYSA-N 0.000 description 1
- GZSUIHUAFPHZSU-UHFFFAOYSA-N 9-ethyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)CCC2 GZSUIHUAFPHZSU-UHFFFAOYSA-N 0.000 description 1
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Allobarbital Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- XUHBBTKJWIBQMY-MHZLTWQESA-N Anatibant Chemical compound O=C([C@@H]1CCCN1S(=O)(=O)C=1C=CC(Cl)=C(C=1Cl)COC1=CC=CC2=C(C)C=C(N=C21)C)NCCCNC(=O)C1=CC=C(C(N)=N)C=C1 XUHBBTKJWIBQMY-MHZLTWQESA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- BCFCRXOJOFDUMZ-ONKRVSLGSA-N Anecortave Chemical compound O=C1CC[C@]2(C)C3=CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 BCFCRXOJOFDUMZ-ONKRVSLGSA-N 0.000 description 1
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 240000000940 Araucaria angustifolia Species 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- MGYMHQJELJYRQS-UHFFFAOYSA-N Ascaridole Chemical compound C1CC2(C)OOC1(C(C)C)C=C2 MGYMHQJELJYRQS-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- MFHMDPATIIJVTE-UHFFFAOYSA-K C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-].[Na+].[Bi+3] Chemical compound C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-].[Na+].[Bi+3] MFHMDPATIIJVTE-UHFFFAOYSA-K 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- FGOQDABVCOAPHM-UHFFFAOYSA-N CC=1NSC=CC1 Chemical compound CC=1NSC=CC1 FGOQDABVCOAPHM-UHFFFAOYSA-N 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- DBBYYRWVNDQECM-CDWOPPGASA-N CG-1521 Chemical compound ONC(=O)\C=C\C=C\C=C\C1=CC=CC=C1 DBBYYRWVNDQECM-CDWOPPGASA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 description 1
- 101150011193 CYP26A1 gene Proteins 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 101100186605 Caenorhabditis elegans ncx-6 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 241000189662 Calla Species 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005745 Captan Substances 0.000 description 1
- 241001060848 Carapidae Species 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 description 1
- 229940122805 Cathepsin S inhibitor Drugs 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000026368 Cestode infections Diseases 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- NENBAISIHCWPKP-UHFFFAOYSA-N Clofenamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NENBAISIHCWPKP-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- XXZAOMJCZBZKPV-UHFFFAOYSA-N DL-bornyl chloride Natural products C1CC2(C)C(Cl)CC1C2(C)C XXZAOMJCZBZKPV-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N Diethylhexyl phthalate Natural products CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- CKNOLMVLQUPVMU-XOMFLMSUSA-N Digitalin Natural products O(C)[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H]([C@H](O)C5)C5=CC(=O)OC5)CC4)CC3)CC2)[C@@H]1O CKNOLMVLQUPVMU-XOMFLMSUSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- JSBWLMOPVBHTTO-UHFFFAOYSA-N Dipegine Natural products O=C1N2C(CCC2=Nc3ccccc13)C4N5CCCC5=Nc6ccccc46 JSBWLMOPVBHTTO-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- CTSPAMFJBXKSOY-UHFFFAOYSA-N Ellipticine Natural products N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 239000005901 Flubendiamide Substances 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 239000005786 Flutolanil Substances 0.000 description 1
- 239000005788 Fluxapyroxad Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- 229920001386 Gefarnate Polymers 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 241000782205 Guibourtia conjugata Species 0.000 description 1
- 239000008961 HMPL-004 Substances 0.000 description 1
- 108010024770 HP 228 Proteins 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PAZQYDJGLKSCSI-UHFFFAOYSA-N Heptabarbital Chemical compound C=1CCCCCC=1C1(CC)C(=O)NC(=O)NC1=O PAZQYDJGLKSCSI-UHFFFAOYSA-N 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- LJOQGZACKSYWCH-AFHBHXEDSA-N Hydroquinidine Natural products C1=C(OC)C=C2C([C@@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-AFHBHXEDSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 229920002177 Icodextrin Polymers 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- CBIAWPMZSFFRGN-UHFFFAOYSA-N Indiplon Chemical compound CC(=O)N(C)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C(=O)C=2SC=CC=2)=C1 CBIAWPMZSFFRGN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 108010070919 LJP 1082 Proteins 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- GQNZGCARKRHPOH-GSSUJARLSA-N Midecamycin acetate Chemical compound CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](OC2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C GQNZGCARKRHPOH-GSSUJARLSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- GNJCUHZOSOYIEC-GAROZEBRSA-N Morphine-6-glucuronide Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)O)O[C@@H]1[C@]52CCN3C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O GNJCUHZOSOYIEC-GAROZEBRSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- YLJXZSWHZFXCDY-UHFFFAOYSA-N Myxoviromycin Natural products NC1CCC(C(=O)NCCC(N)=N)C1 YLJXZSWHZFXCDY-UHFFFAOYSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 1
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- RGWFVVKSJUSKTE-UHFFFAOYSA-N N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-4-(1,3-thiazol-4-yl)benzamide Chemical group COC1=CC=CC=C1N1CCN(CCCCNC(=O)C=2C=CC(=CC=2)C=2N=CSC=2)CC1 RGWFVVKSJUSKTE-UHFFFAOYSA-N 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229940125652 NAMI Drugs 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- HSVIINWFPKEOEQ-NSHDSACASA-N Ofloxacin methyl ester Chemical compound C([C@H](C)N1C=C(C(C(=C11)C=C2F)=O)C(=O)OC)OC1=C2N1CCN(C)CC1 HSVIINWFPKEOEQ-NSHDSACASA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 description 1
- KMXHEXRPYSXLRN-JDVQERKKSA-N PS-519 Chemical compound N1C(=O)[C@H](CCC)[C@@H]2OC(=O)[C@@]21[C@@H](O)C(C)C KMXHEXRPYSXLRN-JDVQERKKSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 102100029500 Prostasin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000377350 Puan Species 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- CPFNIKYEDJFRAT-UHFFFAOYSA-N Strospasid Natural products OC1C(OC)C(O)C(C)OC1OC1CC(CCC2C3(CC(O)C(C3(C)CCC32)C=2COC(=O)C=2)O)C3(C)CC1 CPFNIKYEDJFRAT-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- ZWTVVWUOTJRXKM-UHFFFAOYSA-N Tonapofylline Chemical compound C1CC(CCC(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 ZWTVVWUOTJRXKM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- CKNOLMVLQUPVMU-UHFFFAOYSA-N UNPD183315 Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)C(O)C1OC(C1)CCC2(C)C1CCC(C1(CC3O)O)C2CCC1(C)C3C1=CC(=O)OC1 CKNOLMVLQUPVMU-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- JGGNOCUEWOGWPL-MUUNZHRXSA-N [(2R)-2-(4-carboxybutoxy)-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OCCCCC(O)=O)COP([O-])(=O)OCC[N+](C)(C)C JGGNOCUEWOGWPL-MUUNZHRXSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- XAEMHHAVNYDWEO-CVEVMTCXSA-N [1-[(4e,9e,12e)-hexadeca-4,9,12-trienoyl]oxy-3-[(6e,10e,12e)-hexadeca-6,10,12-trienoyl]oxypropan-2-yl] 2-(trimethylazaniumyl)ethyl phosphate;(2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3- Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1.CCC\C=C\C\C=C\CCC\C=C\CCC(=O)OCC(OP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCC\C=C\CC\C=C\C=C\CCC XAEMHHAVNYDWEO-CVEVMTCXSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YDBCQZCJDPGBBE-BVYOMHTDSA-N [2-(4-methoxyphenyl)-2-oxoethyl] (2z,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound C1=CC(OC)=CC=C1C(=O)COC(=O)\C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C YDBCQZCJDPGBBE-BVYOMHTDSA-N 0.000 description 1
- PZDPVSFZTKORSP-OAHLLOKOSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-[[(3r)-3-aminobutyl]amino]butyl]carbamate Chemical compound C[C@@H](N)CCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N PZDPVSFZTKORSP-OAHLLOKOSA-N 0.000 description 1
- WTAVOESJEWSDJC-OBOLPPCUSA-N [2-methoxy-4-[(E)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound COc1cc(\C=C\C(=O)OCCCCO[N+]([O-])=O)ccc1OC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C WTAVOESJEWSDJC-OBOLPPCUSA-N 0.000 description 1
- FDLQZKYLHJJBHD-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(CN)=C1 FDLQZKYLHJJBHD-UHFFFAOYSA-N 0.000 description 1
- QPMYZGDVKZVLDG-UHFFFAOYSA-N [4,5-bis(acetyloxymethyl)-2-methylpyridin-3-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC1=C(C)N=CC(COC(C)=O)=C1COC(C)=O QPMYZGDVKZVLDG-UHFFFAOYSA-N 0.000 description 1
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
- CWXVMYDJJNKKQC-UHFFFAOYSA-N [ClH]1N=CC=CC=C1 Chemical compound [ClH]1N=CC=CC=C1 CWXVMYDJJNKKQC-UHFFFAOYSA-N 0.000 description 1
- FZDSRQVIUUCVMI-UHFFFAOYSA-N [ClH]1N=CCC1 Chemical compound [ClH]1N=CCC1 FZDSRQVIUUCVMI-UHFFFAOYSA-N 0.000 description 1
- OOIOHEBTXPTBBE-UHFFFAOYSA-N [Na].[Fe] Chemical compound [Na].[Fe] OOIOHEBTXPTBBE-UHFFFAOYSA-N 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- GIEAQDPIWWODTH-UHFFFAOYSA-N [Na].[Na].[Na].[Ca] Chemical compound [Na].[Na].[Na].[Ca] GIEAQDPIWWODTH-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960005488 aceglutamide Drugs 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 1
- 229950000146 acifran Drugs 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229940019903 aclidinium Drugs 0.000 description 1
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- PZMVOUYYNKPMSI-UHFFFAOYSA-N adrenalone Chemical compound CNCC(=O)C1=CC=C(O)C(O)=C1 PZMVOUYYNKPMSI-UHFFFAOYSA-N 0.000 description 1
- 229960002892 adrenalone Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OOUACICUAVTCEC-LZHWUUGESA-N aezs-108 Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OOUACICUAVTCEC-LZHWUUGESA-N 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229950006816 albaconazole Drugs 0.000 description 1
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- VFRROHXSMXFLSN-KVTDHHQDSA-N aldehydo-D-mannose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O VFRROHXSMXFLSN-KVTDHHQDSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 108010050181 aleurone Proteins 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- JMLGXYWHNOKLBE-HOTXNYTESA-A alicaforsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JMLGXYWHNOKLBE-HOTXNYTESA-A 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 229950004424 alovudine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229950007522 altizide Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- GTQLIPQFXVKRKJ-UNSMHXHVSA-N altropane Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\I)[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-UNSMHXHVSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 229940009861 aluminum chloride hexahydrate Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- QFIGQGUHYKRFAI-UHFFFAOYSA-K aluminum;trichlorate Chemical compound [Al+3].[O-]Cl(=O)=O.[O-]Cl(=O)=O.[O-]Cl(=O)=O QFIGQGUHYKRFAI-UHFFFAOYSA-K 0.000 description 1
- 229960000845 alverine Drugs 0.000 description 1
- ZPFXAOWNKLFJDN-UHFFFAOYSA-N alverine Chemical compound C=1C=CC=CC=1CCCN(CC)CCCC1=CC=CC=C1 ZPFXAOWNKLFJDN-UHFFFAOYSA-N 0.000 description 1
- 229960004516 alvimopan Drugs 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 1
- 229950008930 amfenac Drugs 0.000 description 1
- JHQKUXXJPHSPOL-UHFFFAOYSA-N amidotrizoic acid dihydrate Chemical compound O.O.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I JHQKUXXJPHSPOL-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000004469 amino acid formulation Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229960004567 aminohippuric acid Drugs 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- YZQNFFLGIYEXMM-UHFFFAOYSA-N aminopromazine Chemical compound C1=CC=C2N(CC(CN(C)C)N(C)C)C3=CC=CC=C3SC2=C1 YZQNFFLGIYEXMM-UHFFFAOYSA-N 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960002980 amitriptyline oxide Drugs 0.000 description 1
- ZPMKQFOGINQDAM-UHFFFAOYSA-N amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940090948 ammonium benzoate Drugs 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 229940077484 ammonium bromide Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940063284 ammonium salicylate Drugs 0.000 description 1
- 229940039409 ammonium valerate Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229960001444 amodiaquine Drugs 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 229960005238 anethole trithione Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 229950001104 anhydrovinblastine Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- IMHBYKMAHXWHRP-UHFFFAOYSA-N anilazine Chemical compound ClC1=CC=CC=C1NC1=NC(Cl)=NC(Cl)=N1 IMHBYKMAHXWHRP-UHFFFAOYSA-N 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 229950002465 apaziquone Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 description 1
- 229960005397 arbekacin Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- MDJRZSNPHZEMJH-MTMZYOSNSA-N artisone acetate Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 MDJRZSNPHZEMJH-MTMZYOSNSA-N 0.000 description 1
- MGYMHQJELJYRQS-ZJUUUORDSA-N ascaridole Natural products C1C[C@]2(C)OO[C@@]1(C(C)C)C=C2 MGYMHQJELJYRQS-ZJUUUORDSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960000202 aspoxicillin Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 description 1
- 229960002403 atosiban Drugs 0.000 description 1
- 108700007535 atosiban Proteins 0.000 description 1
- 229960001862 atracurium Drugs 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- LHIALLMPKJMSIQ-NSCUHMNNSA-N azanidazole Chemical compound C1=C([N+]([O-])=O)N(C)C(\C=C\C=2N=C(N)N=CC=2)=N1 LHIALLMPKJMSIQ-NSCUHMNNSA-N 0.000 description 1
- 229960004904 azanidazole Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 229950000805 balofloxacin Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940092690 barium sulfate Drugs 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- 229960001871 benproperine Drugs 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- SPPTWHFVYKCNNK-FQEVSTJZSA-N bentiromide Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)[C@@H](NC(=O)C=1C=CC=CC=1)CC1=CC=C(O)C=C1 SPPTWHFVYKCNNK-FQEVSTJZSA-N 0.000 description 1
- 229960002515 bentiromide Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KXNWPJLDKSLKSB-UHFFFAOYSA-N benzenesulfonic acid;1-[8-(2,4-dichlorophenyl)-2-methylquinolin-4-yl]-3,6-dihydro-2h-pyridine-4-carboxamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C=12C=CC=C(C=3C(=CC(Cl)=CC=3)Cl)C2=NC(C)=CC=1N1CCC(C(N)=O)=CC1 KXNWPJLDKSLKSB-UHFFFAOYSA-N 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 229960004001 benznidazole Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 description 1
- 229960003789 benzonatate Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- YYMVPVZYUYQSJE-UHFFFAOYSA-N benzyl-[2-(2,6-dimethylanilino)-2-oxoethyl]-diethylazanium;benzoate;hydrate Chemical compound O.[O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C YYMVPVZYUYQSJE-UHFFFAOYSA-N 0.000 description 1
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- QFFGVLORLPOAEC-SNVBAGLBSA-N besifloxacin Chemical compound C1[C@H](N)CCCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QFFGVLORLPOAEC-SNVBAGLBSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- OFYVIGTWSQPCLF-NWDGAFQWSA-N bicifadine Chemical compound C1=CC(C)=CC=C1[C@@]1(CNC2)[C@H]2C1 OFYVIGTWSQPCLF-NWDGAFQWSA-N 0.000 description 1
- 229950010365 bicifadine Drugs 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 229940104825 bismuth aluminate Drugs 0.000 description 1
- RAQGPBPLJWJAFE-UHFFFAOYSA-N bismuth;ethane Chemical compound CC[Bi] RAQGPBPLJWJAFE-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- NUNIWXHYABYXKF-UHFFFAOYSA-N bromazine Chemical compound C=1C=C(Br)C=CC=1C(OCCN(C)C)C1=CC=CC=C1 NUNIWXHYABYXKF-UHFFFAOYSA-N 0.000 description 1
- 229960003166 bromazine Drugs 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- RUEKPBLTWGFBOD-UHFFFAOYSA-N bromoethyne Chemical group BrC#C RUEKPBLTWGFBOD-UHFFFAOYSA-N 0.000 description 1
- 229960001034 bromopride Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- PXGPQCBSBQOPLZ-UHFFFAOYSA-N butanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCC(O)=O PXGPQCBSBQOPLZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- YBCNXCRZPWQOBR-WVHCHWADSA-N butylscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 YBCNXCRZPWQOBR-WVHCHWADSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- OPFRMDSDETYVHC-UHFFFAOYSA-L cadmium(2+);2-carboxyphenolate Chemical compound [Cd+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O OPFRMDSDETYVHC-UHFFFAOYSA-L 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- KGWAITXYALRFDQ-DKWTVANSSA-L calcium;(2s)-2-(carbamoylamino)butanedioate Chemical compound [Ca+2].NC(=O)N[C@H](C([O-])=O)CC([O-])=O KGWAITXYALRFDQ-DKWTVANSSA-L 0.000 description 1
- LNMAXKMUGYXKPJ-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 LNMAXKMUGYXKPJ-UHFFFAOYSA-L 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- 229950008808 caldaret Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 229940117949 captan Drugs 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229940078916 carbamide peroxide Drugs 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- DLJKPYFALUEJCK-MRVZPHNRSA-N carboprost Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O DLJKPYFALUEJCK-MRVZPHNRSA-N 0.000 description 1
- 229960003395 carboprost Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960002142 cefditoren pivoxil Drugs 0.000 description 1
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 description 1
- 229950000726 cefetamet pivoxil Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- 229960002620 cefuroxime axetil Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- XMEVHPAGJVLHIG-DXDJYCPMSA-N chembl1950577 Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-DXDJYCPMSA-N 0.000 description 1
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 1
- XSRKBFUVSRRJDX-GGZJQHSXSA-N chembl475786 Chemical compound C(/[C@H]1OC[C@@H](CO1)S[C@H](C)[C@](O)(CN1N=CN=C1)C=1C(=CC(F)=CC=1)F)=C\C=C\C1=CC=C(C#N)C=C1F XSRKBFUVSRRJDX-GGZJQHSXSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- NPNSVNGQJGRSNR-UHFFFAOYSA-N chembl73193 Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)O)=C(F)C(N(CC(O)=O)C)=C(F)C=1OC(C=1)=CC=CC=1C1=NCCN1C NPNSVNGQJGRSNR-UHFFFAOYSA-N 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 description 1
- 229960004736 chloroxine Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 1
- 229960002099 cilansetron Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RCUDFXMNPQNBDU-VOTSOKGWSA-N cinepazide Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 RCUDFXMNPQNBDU-VOTSOKGWSA-N 0.000 description 1
- 229960004201 cinepazide Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- 229960005338 clevudine Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960002883 clofenamide Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960001184 clopenthixol Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960002219 cloprednol Drugs 0.000 description 1
- YTJIBEDMAQUYSZ-FDNPDPBUSA-N cloprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C=C(Cl)C2=C1 YTJIBEDMAQUYSZ-FDNPDPBUSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940098691 coco monoethanolamide Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- OTGAHJPFNKQGAE-UHFFFAOYSA-N cresatin Chemical compound CC(=O)OC1=CC=CC(C)=C1 OTGAHJPFNKQGAE-UHFFFAOYSA-N 0.000 description 1
- 229960002042 croconazole Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- LGLFFNDHMLKUMI-UHFFFAOYSA-N crystal violet cation Chemical compound C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)N(C)C)=C1C=CC(=[N+](C)C)C=C1 LGLFFNDHMLKUMI-UHFFFAOYSA-N 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000011641 cupric citrate Substances 0.000 description 1
- 235000019855 cupric citrate Nutrition 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 150000001912 cyanamides Chemical group 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- DVIDIZXCFDHODG-UHFFFAOYSA-N cyclopentylphosphane Chemical compound PC1CCCC1 DVIDIZXCFDHODG-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 description 1
- 229960002947 dapiprazole Drugs 0.000 description 1
- 229950006497 dapivirine Drugs 0.000 description 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 1
- 229960005217 dapoxetine Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- XXLZPUYGHQWHRN-RPBOFIJWSA-N dehydroemetine Chemical compound COC1=C(OC)C=C2[C@@H]3CC(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4)=C(CC)CN3CCC2=C1 XXLZPUYGHQWHRN-RPBOFIJWSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960001610 denatonium benzoate Drugs 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- RUQATQQNXCPTLL-PQMJGINDSA-N desoxymycin Chemical compound O1[C@@H](CO)[C@H](O)[C@@H](O)[C@H](NC)[C@@H]1O[C@@H]1[C@@H](CO)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O RUQATQQNXCPTLL-PQMJGINDSA-N 0.000 description 1
- 229950009432 desoxymycin Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NFHRQQKPEBFUJK-HSZRJFAPSA-N devazepide Chemical compound O=C([C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)N=1)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 NFHRQQKPEBFUJK-HSZRJFAPSA-N 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960003428 dexibuprofen Drugs 0.000 description 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- WMUHBTATSZQNJG-TWOHWVPZSA-N dfa iv Chemical compound C([C@H]1O[C@@](OC2)([C@H]([C@@H]1O)O)CO)O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H]2O1 WMUHBTATSZQNJG-TWOHWVPZSA-N 0.000 description 1
- WMUHBTATSZQNJG-UHFFFAOYSA-N di-D-fructose anhydride IV Natural products C1OC(CO)(C(C2O)O)OC2COC2(CO)C(O)C(O)C1O2 WMUHBTATSZQNJG-UHFFFAOYSA-N 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 1
- 229960005223 diatrizoic acid Drugs 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 239000012954 diazonium Chemical group 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- CKNOLMVLQUPVMU-YMMLYESFSA-N digitalin Chemical compound C1([C@@H]2[C@@]3(C)CC[C@H]4[C@H]([C@]3(C[C@@H]2O)O)CC[C@H]2[C@]4(C)CC[C@@H](C2)O[C@H]2[C@H](O)[C@H]([C@H]([C@@H](C)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)OC)=CC(=O)OC1 CKNOLMVLQUPVMU-YMMLYESFSA-N 0.000 description 1
- 229950004590 digitalin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- 229960003061 dihydroemetine Drugs 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 229960000465 dihydrotachysterol Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 235000010300 dimethyl dicarbonate Nutrition 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 239000009858 dingxin Substances 0.000 description 1
- YKBZOVFACRVRJN-UHFFFAOYSA-N dinotefuran Chemical compound [O-][N+](=O)\N=C(/NC)NCC1CCOC1 YKBZOVFACRVRJN-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- PPSZHCXTGRHULJ-UHFFFAOYSA-N dioxazine Chemical compound O1ON=CC=C1 PPSZHCXTGRHULJ-UHFFFAOYSA-N 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 229940035422 diphenylamine Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 229950003529 diquafosol Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 229940047642 disodium cocoamphodiacetate Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 229940079896 disodium hydrogen citrate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 229940079886 disodium lauryl sulfosuccinate Drugs 0.000 description 1
- 229940047649 disodium sulfosalicylate Drugs 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 description 1
- CSVUNXDXKHELCR-UHFFFAOYSA-L disodium;3-carboxy-4-oxidobenzenesulfonate Chemical compound [Na+].[Na+].OC(=O)C1=CC(S([O-])(=O)=O)=CC=C1[O-] CSVUNXDXKHELCR-UHFFFAOYSA-L 0.000 description 1
- MCPLVIGCWWTHFH-UHFFFAOYSA-M disodium;4-[4-[[4-(4-sulfoanilino)phenyl]-[4-(4-sulfonatophenyl)azaniumylidenecyclohexa-2,5-dien-1-ylidene]methyl]anilino]benzenesulfonate Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)O)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-M 0.000 description 1
- KHIQYZGEUSTKSB-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O.CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O KHIQYZGEUSTKSB-UHFFFAOYSA-L 0.000 description 1
- BJTHMUJCKBTCFR-UHFFFAOYSA-L disodium;ethane-1,2-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCS([O-])(=O)=O BJTHMUJCKBTCFR-UHFFFAOYSA-L 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- DKGJFKPIUSHDIT-UHFFFAOYSA-L disodium;propane-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCS([O-])(=O)=O DKGJFKPIUSHDIT-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 229940048879 dl tartaric acid Drugs 0.000 description 1
- 229940096997 dl- distearoylphosphatidylcholine Drugs 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229960000629 domiphen Drugs 0.000 description 1
- YXUPZGKORWTXID-UHFFFAOYSA-N domiphen Chemical compound CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 YXUPZGKORWTXID-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 description 1
- 229960004483 doxofylline Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 1
- 229960002065 drotaverine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 108010067071 duramycin Proteins 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 1
- 229950002377 ebrotidine Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 229950009714 ecopipam Drugs 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 description 1
- 229960003937 efinaconazole Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229940108623 eicosenoic acid Drugs 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229950010996 enfenamic acid Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 229960002565 eperisone Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229950010920 eptazocine Drugs 0.000 description 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 description 1
- 229960003262 erdosteine Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- FEMINZOAAWPBPP-RHMAUSBNSA-J eritoran tetrasodium Chemical compound [Na+].[Na+].[Na+].[Na+].O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP([O-])([O-])=O)[C@@H](COC)O1 FEMINZOAAWPBPP-RHMAUSBNSA-J 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- TYQXKHPOXXXCTP-CSLYCKPJSA-N erythromycin A 2'-propanoate Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TYQXKHPOXXXCTP-CSLYCKPJSA-N 0.000 description 1
- 229960004213 erythromycin lactobionate Drugs 0.000 description 1
- 229950001028 erythromycin propionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 description 1
- 229960003233 eslicarbazepine acetate Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- XIQVNETUBQGFHX-JOCHJYFZSA-N esoxybutynin Chemical compound C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-JOCHJYFZSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 description 1
- 229960001588 ethacridine Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000569 ethoheptazine Drugs 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- LENNRXOJHWNHSD-UHFFFAOYSA-N ethylnorepinephrine Chemical compound CCC(N)C(O)C1=CC=C(O)C(O)=C1 LENNRXOJHWNHSD-UHFFFAOYSA-N 0.000 description 1
- 229960002267 ethylnorepinephrine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 229960004585 etidronic acid Drugs 0.000 description 1
- 229960001003 etilamfetamine Drugs 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 229960005437 etoperidone Drugs 0.000 description 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004514 etozolin Drugs 0.000 description 1
- ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 description 1
- 229950004912 etrolizumab Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- VZPPEUOYDWPUKO-MQWDNKACSA-N fenbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C=1C=CC=CC=1)OC1=CC=CC=C1 VZPPEUOYDWPUKO-MQWDNKACSA-N 0.000 description 1
- 229950002965 fenbenicillin Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- UBAJTZKNDCEGKL-UHFFFAOYSA-N fenoverine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)CN1CCN(CC=2C=C3OCOC3=CC=2)CC1 UBAJTZKNDCEGKL-UHFFFAOYSA-N 0.000 description 1
- 229960001966 fenoverine Drugs 0.000 description 1
- 229960004970 fenoxazoline Drugs 0.000 description 1
- GFYSWQDCHLWRMQ-UHFFFAOYSA-N fenoxazoline Chemical compound CC(C)C1=CC=CC=C1OCC1=NCCN1 GFYSWQDCHLWRMQ-UHFFFAOYSA-N 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229960002912 fenspiride Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229950005849 firategrast Drugs 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 1
- 229960002053 flibanserin Drugs 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960000702 flumequine Drugs 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940044117 fluorodeoxyglucose f18 Drugs 0.000 description 1
- RLWXXXHAQBWSPA-UHFFFAOYSA-N fluoromethanol Chemical compound OCF RLWXXXHAQBWSPA-UHFFFAOYSA-N 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- SXSGXWCSHSVPGB-UHFFFAOYSA-N fluxapyroxad Chemical compound FC(F)C1=NN(C)C=C1C(=O)NC1=CC=CC=C1C1=CC(F)=C(F)C(F)=C1 SXSGXWCSHSVPGB-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940094417 fumaryl diketopiperazine Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950000337 furaltadone Drugs 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- TUWCZRFHNIOVTC-UHFFFAOYSA-N fuzapladib Chemical compound CCS(=O)(=O)NC1=NC=C(C(F)(F)F)C=C1NC(=O)C1CCCCC1 TUWCZRFHNIOVTC-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229950004346 gaboxadol Drugs 0.000 description 1
- 229960003411 gadobutrol Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229940075613 gadolinium oxide Drugs 0.000 description 1
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 1
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229950006567 ganaxolone Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- SDIFKXLSGXCGEN-WJUBNSBASA-L gantacurium chloride Chemical compound [Cl-].[Cl-].C1([C@H]2C3=CC(OC)=C(OC)C=C3CC[N@+]2(C)CCCOC(=O)/C=C(\Cl)C(=O)OCCC[N@@+]2(CCC=3C=C(C(=CC=3[C@H]2CC=2C=C(OC)C(OC)=C(OC)C=2)OC)OC)C)=CC(OC)=C(OC)C(OC)=C1 SDIFKXLSGXCGEN-WJUBNSBASA-L 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960003779 gefarnate Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229950004781 gemcabene Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 229940116922 gentisic acid ethanolamide Drugs 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229960004761 gestrinone Drugs 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- SQQCWHCJRWYRLB-AGNGBHFPSA-N glucosulfone Chemical compound C1=CC(NC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)S(O)(=O)=O)=CC=C1S(=O)(=O)C1=CC=C(NC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)S(O)(=O)=O)C=C1 SQQCWHCJRWYRLB-AGNGBHFPSA-N 0.000 description 1
- 229950009858 glucosulfone Drugs 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229960003707 glutamic acid hydrochloride Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- AZMMUMQYPBKXHS-UHFFFAOYSA-N gold sodium Chemical compound [Na].[Au] AZMMUMQYPBKXHS-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- ZFSXZJXLKAJIGS-UHFFFAOYSA-N halocarban Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=CC(Cl)=CC=2)=C1 ZFSXZJXLKAJIGS-UHFFFAOYSA-N 0.000 description 1
- 229950006625 halocarban Drugs 0.000 description 1
- 229950000958 halofenate Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- YVWGMAFXEJHFRO-UHFFFAOYSA-N halopropane Chemical compound FC(F)C(F)(F)CBr YVWGMAFXEJHFRO-UHFFFAOYSA-N 0.000 description 1
- 229950000188 halopropane Drugs 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 229940016462 heptabarbital Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 description 1
- SLKWROUNLHVIIQ-UHFFFAOYSA-N hexachlorocyclohexa-2,5-dien-1-one Chemical compound ClC1=C(Cl)C(Cl)(Cl)C(Cl)=C(Cl)C1=O SLKWROUNLHVIIQ-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-O hexylazanium Chemical compound CCCCCC[NH3+] BMVXCPBXGZKUPN-UHFFFAOYSA-O 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- NYQCKFLLTCINSJ-UHFFFAOYSA-N hydron;3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1h-pyridazin-6-one;chloride Chemical compound Cl.N1C(=O)CCC(C=2C=CC(NC=3C=CN=CC=3)=CC=2)=N1 NYQCKFLLTCINSJ-UHFFFAOYSA-N 0.000 description 1
- 229960000811 hydroquinidine Drugs 0.000 description 1
- 229960004251 hydroquinine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- JRFKIOFLCXKVOT-UHFFFAOYSA-N hydroxymethylnicotinamide Chemical compound OCNC(=O)C1=CC=CN=C1 JRFKIOFLCXKVOT-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229940072322 hylan Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229960004053 ibutilide Drugs 0.000 description 1
- 229940016836 icodextrin Drugs 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 229960003998 ifenprodil Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229950003909 iguratimod Drugs 0.000 description 1
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 description 1
- 229950008491 ilaprazole Drugs 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- XJYNBZQTAZDMHZ-UHFFFAOYSA-N imidacrine Chemical compound O.Cl.Cl.O=C1C2=CC(O)=CC=C2N2C=NC3=CC=C(NCCN(CC)CC)C1=C32 XJYNBZQTAZDMHZ-UHFFFAOYSA-N 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- WXEMWBBXVXHEPU-XNPJUPKFSA-L imisopasem manganese Chemical compound Cl[Mn]Cl.N([C@@H]1CCCC[C@H]1NC1)CCN[C@@H]2CCCC[C@H]2NCC2=CC=CC1=N2 WXEMWBBXVXHEPU-XNPJUPKFSA-L 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MNLULKBKWKTZPE-UHFFFAOYSA-N indantadol Chemical compound C1=CC=C2CC(NCC(=O)N)CC2=C1 MNLULKBKWKTZPE-UHFFFAOYSA-N 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 229950003867 indiplon Drugs 0.000 description 1
- 229950007467 indisetron Drugs 0.000 description 1
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 description 1
- 229960003422 indobufen Drugs 0.000 description 1
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- HXLVCCRPDYIRRX-UHFFFAOYSA-N iodoamine Chemical compound IN HXLVCCRPDYIRRX-UHFFFAOYSA-N 0.000 description 1
- VJOVAKSZILJDBB-UHFFFAOYSA-N iodol Chemical compound IC=1NC(I)=C(I)C=1I VJOVAKSZILJDBB-UHFFFAOYSA-N 0.000 description 1
- 229950000077 iodol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 229960002611 ioxilan Drugs 0.000 description 1
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 108010084684 iron protein succinylate Proteins 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960003825 ivabradine Drugs 0.000 description 1
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- KCWGETCFOVJEPI-UHFFFAOYSA-N jtv-519 Chemical compound C1C2=CC(OC)=CC=C2SCCN1C(=O)CCN(CC1)CCC1CC1=CC=CC=C1 KCWGETCFOVJEPI-UHFFFAOYSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 1
- 229960000194 kebuzone Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 108010075606 kynostatin 272 Proteins 0.000 description 1
- 229960002623 lacosamide Drugs 0.000 description 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960001159 lactitol monohydrate Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- SFWLDKQAUHFCBS-WWXQEMPQSA-N lancovutide Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@H]([C@@H](SC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSC3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 SFWLDKQAUHFCBS-WWXQEMPQSA-N 0.000 description 1
- 229950010163 lanoconazole Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 1
- 229960001633 lanthanum carbonate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940100556 laureth-23 Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960004771 levobetaxolol Drugs 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960003221 levopropoxyphene Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 description 1
- 229950009365 limaprost Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 lofentanil Drugs 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229950002384 loflucarban Drugs 0.000 description 1
- ZHNUMLOCJMCLIT-UHFFFAOYSA-N loflucarban Chemical compound C1=CC(F)=CC=C1NC(=S)NC1=CC(Cl)=CC(Cl)=C1 ZHNUMLOCJMCLIT-UHFFFAOYSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- 229950010501 lotrafiban Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 1
- 229960000345 lubiprostone Drugs 0.000 description 1
- 229930186179 lupulin Natural products 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 108700003825 lysine(6)-doxorubicin LHRH Proteins 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- YUZJJFWCXJDFOQ-UHFFFAOYSA-K manganese(3+);2-methoxy-6-[2-[(3-methoxy-2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;chloride Chemical compound [Cl-].[Mn+3].COC1=CC=CC(C=NCCN=CC=2C(=C(OC)C=CC=2)[O-])=C1[O-] YUZJJFWCXJDFOQ-UHFFFAOYSA-K 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 229960002937 meldonium Drugs 0.000 description 1
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 1
- YSRVJVDFHZYRPA-UHFFFAOYSA-N melem Chemical compound NC1=NC(N23)=NC(N)=NC2=NC(N)=NC3=N1 YSRVJVDFHZYRPA-UHFFFAOYSA-N 0.000 description 1
- 229960004805 melengestrol Drugs 0.000 description 1
- OKHAOBQKCCIRLO-IBVJIVQJSA-N melengestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)C)(O)[C@@]1(C)CC2 OKHAOBQKCCIRLO-IBVJIVQJSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- VYQSSWZYPCCBRN-HZSPNIEDSA-N menthyl isovalerate Chemical compound CC(C)CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C VYQSSWZYPCCBRN-HZSPNIEDSA-N 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- 229960000906 mephenytoin Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical compound N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 description 1
- 229940075610 mercuric cyanide Drugs 0.000 description 1
- NGYIMTKLQULBOO-UHFFFAOYSA-L mercury dibromide Chemical compound Br[Hg]Br NGYIMTKLQULBOO-UHFFFAOYSA-L 0.000 description 1
- PCWIWQHAGMGLFA-CVBJKYQLSA-L mercury(2+);(z)-octadec-9-enoate Chemical compound [Hg+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O PCWIWQHAGMGLFA-CVBJKYQLSA-L 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- ZQEIXNIJLIKNTD-GFCCVEGCSA-N metalaxyl-M Chemical compound COCC(=O)N([C@H](C)C(=O)OC)C1=C(C)C=CC=C1C ZQEIXNIJLIKNTD-GFCCVEGCSA-N 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 229950008620 methopromazine Drugs 0.000 description 1
- VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 description 1
- MMHHPKCJJIFLBQ-QFIPXVFZSA-N methyl (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoate Chemical compound N([C@@H](CC=1C=CC(=CC=1)N1C(C2=CC(=CC=C2N(C)C1=O)N(C)C)=O)C(=O)OC)C(=O)C1=C(Cl)C=CC=C1Cl MMHHPKCJJIFLBQ-QFIPXVFZSA-N 0.000 description 1
- FLEVIENZILQUKB-DMJMAAGCSA-N methyl 4-[3-[6-amino-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CCC3CCC(CC3)C(=O)OC)=NC(N)=C2N=C1 FLEVIENZILQUKB-DMJMAAGCSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960001094 midodrine Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960000931 miocamycin Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229950002481 moprolol Drugs 0.000 description 1
- LFTFGCDECFPSQD-UHFFFAOYSA-N moprolol Chemical compound COC1=CC=CC=C1OCC(O)CNC(C)C LFTFGCDECFPSQD-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
- SKDZEPBJPGSFHS-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)N(CCO)CCO SKDZEPBJPGSFHS-UHFFFAOYSA-N 0.000 description 1
- ARGDYOIRHYLIMT-UHFFFAOYSA-N n,n-dichloro-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(Cl)Cl)C=C1 ARGDYOIRHYLIMT-UHFFFAOYSA-N 0.000 description 1
- DADSZOFTIIETSV-UHFFFAOYSA-N n,n-dichloroaniline Chemical compound ClN(Cl)C1=CC=CC=C1 DADSZOFTIIETSV-UHFFFAOYSA-N 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- APRJFNLVTJWEPP-UHFFFAOYSA-M n,n-diethylcarbamate Chemical compound CCN(CC)C([O-])=O APRJFNLVTJWEPP-UHFFFAOYSA-M 0.000 description 1
- RQTZMTMTBWAQAI-UHFFFAOYSA-N n,n-dimethyl-2-[5-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-3-yl]ethanamine Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C1=CCN(C)CC1 RQTZMTMTBWAQAI-UHFFFAOYSA-N 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- AJBBEYXFRYFVNM-XEMFKVMZSA-N n-(4-cyanophenyl)-2-[4-[2,6-dioxo-1,3-bis(2,2,3,3,3-pentatritiopropyl)-7h-purin-8-yl]phenoxy]acetamide Chemical compound N1C=2C(=O)N(CC([3H])([3H])C([3H])([3H])[3H])C(=O)N(CC([3H])([3H])C([3H])([3H])[3H])C=2N=C1C(C=C1)=CC=C1OCC(=O)NC1=CC=C(C#N)C=C1 AJBBEYXFRYFVNM-XEMFKVMZSA-N 0.000 description 1
- OCKHRKSTDPOHEN-BQYQJAHWSA-N n-(4-methoxyphenyl)sulfonyl-n-[2-[(e)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C)=O)C1=CC=CC=C1\C=C\C1=CC=[N+]([O-])C=C1 OCKHRKSTDPOHEN-BQYQJAHWSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- ACAXGYADTLFREX-CQSZACIVSA-N n-[(2r)-1-(dimethylamino)propan-2-yl]-4-methoxybenzo[a]phenazine-11-carboxamide Chemical compound C1=CC2=NC3=CC=CC(C(=O)N[C@H](C)CN(C)C)=C3N=C2C2=C1C(OC)=CC=C2 ACAXGYADTLFREX-CQSZACIVSA-N 0.000 description 1
- IHDRUIHIJWCTIY-JOCHJYFZSA-N n-[(2r)-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(C)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 IHDRUIHIJWCTIY-JOCHJYFZSA-N 0.000 description 1
- BPLYVSYSBPLDOA-GYOJGHLZSA-N n-[(2r,3r)-1,3-dihydroxyoctadecan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-GYOJGHLZSA-N 0.000 description 1
- RHJLQMVZXQKJKB-FPHSVDBKSA-N n-[(2s)-1-[[(e,3s)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)N[C@H](C(=O)N[C@@H](CCC=1C=CC=CC=1)\C=C\S(=O)(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 RHJLQMVZXQKJKB-FPHSVDBKSA-N 0.000 description 1
- LZGACSIEPSVAQK-UHFFFAOYSA-N n-[2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)naphthalen-1-yl]acetamide Chemical compound C1=CC=C2C(NC(=O)C)=C(C(O)(C(F)(F)F)C(F)(F)F)C=CC2=C1 LZGACSIEPSVAQK-UHFFFAOYSA-N 0.000 description 1
- KWQWWUXRGIIBAS-UHFFFAOYSA-N n-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 KWQWWUXRGIIBAS-UHFFFAOYSA-N 0.000 description 1
- YZHGXYNLMHGNJZ-UHFFFAOYSA-N n-[2-[4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)piperidin-1-yl]ethyl]-1-formylpiperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1CN(C=O)CCC1C(=O)NCCN(CC1)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 YZHGXYNLMHGNJZ-UHFFFAOYSA-N 0.000 description 1
- ZOQHJQODUHVVEV-UHFFFAOYSA-N n-[3-amino-4-[2-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1N ZOQHJQODUHVVEV-UHFFFAOYSA-N 0.000 description 1
- 229940099459 n-acetylmethionine Drugs 0.000 description 1
- KGXPDNOBLLACKL-BWLGBDCWSA-N n-benzyl-2-[(3z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydron;chloride Chemical compound Cl.C12=CC(F)=CC=C2\C(=C/C=2C=CN=CC=2)C(C)=C1CC(=O)NCC1=CC=CC=C1 KGXPDNOBLLACKL-BWLGBDCWSA-N 0.000 description 1
- NBMBIEOUVBHEBM-UHFFFAOYSA-N n-benzyl-n-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide Chemical compound C12=NC(C=3C=CC=CC=3)=NC=C2N(C)C(=O)N1CC(=O)N(CC)CC1=CC=CC=C1 NBMBIEOUVBHEBM-UHFFFAOYSA-N 0.000 description 1
- PISQNYYKVIWAKE-UHFFFAOYSA-N n-carbamoyl-n-phenylacetamide Chemical compound CC(=O)N(C(N)=O)C1=CC=CC=C1 PISQNYYKVIWAKE-UHFFFAOYSA-N 0.000 description 1
- CHVZPRDGLWBEMJ-UHFFFAOYSA-N n-chlorobenzenesulfonamide Chemical compound ClNS(=O)(=O)C1=CC=CC=C1 CHVZPRDGLWBEMJ-UHFFFAOYSA-N 0.000 description 1
- QRZLMPANXOGORV-UHFFFAOYSA-N n-cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine Chemical compound N=1C2=CC=CC=C2N2C(C)=CN=C2C=1NC1CCCC1 QRZLMPANXOGORV-UHFFFAOYSA-N 0.000 description 1
- HATVWQUAXNOKEY-UHFFFAOYSA-N n-iodo-1-phenylpropan-2-amine Chemical compound INC(C)CC1=CC=CC=C1 HATVWQUAXNOKEY-UHFFFAOYSA-N 0.000 description 1
- VQVCFYIDCWPSNE-UHFFFAOYSA-N n-methyl-3-[(2-naphthalen-2-ylacetyl)amino]benzamide Chemical compound CNC(=O)C1=CC=CC(NC(=O)CC=2C=C3C=CC=CC3=CC=2)=C1 VQVCFYIDCWPSNE-UHFFFAOYSA-N 0.000 description 1
- BKUFESVLWSPJHJ-UHFFFAOYSA-N n-propan-2-ylaniline;hydrochloride Chemical compound Cl.CC(C)NC1=CC=CC=C1 BKUFESVLWSPJHJ-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229950005705 naftopidil Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229940075566 naphthalene Drugs 0.000 description 1
- HTKWJLCTSHNBEL-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N.C1=C(C=CC2=CC=CC=C12)C(=O)N HTKWJLCTSHNBEL-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 239000010447 natron Substances 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 229950010963 nebracetam Drugs 0.000 description 1
- LCAFGJGYCUMTGS-UHFFFAOYSA-N nebracetam Chemical compound O=C1CC(CN)CN1CC1=CC=CC=C1 LCAFGJGYCUMTGS-UHFFFAOYSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- IKHFJPZQZVMLRH-UHFFFAOYSA-N negamycin Natural products OC(=O)CN(C)NC(=O)CC(N)CC(O)CN IKHFJPZQZVMLRH-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
- 229950004543 neramexane Drugs 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- GXKIIWJLNFCAOA-UHFFFAOYSA-N o-butyl dodecanethioate Chemical compound CCCCCCCCCCCC(=S)OCCCC GXKIIWJLNFCAOA-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960002888 oxitriptan Drugs 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- SPPNVMTVMQOKSC-UHFFFAOYSA-A pentaaluminum decamagnesium hentriacontahydroxide disulfate hydrate Chemical compound O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O SPPNVMTVMQOKSC-UHFFFAOYSA-A 0.000 description 1
- LVECZGHBXXYWBO-UHFFFAOYSA-N pentadecanolide Natural products CC1CCCCCCCCCCCCC(=O)O1 LVECZGHBXXYWBO-UHFFFAOYSA-N 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- OUQWFYPEOAFGGT-UHFFFAOYSA-I pentasodium pentanoate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CCCCC([O-])=O.CCCCC([O-])=O.CCCCC([O-])=O.CCCCC([O-])=O.CCCCC([O-])=O OUQWFYPEOAFGGT-UHFFFAOYSA-I 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- DAFOCGYVTAOKAJ-UHFFFAOYSA-N phenibut Chemical compound OC(=O)CC(CN)C1=CC=CC=C1 DAFOCGYVTAOKAJ-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960003506 piperazine hexahydrate Drugs 0.000 description 1
- AVRVZRUEXIEGMP-UHFFFAOYSA-N piperazine;hexahydrate Chemical compound O.O.O.O.O.O.C1CNCCN1 AVRVZRUEXIEGMP-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229940059101 polycarbophil calcium Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- BFZNCPXNOGIELB-UHFFFAOYSA-N propan-2-yl 10-[5,6-dihexyl-2-(8-oxo-8-propan-2-yloxyoctyl)cyclohex-3-en-1-yl]dec-9-enoate Chemical compound CCCCCCC1C=CC(CCCCCCCC(=O)OC(C)C)C(C=CCCCCCCCC(=O)OC(C)C)C1CCCCCC BFZNCPXNOGIELB-UHFFFAOYSA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Natural products CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N pyrocatechol monomethyl ether Natural products COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical class OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- SCTZUZTYRMOMKT-UHFFFAOYSA-N senicapoc Chemical compound C=1C=C(F)C=CC=1C(C=1C=CC(F)=CC=1)(C(=O)N)C1=CC=CC=C1 SCTZUZTYRMOMKT-UHFFFAOYSA-N 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 229940080299 sodium 2-naphthalenesulfonate Drugs 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940045640 sodium aminobenzoate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229960005076 sodium hypochlorite Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940083599 sodium iodide Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 229940045990 sodium laureth-2 sulfate Drugs 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229940001516 sodium nitrate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940075562 sodium phosphate dihydrate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940057396 sodium polyacrylate (2500000 mw) Drugs 0.000 description 1
- 229940045919 sodium polymetaphosphate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- ZBTUYCUNQBRXOR-UHFFFAOYSA-L sodium succinate hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O ZBTUYCUNQBRXOR-UHFFFAOYSA-L 0.000 description 1
- 229940074453 sodium succinate hexahydrate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 description 1
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 1
- PEVNIEPIRVCPAW-UHFFFAOYSA-J sodium;1h-imidazole;methylsulfinylmethane;ruthenium(3+);tetrachloride Chemical compound [Na+].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].CS(C)=O.C1=CNC=N1 PEVNIEPIRVCPAW-UHFFFAOYSA-J 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- GUQPDKHHVFLXHS-UHFFFAOYSA-M sodium;2-(2-dodecoxyethoxy)ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOS([O-])(=O)=O GUQPDKHHVFLXHS-UHFFFAOYSA-M 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-N sodium;2-hydroxypropane-2-sulfonic acid Chemical compound [Na+].CC(C)(O)S(O)(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-N 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- XETSAYZRDCRPJY-UHFFFAOYSA-M sodium;4-aminobenzoate Chemical compound [Na+].NC1=CC=C(C([O-])=O)C=C1 XETSAYZRDCRPJY-UHFFFAOYSA-M 0.000 description 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 1
- DRHZPIKFHOPWLX-UHFFFAOYSA-M sodium;4-octadecoxy-4-oxo-3-sulfobutanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O DRHZPIKFHOPWLX-UHFFFAOYSA-M 0.000 description 1
- YWPOLRBWRRKLMW-UHFFFAOYSA-M sodium;naphthalene-2-sulfonate Chemical compound [Na+].C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 YWPOLRBWRRKLMW-UHFFFAOYSA-M 0.000 description 1
- QGLITUFXHVRMGV-UHFFFAOYSA-M sodium;tetratriacontyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOS([O-])(=O)=O QGLITUFXHVRMGV-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940094938 stannous 2-ethylhexanoate Drugs 0.000 description 1
- 229940037312 stearamide Drugs 0.000 description 1
- 229940032160 stearamidoethyl diethylamine Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- OPTBBAGXQYOFTL-UHFFFAOYSA-N tetraethylphthalamide Chemical class CCN(CC)C(=O)C1=CC=CC=C1C(=O)N(CC)CC OPTBBAGXQYOFTL-UHFFFAOYSA-N 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- ZXFRFPSZAKNPQQ-YTWAJWBKSA-N tezampanel Chemical compound C([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)O)CC=1N=NNN=1 ZXFRFPSZAKNPQQ-YTWAJWBKSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003567 thiocyanates Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- ZHAKYGFJVGCOAE-UHFFFAOYSA-N topixantrone Chemical compound OCCNCCN1N=C2C3=CN=CC=C3C(=O)C3=C2C1=CC=C3NCCN(C)C ZHAKYGFJVGCOAE-UHFFFAOYSA-N 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- BJIOGJUNALELMI-ONEGZZNKSA-N trans-isoeugenol Chemical compound COC1=CC(\C=C\C)=CC=C1O BJIOGJUNALELMI-ONEGZZNKSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QKHROXOPRBWBDD-UHFFFAOYSA-N tribromometacresol Chemical compound CC1=C(Br)C=C(Br)C(O)=C1Br QKHROXOPRBWBDD-UHFFFAOYSA-N 0.000 description 1
- STDMRMREKPZQFJ-UHFFFAOYSA-H tricopper;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[Cu+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O STDMRMREKPZQFJ-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229940057400 trihydroxystearin Drugs 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- GVPDNFYOFKBFEN-UHFFFAOYSA-N trimethyl(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](C)(C)C GVPDNFYOFKBFEN-UHFFFAOYSA-N 0.000 description 1
- 229940113164 trimyristin Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- FYZXEMANQYHCFX-UHFFFAOYSA-K tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [K+].[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O FYZXEMANQYHCFX-UHFFFAOYSA-K 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- GYHQJCFKQZOTBN-UHFFFAOYSA-N trisodium;borate;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]B([O-])[O-] GYHQJCFKQZOTBN-UHFFFAOYSA-N 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 description 1
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 1
- NCPXQVVMIXIKTN-UHFFFAOYSA-N trisodium;phosphite Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])[O-] NCPXQVVMIXIKTN-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960000438 udenafil Drugs 0.000 description 1
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- 239000004061 uncoupling agent Substances 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 229960005088 urethane Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229950008737 vadimezan Drugs 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- MWAYRGBWOVHDDZ-UHFFFAOYSA-N vanillic acid ethyl ester Natural products CCOC(=O)C1=CC=C(O)C(OC)=C1 MWAYRGBWOVHDDZ-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229950002148 vatelizumab Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 150000003718 vitamin K5 derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本公开涉及具有一种或多种性质的氯硝柳胺化合物(或其药学上可接受的盐和/或共结晶,例如氯硝柳胺),所述一种或多种性质包括但不限于:特定纯度(例如,高于约99.0%的化学纯度)和特定粒径(例如,特定粒径分布和/或特定粒径范围和/或比表面积范围)。在一个方面,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)可形成组合物、剂型(例如,单位剂型)等的一部分,其适合口服给予。本公开还涉及制造和使用其的方法。
Description
相关申请的交叉引用
本申请要求2019年10月18日提交的美国临时申请62/923,290的权益,通过引用将该申请全文纳入本文。
技术领域
本公开涉及具有一种或多种性质的氯硝柳胺化合物(或其药学上可接受的盐和/或共结晶,例如氯硝柳胺),所述一种或多种性质包括但不限于:特定纯度(例如,高于约99.0%的化学纯度)或特定粒径(例如,特定粒径分布和/或特定粒径范围和/或比表面积范围)。在一个方面,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)可形成组合物、剂型(例如,单位剂型)等的一部分,其适合口服给予。本公开还涉及制造和使用其的方法。
背景技术
溃疡性结肠炎(UC)和克罗恩病(CD)是人类主要的慢性炎症性肠病(IBD)。这些疾病本质上是自身免疫性的,并且在没有感染的情况下发生。IBD影响多达2,000,000名美国人(每年增加约15%),并且与不可接受的高发病率和死亡率相关。IBD也是美国医疗保健系统的一个重大负担,因为最有效的治疗方法是成本相当高的生物药物。
IBD是由于环境刺激、微生物因素和肠道免疫系统之间的复杂相互作用介导的遗传易感个体中不适当的免疫反应的结果。IBD的标志是过度的免疫反应,直接或通过可溶性促炎介质的释放介导胃肠组织损伤。
T细胞是一种浸润肠黏膜的免疫细胞,是IBD中胃肠道组织损伤的关键驱动因素。这些细胞在肠黏膜中持续存在并积聚,因为旨在检查或消除活化T细胞的正常生理机制在IBD的情况下不起作用。虽然IBD中T细胞积累的确切基础尚未完全阐明,但微生物刺激的慢性激活以及胃肠道组织炎症部位的细胞因子环境被认为是重要的。不管这些细胞如何持续存在,增强肠黏膜中的T细胞死亡与IBD的消退和对管理IBD功能最有效的药物(部分)有关,这通过杀死肠道中的致病性T细胞而实现。
尽管不同形式的IBD表现出病理生理和临床差异,但管理IBD的治疗方法有许多共同点。IBD的医疗管理主要是经验性的,使用抗炎或免疫抑制药物。水杨偶氮磺吡啶和5-氨基水杨酸用于治疗轻度IBD,如果可以实现疾病缓解,则作为维持治疗。皮质类固醇用于中度至重度疾病的患者。然而,临床缓解只能在约60%的患者中获得,并且只有大约一半的患者在停止治疗后仍处于缓解状态。最后一点很重要,因为长期使用皮质类固醇会带来严重副作用的重大风险。
免疫抑制药物也可用于治疗中度至重度IBD病例,通常作为类固醇治疗的替代品。然而,免疫抑制药物(如硫唑嘌呤)通常不能确保症状得到控制,并且治疗伴随着许多禁忌症和严重的副作用。
通常在治疗IBD中表现出最佳疗效的药物是全身给予(通过注射或输注)阻断TNF-α的单克隆抗体,其是一种在所有形式的IBD(例如,UC、CD、移植物抗宿主病、乳糜泻、医源性结肠炎,如检查点抑制剂引起的结肠炎等)过程中过度产生的促炎细胞因子。在IBD的情况下降低TNF-α水平有两个后果。首先,作为一种炎症细胞因子,TNF-α介导组织损伤。其次,高水平的TNF-α有助于导致T细胞存活的疾病,而阻断TNF-α活性最终会导致T细胞死亡。事实上,像英夫利昔单抗这样的抗TNF-α药物诱导细胞死亡可以预测患者的临床改善。
尽管有效,但使用抗TNF-α药物与严重的全身副作用有关,包括潜伏病原体的重新激活、超敏现象、癌症和自身抗体的形成。一些患者天生就对抗TNF-α药物产生抗药性,随着时间的推移,几乎有一半确实表现出反应的患者会产生抗药性。
从上述内容可以清楚地看出,与标准护理相比,需要更有效、毒性更小、更便宜和更方便管理的新药来治疗IBD。
氯硝柳胺(5-氯-N-(2-氯-4-硝基苯基)-2-氢苯甲酰胺)是一种卤代水杨酰苯胺,属于一组称为驱虫药的药物。驱虫药是用于治疗蠕虫感染的药物。氯硝柳胺具有低全身生物利用度和出色的安全性,用于治疗宽或鱼绦虫、矮绦虫和牛肉绦虫感染。据信,氯硝柳胺抑制氧化磷酸化并刺激绦虫类(例如绦虫)线粒体中的三磷酸腺苷酶活性,在体外和体内杀死绦虫的头节和近端节段(参见Li,Y.等人,Cancer Lett.2014 349,8-14。)。
口服给予是药物给予的优选途径之一,因为该途径通常方便且患者可接受。在这种类型的给予中,药物物质通常需要穿过至少一个膜被吸收。在药物物质是固体口服剂型的一部分的情况下,药物物质的吸收通常在固体口服剂型溶解后发生。上述情况有时会对药物的药代动力学产生相当大的影响,并可能导致药物吸收的实际量减少。
发明内容
本公开涉及具有一种或多种性质的氯硝柳胺化合物(或其药学上可接受的盐和/或共结晶,例如,氯硝柳胺或其药学上可接受的盐和/或共结晶),所述一种或多种性质包括但不限于:特定纯度(例如,高于约99.0%的化学纯度)或特定粒径(例如,特定粒径分布和/或特定粒径范围和/或比表面积范围)。在一个方面,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)可形成组合物、剂型(例如,单位剂型)等的一部分,其适合口服给予。有利地和出乎意料地,将本文所述的具有降低的粒径的氯硝柳胺化合物(例如,氯硝柳胺)给予(例如,口服给予)对象提供了对象中相对于高的结肠暴露。因此,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)可用于治疗多种胃肠(“GI”)相关适应症,例如炎症性肠病(例如,溃疡性结肠炎和克罗恩病)。本公开还涉及制造和使用氯硝柳胺化合物的方法。
在一个方面,本公开涉及高纯度氯硝柳胺化合物、或其药学上可接受的盐。
在另一个方面,本公开涉及高纯度氯硝柳胺、或其药学上可接受的盐:
在一些实施方式中,高纯度氯硝柳胺化合物例如氯硝柳胺是有用的起始材料,例如,用于具有降低的粒径范围(例如,通过测量粒径分布确定)的氯硝柳胺化合物例如氯硝柳胺的制备。
在一个方面,本公开涉及具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的氯硝柳胺化合物、或其药学上可接受的盐。
在另一个方面,本公开涉及具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的氯硝柳胺、或其药学上可接受的盐:
在一个方面,本公开涉及具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的高纯度氯硝柳胺化合物、或其药学上可接受的盐。
在另一个方面,本公开涉及具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的高纯度氯硝柳胺、或其药学上可接受的盐:
在另一个方面,本公开涉及共结晶,其包括氯硝柳胺化合物(例如,具有任一种或多种或本文所述的性质的氯硝柳胺)、或其药学上可接受的盐和药学上可接受的共形成物。在一些实施方式中,如本文任何地方所述,共结晶具有降低的粒径(例如,共结晶本身可被减小为具有本文所述的氯硝柳胺化合物的降低的粒径范围和/或降低的粒径分布)。
共形成物的非限制性实例包括1-磷酸鞘氨醇(S1P)受体调节剂(例如,艾曲莫德(etrasimod)或奥扎莫德(ozanimod));甾体抗炎药(例如,倍氯米松(beclomethasone)17或布地奈德(budesonide));非甾体抗炎药(例如,5-ASA);受体相互作用蛋白激酶1(RIPK1)抑制剂(例如,GSK2982772);EP4调节剂(例如,KAG-308);toll样受体(例如,TLR4,TLR9)调节剂(例如,JKB-122,可比托莫德(cobitolimod));Janus激酶(JAK)抑制剂(例如,TD-1473,托法替尼(tofacitinib),乌帕替尼(upadacitinib),非戈替尼(filgotinib),PF-06651600,和PF-06700841);羊毛硫氨酸合成酶C样2(LANCL2)调节剂(例如,BT-11);磷脂酰胆碱(例如,LT-02);整合素(例如,α4整合素)调节剂(例如,AJM-300(卡泰司特(carotegrast)));Smad7调节剂(例如,蒙格生(mongersen));磷酸二酯酶4(PDE4)调节剂(例如,阿普斯特(apremilast));肿瘤进展位点2(TPL2)抑制剂(例如,GS-4875);酪氨酸激酶2(TYK2)抑制剂(例如,BMS-986165,PF-06700841,和PF-06826647);和TEC激酶抑制剂(例如,PF-06651600)。
本文公开和要求保护的主题部分基于以下发现:氯硝柳胺可被纯化到超过目前纯度基准的水平,例如含有相对少量的常见杂质,如以下一种或多种:5-氯-水杨酸,2-氯-4硝基-苯胺,和水合氯硝柳胺固体形式。在一些实施方式中,存在相对少量的2-氯-4硝基苯胺(已知其有时表现出诱变特性)。
本文公开和要求保护的主题也部分地且独立地基于以下令人惊讶的发现:降低氯硝柳胺的粒径导致结肠组织中氯硝柳胺的局部暴露显著增加。例如,发现直肠给予粒径分布D(0.9)约5μm的氯硝柳胺在结肠组织中提供了比粒径分布D(0.9)约30μm的氯硝柳胺高约200倍的氯硝柳胺的局部浓度。
因此,本文所述的具有降低的粒径的氯硝柳胺化合物(例如,氯硝柳胺)可因此容易且高效地给予,使得给予的氯硝柳胺化合物(例如氯硝柳胺)在胃肠道例如结肠中的最终局部生物利用度相对较高(例如与给予的氯硝柳胺化合物(例如氯硝柳胺)的最终全身生物利用度相比)。在所需治疗区域(例如,胃肠道,例如结肠)局部(非全身)给予氯硝柳胺化合物(例如,氯硝柳胺)显著降低了患者经历与某些当前护理标准相关的全身毒性的可能性。另外且有利地,预期在胃肠道(例如结肠)中实现所需API水平所需的降低粒径的氯硝柳胺化合物(例如,氯硝柳胺)的量将小于具有较大粒径的氯硝柳胺化合物(例如,氯硝柳胺)所需的量。
因此,在一些实施方式中,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)(例如,降低的粒径的氯硝柳胺化合物(例如,氯硝柳胺))可以将氯硝柳胺化合物(例如,氯硝柳胺)靶向递送至胃肠道的某些区域(例如结肠,例如升结肠和/或横结肠和/或远端结肠)。在一些实施方式中,向对象给予(例如,口服给予)本文所述的氯硝柳胺化合物(例如,氯硝柳胺)会在对象的胃肠道(例如结肠,如上文)中产生高于对象血浆室中氯硝柳胺化合物(例如,氯硝柳胺)的浓度的氯硝柳胺化合物(例如,氯硝柳胺)的局部浓度,从而例如,更有效地向胃肠道(如上文)中的病变组织提供氯硝柳胺化合物(例如,氯硝柳胺),并降低与高全身性氯硝柳胺化合物(例如,氯硝柳胺)暴露(例如,毒性)相关的风险。此外,使用本文所述的降低粒径的氯硝柳胺化合物(例如,氯硝柳胺)的较低剂量可潜在地实现前述目标。
鉴于上述优点和特征,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)、方法和组合物也有望在不同的患者群体中起作用和/或对细胞死亡机制中的阻断不太敏感。此外,利用传统小分子(如氯硝柳胺)的能力有助于降低成本并促进患者给予。
在一些实施方式中,本文所述的方法和组合物适合用于与各种其他治疗方案(例如,化学疗法和/或放射疗法)的联合疗法。在某些实施方式中,本文所述的化学实体和方法可用于治疗由此类治疗方案产生的副作用,例如由化学治疗性免疫调节剂(例如检查点抑制剂)诱导的炎症性肠病,其在一些情况下可能非常严重。
在某些实施方式中,本文所述的方法和组合物适合用于与一种或多种其他治疗剂的联合治疗。例如,用于治疗或预防炎症性肠病(IBD)(例如,克罗恩病、溃疡性结肠炎)的治疗剂。其他的治疗剂的非限制性实例包括:1-磷酸鞘氨醇(S1P)受体调节剂(例如,艾曲莫德(etrasimod)或奥扎莫德(ozanimod));甾体抗炎药(例如,倍氯米松(beclomethasone)17或布地奈德(budesonide));非甾体抗炎药(例如,5-ASA);受体相互作用蛋白激酶1(RIPK1)抑制剂(例如,GSK2982772);EP4调节剂(例如,KAG-308);toll样受体(例如,TLR4,TLR9)调节剂(例如,JKB-122,可比托莫德(cobitolimod));Janus激酶(JAK)抑制剂(例如,TD-1473,托法替尼(tofacitinib),乌帕替尼(upadacitinib),非戈替尼(filgotinib),PF-06651600,和PF-06700841);羊毛硫氨酸合成酶C样2(LANCL2)调节剂(例如,BT-11);磷脂酰胆碱(例如,LT-02);整合素(例如,α4整合素)调节剂(例如,AJM-300(卡泰司特(carotegrast)));Smad7调节剂(例如,蒙格生(mongersen));磷酸二酯酶4(PDE4)调节剂(例如,阿普斯特(apremilast));肿瘤进展位点2(TPL2)抑制剂(例如,GS-4875);酪氨酸激酶2(TYK2)抑制剂(例如,BMS-986165,PF-06700841,和PF-06826647);和TEC激酶抑制剂(例如,PF-06651600)。
此外,本文所述的化学实体、方法和组合物也预期可用于某些抗治疗的患者群体,例如对抗TNFα疗法(例如修美乐,恩利,类克)的治疗或抗整合素治疗(例如,安吉优,依曲利珠单抗(Etrolizumab))或皮质类固醇无反应或有抗性的患者群体。
在个一方面,提供了用于诱导对象的(例如消化道和/或胃肠道(GI)中的)一种或多种T细胞的细胞死亡的方法。该方法包括使一种或多种T细胞与有效量的氯硝柳胺化合物或其药学上可接受的盐和/或共结晶接触;例如,如本文所述的具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的氯硝柳胺或其药学上可接受的盐和/或共结晶(例如,氯硝柳胺化合物,例如氯硝柳胺)。在实施方式中,氯硝柳胺化合物如氯硝柳胺,具有或进一步具有高化学纯度。
在另一方面,提供了用于治疗患有与对象的(例如消化道和/或胃肠道(GI)中的)一种或多种T细胞的不受调节的(异常的、升高的)募集和/或滞留相关的病症的方法。氯硝柳胺化合物或其药学上可接受的盐和/或共结晶;例如,如本文所述的具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的氯硝柳胺或其药学上可接受的盐和/或共结晶(例如,氯硝柳胺化合物,例如氯硝柳胺)。在实施方式中,氯硝柳胺化合物如氯硝柳胺,具有或进一步具有高化学纯度。在一些实施方式中,所述方法包括口服给予氯硝柳胺化合物。
在一些实施方式中,至少一些所述T细胞位于对象的小肠中(例如,在小肠的回肠部分中)。因此,本文所述的方法可用于例如治疗炎症性肠病,例如克罗恩病。
在一些实施方式中,至少一些所述T细胞位于对象的结肠中。因此,本文所述的方法可用于例如治疗炎症性肠病,例如溃疡性结肠炎。
在另一方面,提供了在有需要的对象中治疗以异常炎症反应为特征的病症(或其一种或多种症状)的方法(例如,自身免疫性疾病,例如,结肠炎,例如,自身免疫性结肠炎,例如,炎症性肠病,例如,克罗恩病、溃疡性结肠炎)。该方法包括向对象给予(例如,口服)有效量的氯硝柳胺化合物或其药学上可接受的盐和/或共结晶;例如,如本文所述的具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的氯硝柳胺或其药学上可接受的盐和/或共结晶(例如,氯硝柳胺化合物,例如氯硝柳胺)。在实施方式中,如本文所述的氯硝柳胺化合物如氯硝柳胺,具有或进一步具有高化学纯度。
在另一方面,提供了用于治疗对象的结肠炎(或其一种或多种症状)的方法。该方法包括向对象给予有效量的氯硝柳胺化合物或其药学上可接受的盐和/或共结晶;例如,如本文所述的具有降低的粒径(例如,具有降低的粒径范围,具有降低的粒径分布)的氯硝柳胺或其药学上可接受的盐和/或共结晶(例如,氯硝柳胺化合物,例如氯硝柳胺)。在实施方式中,如本文所述的氯硝柳胺化合物如氯硝柳胺,具有或进一步具有高化学纯度。
在另一方面,提供了用于治疗自身免疫性疾病、癌症、代谢紊乱、心血管疾病、与微生物(例如,病毒或细菌)感染相关的病症、过敏性疾病、与NF-κB活化和/或炎性细胞因子产生相关的病症、由水通道蛋白介导的病症或神经变性或精神疾病的方法。该方法包括向对象给予有效量的式(I)化合物或其药学上可接受的盐和/或共结晶。在一些实施方式中,所述方法包括口服给予式(I)的化合物。在一些实施方式中,所述方法包括直肠(例如,通过灌肠)给予式(I)的化合物。
实施方式可以包括以下特征中的一个或多个。
氯硝柳胺化合物,如氯硝柳胺,可以口服给予。
所述对象可以是人。
该病症可能与对象胃肠道(GI)中一种或多种T细胞的不受调节的(例如异常或升高的)募集和/或滞留有关。
该病症可能与对象胃肠道(GI)中一种或多种T细胞的不受调节的(例如异常或升高的)活化有关。
这种情况可能是结肠炎。例如,该病症可以是自身免疫性结肠炎;该病症可以是炎症性肠病(例如,溃疡性结肠炎或克罗恩病)。该病症可以是医源性自身免疫性结肠炎。
该病症可以是由一种或多种化疗剂诱导的结肠炎(例如,医源性自身免疫性结肠炎)。
一种或多种化疗剂中的至少一种可以是化疗免疫调节剂,如免疫检查点抑制剂。该免疫检查点抑制剂可以是靶向选自下组的免疫检查点受体的抑制剂:CTLA-4、PD-1、PD-L1、PD-1–PD-L1、PD-1–PD-L2、白细胞介素-2(IL-2)、吲哚胺2,3-双加氧酶(IDO)、IL-10、转化生长因子-β(TGFβ)、T细胞免疫球蛋白和粘蛋白3(TIM3或HAVCR2)、半乳糖凝集素9–TIM3、磷脂酰丝氨酸–TIM3、淋巴细胞激活基因3蛋白(LAG3)、MHC II类–LAG3、4-1BB–4-1BB配体、OX40–OX40配体、GITR、GITR配体-GITR、CD27、CD70-CD27、TNFRSF25、TNFRSF25–TL1A、CD40L、CD40–CD40配体、HVEM–LIGHT–LTA、HVEM、HVEM-BTLA、HVEM-CD160、HVEM-LIGHT、HVEM–BTLA–CD160、CD80、CD80-PDL-1、PDL2-CD80、CD244、CD48-CD244、CD244、ICOS、ICOS–ICOS配体、B7-H3、B7-H4、VISTA、TMIGD2、HHLA2–TMIGD2、丁酰肌醇、包括BTNL2、Siglec家族、TIGIT和PVR家族成员、KIR、ILT和LIR、NKG2D和NKG2A、MICA和MICB、CD244、CD28、CD86-CD28、CD86-CTLA、CD80-CD28、CD39、CD73腺苷–CD39–CD73、CXCR4–CXCL12、磷脂酰丝氨酸、TIM3、磷脂酰丝氨酸–TIM3、SIRPA–CD47、VEGF、神经纤毛蛋白、CD160、CD30、和CD155。免疫检查点抑制剂可选自下组:乌瑞芦单抗(Urelumab)、PF-05082566、MEDI6469、TRX518、伐立鲁单抗(Varlilumab)、CP-870893、帕博利珠单抗(Pembrolizumab)(PD1)、纳武单抗(Nivolumab)(PD1)、阿替利珠单抗(Atezolizumab)(原称MPDL3280A)(PDL1)、MEDI4736(PD-L1)、阿维鲁单抗(Avelumab)(PD-L1)、PDR001(PD1)、BMS-986016、MGA271、利瑞鲁单抗(Lirilumab)、IPH2201、依米妥珠单抗(Emactuzumab)、INCB024360、Galunisertib、乌洛鲁单抗(Ulocuplumab)、BKT140、巴维妥昔单抗(Bavituximab)、CC-90002、贝伐珠单抗(Bevacizumab)、和MNRP1685A、和MGA271。该免疫检查点抑制剂可以是靶向CTLA-4的抑制剂。该免疫检查点抑制剂可以是抗体。该抗体可以是伊皮木单抗(ipilimumab)或曲美木单抗(tremelimumab)。该免疫检查点抑制剂可选自纳武单抗(Nivolumab)、兰布罗珠单抗(lambroizumab)、和BMS-936559。
该病症可以选自乳糜泻、肠易激综合征、粘膜炎、葡萄膜炎、放射性肠炎、类风湿性关节炎、狼疮、硬皮病、银屑病、皮肤T细胞淋巴瘤、急性移植物抗宿主病和慢性移植物抗宿主病。
该方法还可以包括给予一种或多种另外的治疗剂。
例如,用于治疗或预防炎症性肠病(IBD)(例如、克罗恩病、溃疡性结肠炎)的治疗剂,例如、1-磷酸鞘氨醇(S1P)受体调节剂(例如、艾曲莫德(etrasimod)或奥扎莫德(ozanimod));甾体抗炎药(例如、倍氯米松(beclomethasone)17或布地奈德(budesonide));非甾体抗炎药(例如、5-ASA);受体相互作用蛋白激酶1(RIPK1)抑制剂(例如、GSK2982772);EP4调节剂(例如、KAG-308);toll样受体(例如、TLR4、TLR9)调节剂(例如、JKB-122、可比托莫德(cobitolimod));Janus激酶(JAK)抑制剂(例如、TD-1473、托法替尼(tofacitinib)、乌帕替尼(upadacitinib)、非戈替尼(filgotinib)、PF-06651600、andPF-06700841);羊毛硫氨酸合成酶C样2(LANCL2)调节剂(例如、BT-11);磷脂酰胆碱(例如、LT-02);整合素(例如、α4整合素)调节剂(例如、AJM-300(卡泰司特(carotegrast)));Smad7调节剂(例如、蒙格生(mongersen));磷酸二酯酶4(PDE4)调节剂(例如、阿普斯特(apremilast));肿瘤进展位点2(TPL2)抑制剂(例如、GS-4875);酪氨酸激酶2(TYK2)抑制剂(例如、BMS-986165、PF-06700841、和PF-06826647);和/或TEC激酶抑制剂(例如、PF-06651600)。
作为另一个实例,该一种或多种治疗剂可以是:布地奈德;表皮生长因子;皮质类固醇;环孢素;柳氮磺吡啶;氨基水杨酸盐;6-巯基嘌呤;硫唑嘌呤;甲硝唑;脂肪氧合酶抑制剂;美沙拉秦;奥沙拉嗪;巴柳氮;抗氧化剂;血栓烷抑制剂;IL-1受体拮抗剂;抗IL-1单克隆抗体;抗IL-6单克隆抗体(例如,抗IL-6受体抗体和抗IL-6抗体);生长因子;弹性蛋白酶抑制剂;吡啶-咪唑化合物;如本文所述的TNF拮抗剂;IL-4,IL-10,IL-13和/或TGF beta,细胞因子或其激动剂(例如,激动剂抗体);IL-11;葡糖苷酸或右旋糖苷偶联的泼尼松龙的前药,地塞米松或布地奈德(budesonide);ICAM-1反义硫代磷酸寡核苷酸(ISIS 2302;伊希斯制药公司);可溶性补体受体1(TP10;T细胞科学公司);缓释美沙拉秦;甲氨蝶呤;血小板活化因子(PAF)的拮抗剂;环丙沙星;和/或利多卡因。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗自身免疫性结肠炎的治疗剂和/或方案。非限制性实例皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、美沙拉秦、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗医源性自身免疫性结肠炎的治疗剂和/或方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗由一种或多种化疗剂引起的结肠炎的治疗剂和/或方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、美沙拉秦、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗用过继细胞疗法治疗引起的结肠炎的治疗剂和/或方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗与一种或多种同种免疫疾病相关的结肠炎的治疗剂和/或方案。非限制性实例包括皮质类固醇(例如,布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、柳氮磺吡啶、和二十碳烯酸。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗放射性肠炎的治疗剂和/或方案。非限制性实例包括替度鲁肽(teduglutide)、氨磷汀(amifostine)、血管紧张素转换酶(ACE)抑制剂(例如、贝那普利(benazepril)、卡托普利(captopril)、依那普利(enalapril)、福辛普利(fosinopril)、赖诺普利(lisinopril)、莫西普利(moexipril)、培哚普利(perindopril)、喹那普利(quinapril)、雷米普利(ramipril)、和泉多普利(trandolapril))、益生菌(probiotics)、硒补充剂、他汀类(例如、阿托伐他汀(atorvastatin)、氟伐他汀(fluvastatin)、洛伐他汀(lovastatin)、普伐他汀(pravastatin)、瑞舒伐他汀(rosuvastatin)、辛伐他汀(simvastatin)、和匹伐他汀(pitavastatin))、硫糖铝、和维生素E。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗胶原性结肠炎的治疗剂和/或方案。非限制性实例包括6-巯基嘌呤、硫唑嘌呤、次水杨酸铋、消胆胺、考来替泊(ColestiPol)、皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、洛哌丁胺、美沙拉秦、甲氨蝶呤、和柳氮磺吡啶。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗淋巴细胞性结肠炎的治疗剂和/或方案。非限制性实例包括6-巯基嘌呤、硫唑嘌呤、次水杨酸铋、齿叶乳香(Boswellia serrata)提取物、消胆胺、考来替泊(ColestiPol)、皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、粪便微生物移植、洛哌丁胺、美沙拉秦、甲氨蝶呤、益生菌(probiotics)、和柳氮磺吡啶。
作为进一步的实例,一种或多种另外的治疗剂可以是用于治疗显微结肠炎的治疗剂和/或方案。非限制性实例包括6-巯基嘌呤、硫唑嘌呤、次水杨酸铋、齿叶乳香(Boswelliaserrata)提取物、消胆胺、考来替泊(ColestiPol)、皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、粪便微生物移植、洛哌丁胺、美沙拉秦、甲氨蝶呤、益生菌(probiotics)、和柳氮磺吡啶。
作为进一步的例子,一种或多种另外的治疗剂可以是用于治疗UC的治疗剂和/或方案。非限制性实例包括AbGn-168H、ABT-494、ABX464、阿普斯特(apremilast)、PF-00547659、PF-06687234、6-巯基嘌呤、阿达木单抗(adalimumab)、硫唑嘌呤、柏替木单抗(bertilimumab)、布雷库单抗(brazikumab)(MEDI2070)、可比托莫德(cobitolimod)、赛妥珠单抗聚乙二醇(certolizumab pegol)CP-690/550、皮质类固醇(例如、multimax布地奈德(budesonide)、Methyl泼尼松龙)、环孢素、E6007、艾曲莫德(etrasimod)、依曲利珠单抗(Etrolizumab)、粪便微生物移植、非戈替尼(figlotinib)、古塞奇尤单抗(guselkumab)、戈利木单抗(golimumab)、IL-2、IMU-838、英夫利昔单抗、基质金属蛋白酶9(MMP9)抑制剂(例如、GS-5745)、美沙拉秦、美沙拉秦、米吉珠单抗(mirikizumab)(LY3074828)、RPC1063、瑞莎珠单抗(risankizumab)(BI6555066)、SHP647、柳氮磺吡啶、TD-1473、TJ301、替拉珠单抗(tildrakizumab)(MK 3222)、托法替尼(tofacitinib)、托法替尼(tofacitinib)、乌司奴单抗(ustekinumab)、UTTR1147A、和维得利珠单抗(vedolizumab)。
作为进一步的例子,一种或多种另外的治疗剂可以是用于治疗克罗恩病(CD)的治疗剂和/或方案。非限制性实例包括阿达木单抗(adalimumab)、自体CD34选择的外周血干细胞移植、6-巯基嘌呤、硫唑嘌呤、赛妥珠单抗聚乙二醇(certolizumab pegol)皮质类固醇(例如、强的松)、依曲利珠单抗(Etrolizumab)、E6011、粪便微生物移植、非戈替尼(figlotinib)、古塞奇尤单抗(guselkumab)、英夫利昔单抗、IL-2、JAK抑制剂、基质金属蛋白酶9(MMP 9)抑制剂(例如、GS-5745)、MEDI2070、美沙拉秦、甲氨蝶呤、那他珠单抗(natalizumab)、奥扎莫德(ozanimod)、RHB-104、利福昔明(rifaximin)、瑞莎珠单抗(risankizumab)、SHP647、柳氮磺吡啶、沙利度胺(thalidomide)、乌帕替尼(upadacitinib)、V565、和维得利珠单抗(vedolizumab)。
作为进一步的例子,一种或多种另外的治疗剂可以是用于治疗IBD的治疗剂和/或方案。非限制性实例包括6-巯基嘌呤、AbGn-168H、ABX464、ABT-494、阿达木单抗(adalimumab)、AJM300、阿利福生(alicaforsen)、AMG139、安芦珠单抗(anrukinzumab)、阿普斯特(apremilast)、ATR-107(PF0530900)、自体CD34选择的外周血干细胞移植、硫唑嘌呤、柏替木单抗(bertilimumab)、BI 655066、BMS-936557、赛妥珠单抗聚乙二醇(certolizumab pegol)可比托莫德(cobitolimod)、皮质类固醇(例如、强的松、Methyl泼尼松龙、强的松)、CP-690,550、CT-P13、环孢素、DIMS0150、E6007、E6011、艾曲莫德(etrasimod)、依曲利珠单抗(Etrolizumab)、粪便微生物移植、非戈替尼(figlotinib)、芬戈莫德(fingolimod)、非拉司特(firategrast)(SB-683699)(formerlyT-0047)、GED0301、GLPG0634、GLPG0974、古塞奇尤单抗(guselkumab)、戈利木单抗(golimumab)、GSK1399686、HMPL-004(Andrographis paniculata extract)、IMU-838、英夫利昔单抗、白细胞介素2(IL-2)、Janus激酶(JAK)抑制剂、拉喹莫德(laquinimod)、马赛替尼(masitinib)(AB1010)、基质金属蛋白酶9(MMP 9)抑制剂(例如、GS-5745)、MEDI2070、美沙拉秦、甲氨蝶呤、米吉珠单抗(mirikizumab)(LY3074828)、那他珠单抗(natalizumab)、NNC0142-0000-0002、NNC0114-0006、奥扎莫德(ozanimod)、吡西替尼(peficitinib)(JNJ-54781532)、PF-00547659、PF-04236921、PF-06687234、QAX576、RHB-104、利福昔明(rifaximin)、瑞莎珠单抗(risankizumab)、RPC1063、SB012、SHP647、柳氮磺吡啶、TD-1473、沙利度胺(thalidomide)、替拉珠单抗(tildrakizumab)(MK3222)、TJ301、TNF-/>托法替尼(tofacitinib)、曲罗芦单抗(tralokinumab)、TRK-170、乌帕替尼(upadacitinib)、乌司奴单抗(ustekinumab)、UTTR1147A、V565、vatelizumab、VB-201、维得利珠单抗(vedolizumab)、和维多氟拉迪莫(vidofludimus)。
在一个方面,提供一种共结晶,其包括:(i)氯硝柳胺化合物,如氯硝柳胺或其药学上可接受的盐和/或水合物;和(ii)一种或多种药学上可接受的共形成物。在一些实施方式中,该共结晶如本文任何地方所述,具有降低的粒径。在实施方式中,该共结晶共形成物可包括本文所述的任意共形成物,其包括如上所述和本文任何地方的第二治疗剂。
定义
为了便于理解本文阐述的公开内容,以下定义了多个术语。通常,本文使用的命名法和本文所述的有机化学、药物化学和药理学中的实验室程序是本领域众所周知的和常用的。除非另有定义,否则本文使用的所有技术和科学术语通常具有与本公开所属领域的普通技术人员通常理解的相同含义。在整个说明书和所附附录中提及的每个专利、申请、公开的申请和其他出版物都通过引用整体并入本文。
术语“氯硝柳胺化合物”或“氯硝柳胺化合物”包括在WO 2017/040864中描述的氯硝柳胺以及氯硝柳胺类似物,其通过引用整体并入本文。在一些实施方式中,氯硝柳胺化合物是氯硝柳胺。
“氯硝柳胺”是指具有下述化学结构的化合物:
氯硝柳胺被IUPAC命名为:2′5-二氯-4′-亚硝基水杨酰苯胺并被CAS命名为:CAS:5-氯-N-(2-氯-4-硝基苯基)-2-羟基苯甲酰胺。氯硝柳胺的水溶性较低,在20℃下约为5-8mg/L,微溶于乙醚、乙醇和氯仿,溶于丙酮。乙醇胺盐在20℃下以180-280mg/L溶于蒸馏水中。
氯硝柳胺有多种盐或溶剂化物形式。这些包括但不限于:乙醇胺盐,IUPAC命名为5-氯-水杨基-(2-氯-4-硝基)苯胺2-氨基乙醇盐或CAS命名为5-氯-N-(2-氯-4-硝基苯基)-2-羟基苯甲酰胺与2-氨基乙醇(1:1)——参见例如,US2013/0231312;哌嗪盐,IUPAC命名为5-氯-水杨基-(2-氯-4-硝基)苯胺哌嗪盐或CAS命名为5-氯-N-(2-氯-4-硝基苯基)-2-羟基苯甲酰胺与哌嗪(2:1);和氯硝柳胺一水合物,IUPAC命名为5-氯-水杨基-(2-氯-4-硝基)苯胺一水合物或CAS命名为5-氯-N-(2-氯-4-硝基苯基)-2-羟基苯甲酰胺与一水合物(1:1)。
氯硝柳胺有多种制剂可商购,包括但不限于BAYERBAYER/>BAYER 25CLONITRALID、HL /> 等。
术语“消化道”被理解为包括口、咽、食道、胃、小肠(十二指肠、空肠、回肠)、大肠(盲肠、结肠、直肠)和肛门。
术语“口腔”被理解为包括口、咽和食道。
术语“胃肠道”或“GI道”被理解为包括胃、小肠(十二指肠、空肠、回肠)、大肠(盲肠、结肠、直肠)和肛门。
如本文所用,关于制剂、组合物或成分的术语“可接受的”是指对接受治疗的对象的总体健康没有持续的有害影响。
“API”是指活性药物成分(例如,氯硝柳胺化合物,例如,氯硝柳胺)。
如本文所用,术语“有效量”或“治疗有效量”是指给予的足够量的化学实体(例如,显示作为线粒体解偶联剂的活性的化合物或其药学上可接受的盐和/或水合物和/或共结晶;例如,化合物如氯硝柳胺或其药学上可接受的盐和/或水合物和/或共结晶;例如,化合物如氯硝柳胺类似物、或其药学上可接受的盐和/或水合物和/或共结晶),其将在一定程度上缓解所治疗的疾病或病症的一种或多种症状。结果包括减少和/或减轻疾病的体征、症状或原因,或生物系统的任何其他所需改变。例如,用于治疗用途的“有效量”是提供临床上显著的疾病症状减轻所需的包含本文公开的化合物的组合物的量。使用任何合适的技术(例如剂量递增研究)确定任何个别情况下的合适“有效”量。
术语“赋形剂”或“药学上可接受的赋形剂”是指药学上可接受的材料、组合物或载体,例如液体或固体填充剂、稀释剂、载体、溶剂或包封材料。在一个实施方式中,每种组分在与药物制剂的其他成分相容的意义上是“药学上可接受的”,并且适用于与人和动物的组织或器官接触而没有过度毒性、刺激、过敏反应、免疫原性或其他问题或并发症,与合理的收益/风险比相称。参见Remington:The Science and Practice of Pharmacy,第21版;Lippincott Williams&Wilkins:Philadelphia,PA,2005;Handbook of PharmaceuticalExcipients,第6版,Rowe等编,The Pharmaceutical Press and the AmericanPharmaceutical Association:2005;以及Handbook of Pharmaceutical Additives,第3版,Ash和Ash编,Gower Publishing Company:2007;Pharmaceutical Preformulation andFormulation,第2版;Gibson编,CRC Press LLC:Boca Raton,FL,2009。
术语“药学上可接受的盐”是指化合物的制剂,其不会对所给予的生物体造成显著刺激并且不会消除该化合物的生物活性和性质。在某些情况下,药学上可接受的盐通过本文所述的化合物与酸如盐酸、氢溴酸、硫酸、硝酸、磷酸、甲磺酸、乙磺酸、对甲苯磺酸、水杨酸等反应而获得。在一些情况下,在一些情况下,药学上可接受的盐通过使本文所述的具有酸性基团的化合物与碱反应形成盐(例如铵盐、碱金属盐例如钠盐或钾盐、碱土金属盐例如钙盐或镁盐、有机碱盐例如二环己胺、N-甲基-D-葡糖胺、三(羟甲基)甲胺和与氨基酸如精氨酸、赖氨酸等形成的盐)或通过先前确定的其他方法获得。药理学上可接受的盐没有特别限制,只要它可以用于药物。本文所述的化合物与碱形成的盐的实例包括以下:其与无机碱如钠、钾、镁、钙和铝形成的盐;其与有机碱如甲胺、乙胺和乙醇胺的盐;其与赖氨酸和鸟氨酸等碱性氨基酸的盐;和铵盐。该盐可以是酸加成盐,其可通过以下酸加成盐例举:无机酸例如盐酸、氢溴酸、氢碘酸、硫酸、硝酸和磷酸:有机酸例如甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、甲磺酸、乙磺酸;天冬氨酸、谷氨酸等酸性氨基酸。
术语“药物组合物”是指本文所述的化合物与其他化学成分(本文统称为“赋形剂”)如载体、稳定剂、稀释剂、分散剂、悬浮剂和/或增稠剂的混合物。药物组合物有助于将化合物给予生物体。本领域存在多种给予化合物的技术,包括但不限于:直肠、口服、静脉内、气雾剂、肠胃外、眼部、肺部和局部给予。
术语“对象”是指动物,包括但不限于灵长类动物(例如人)、猴、牛、猪、绵羊、山羊、马、狗、猫、兔、大鼠或小鼠。术语“对象”和“患者”在指例如哺乳动物对象诸如人类时可互换使用。
在治疗疾病或紊乱的情况下,术语“治疗”意在包括减轻或消除病症、疾病或失调,或与病症、疾病或失调相关的一种或多种症状;或减缓疾病、病症或失调或其一种或多种症状的进展、扩散或恶化。通常,对象从治疗剂中获得的有益效果不会导致疾病、病症或失调的完全治愈。
在附图和以下描述中详细说明了本发明的一种或多种实施方式。通过说明书和附图以及权利要求书,不难了解本发明的其它特征、目的和优点。
发明详述
本公开涉及具有一种或多种性质的氯硝柳胺化合物(或其药学上可接受的盐和/或共结晶,例如,氯硝柳胺或其药学上可接受的盐和/或共结晶),所述一种或多种性质包括但不限于:特定纯度(例如,高于约99.0%的化学纯度)和特定粒径(例如,特定粒径分布和/或特定粒径范围和/或比表面积范围)。在一个方面,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)可形成组合物、剂型(例如,单位剂型)等的一部分,其适合口服给予。有利地和出乎意料地,将本文所述的具有降低的粒径的氯硝柳胺化合物(例如,氯硝柳胺)给予(例如,口服给予)对象提供了对象中相对于高的结肠暴露。因此,本文所述的氯硝柳胺化合物(例如,氯硝柳胺)可用于治疗多种胃肠(“GI”)相关适应症,例如炎症性肠病(例如,溃疡性结肠炎和克罗恩病)。本公开还涉及制造和使用氯硝柳胺化合物的方法。
氯硝柳胺化合物
化学纯度
在一些实施方式中,氯硝柳胺化合物(例如,氯硝柳胺)具有高于约99.0%;例如,高于约99.5%;或高于约99.7%;或高于约99.8%的化学纯度。
在一些实施方式中,氯硝柳胺化合物(例如,氯硝柳胺)具有少于约45ppm的5-氯-水杨酸;例如,少于约30ppm的5-氯-水杨酸。
在一些实施方式中,化合物具有少于约50ppm的2-氯-4硝基-苯胺。在某些实施方式中,化合物具有少于约10ppm的2-氯-4硝基-苯胺。
在一些实施方式中,化合物具有少于约45ppm的5-氯-水杨酸和少于约50ppm的2-氯-4硝基-苯胺。
在一些实施方式中,化合物具有少于约30ppm的5-氯-水杨酸和少于约10ppm的2-氯-4硝基-苯胺。
在一些实施方式中,化合物具有少于约0.05%的水。在某些实施方式中,化合物基本上不含水和氯硝柳胺固体形式。作为一个非限制性实例,化合物可以是无水氯硝柳胺。
在一些实施方式中,可以根据以下过程进行纯化。将丙酮和粗氯硝柳胺在容器中混合并加热至回流(~56℃)直至固体溶解。通过过滤使溶液澄清并转移到第二个容器中,加热至45℃至55℃以溶解固体,冷却至-5℃至5℃并在该温度下搅拌至少2小时。过滤固体并用丙酮洗涤。在70℃真空干燥固体后获得结晶的氯硝柳胺。IPC LOD测试是针对规格<1.0%的干燥固体进行的。如果LOD结果>1.0%,则干燥步骤可以再重复两次。还进行了IPC测试以确保起始材料2-氯-4-硝基苯胺的水平<100ppm。如果2-氯-4-硝基苯胺的含量>100ppm,则可以进行第二次结晶。
在一些实施方式中,纯度分析可以根据以下程序实现。色谱仪:UPLC系统由以下组成:泵、二极管阵列;检测器、自动采样器、自动进样器和色谱柱冷却器/加热器或同等设备。柱:Agilent Poroshell 120EC-C18色谱柱,4.6×50mm,2.7μm或同等尺寸。柱温:35℃。流动相A:20mM乙酸铵(pH 5.50)。流动相B:甲醇:乙腈(70:30,v/v)。稀释剂:MeOH:DMSO(70:30,v/v)。
流速:1.0ml/分钟。注入体积:3.00μl。标准溶液和样品溶液的制备。氯硝柳胺标准溶液:该溶液的标称浓度为0.8mg/mL。保留时间:5-氯水杨酸(2.9分钟);2-氯-4-硝基苯胺(7.0分钟);和氯硝柳胺(18.8分钟)。
粒径
在一些实施方式中,化合物具有降低的粒径(例如,通过包括但不限于研磨的技术实现的)。
在一些实施方式中,可通过喷射研磨制备具有降低粒径的氯硝柳胺化合物,例如,使用由Sturtevant制造的CMTI设备NGMP-Mill-A,一种2英寸薄饼微粉机;在研磨过程中使用了一个灵活的容器单元(磨机和文丘里压力均=50psi;进料速度96.0g/小时)。
在前述的一些实施方式中,化合物具有约0.1μm至约30μm的粒径范围。在某些实施方式中,化合物具有约0.1μm至约20μm的粒径范围。在某些实施方式中,化合物具有约0.1μm至约10μm的粒径范围。
如在本申请中使用的,术语粉末或颗粒材料或分散在流体中的颗粒的“粒径分布”是定义存在的颗粒的相对量的数值列表或数学函数,根据尺寸分类。d(0.1)、d(0.5)和d(0.9)值表明10%、50%和90%的测量颗粒小于或等于所述尺寸。例如,d(0.1)=0.6,d(0.5)=3.1,d(0.9)=7.3表示10%的颗粒小于或等于0.6μm,50%小于或等于3.1μm,90%小于或等于7.3μm。
粒径分布(PSD)可以通过激光衍射技术测定,例如,使用“MALVERN MASTERSIZER2000”(标准范围在0.020和2000.0微米之间),型号“APA2000”,配备“Hydro 2000sm”作为分散单元。代表性程序包括:将大约50mg氯硝柳胺手动分散到25ml水中;分散后,用外部超声波对样品进行2分钟的超声波处理(超声波频率;37kHz-Elmasonic S100(H)-ElmaSchmidbauer GmbH,德国);考虑以下操作条件/机器参数:分散剂:水+3滴泰洛沙泊(Tyloxapol)1.5%;背景测量时间:10秒;测量周期数:3(取平均值);搅拌速度(分散单元):1500rpm。
在一些实施方式中,化合物具有约1.0μm至约15.0μm的粒径分布D(0.9)。在某些实施方式中,化合物具有约1.0μm至约10.0μm的粒径分布D(0.9)。在某些实施方式中,化合物具有约6.0μm至约8.0μm(例如,约7.3μm(例如,7.3μm))的粒径分布D(0.9)。在其他实施方式中,化合物具有约2.2μm至约3.2μm的粒径分布D(0.9)。
在一些实施方式中,化合物具有约0.1μm至约1.5μm的粒径分布D(0.1)。在某些实施方式中,化合物具有约0.1μm至约1.0μm的粒径分布D(0.1)。在某些实施方式中,化合物具有约0.3μm至约0.9μm的粒径分布D(0.1)。在某些实施方式中,化合物具有约0.45μm至约0.75μm(例如,约0.6μm(例如,0.6μm))的粒径分布D(0.1)。
在一些实施方式中,化合物具有约0.5μm至约6.0μm的粒径分布D(0.5)。在某些实施方式中,化合物具有约1.0μm至约4.0μm的粒径分布D(0.5)。在某些实施方式中,化合物具有约1.0μm至约2.0μm的粒径分布D(0.5)。在某些实施方式中,化合物具有约2.5μm至约3.5μm(例如,约3.1μm(例如,3.1μm))的粒径分布D(0.5)。
如本文所用,参数D(0.1)是指允许样品的所有颗粒总数的10%通过的单个名义筛的筛目尺寸。因此D(0.1)=0.1-1.5μm意味着定义样品中10%最小颗粒的粒径范围的上限在0.1μm到1.5μm之间。因此,总颗粒的10%的颗粒尺寸不超过D(0.1),这意味着在这种情况下,它们的最大尺寸为0.1μm至1.5μm。
参数D(0.5)是指允许样品的所有颗粒总数的50%通过的单个名义筛的筛目尺寸。因此,D(0.5)=0.5-6.0μm意味着定义包含较小颗粒的样品的名义一半的粒径范围的上限在0.5μm到6.0μm之间。因此,所有粒子总数的50%的粒径不超过D(0.5),这意味着在这种情况下,它们的最大粒径为0.5m至6.0μm。
参数D(0.9)是指允许样品的所有颗粒总数的90%通过的单个名义筛的筛目尺寸,即仅滞留10%的样本。。因此D(0.9)=1.0-15.0μm意味着定义样品中10%最小颗粒的粒径范围的上限在1.0μm到15.0μm之间。因此,总颗粒的90%的颗粒尺寸不超过D(0.9),这意味着在这种情况下,它们的最大尺寸为1.0μm至15.0μm。
在一些实施方式中,化合物具有少于约0.05%的水(例如,由Karl Fisher技术确定)。在某些实施方式中,化合物基本上不含水和氯硝柳胺固体形式。作为一个非限制性实例,化合物可以是无水氯硝柳胺。
在一些实施方式中,化合物是晶体。
在一些实施方式中,化合物具有约5m2/g至约10m2/g的比表面积。
非限制组合
非限制性组合[A]
在一些实施方式中,化合物具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有约7.0μm至约7.5μm(例如,约7.3μm)的粒径分布D(0.9),约2.5μm至约4.0μm(例如,约3.1μm)的粒径分布D(0.5),和约0.45μm至约0.75μm(例如,约0.6μm)的粒径分布D(0.1)。
在一些实施方式中,化合物具有约7.3μm的粒径分布D(0.9),约3.1μm的粒径分布D(0.5),和约0.6μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有高于约99.0%的化学纯度,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有高于约99.0%的化学纯度,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有高于约99.0%的化学纯度,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在[A]的某些实施方式中,化合物具有约2.5μm至约3.5μm的粒径分布D(0.5)。
在[A]的某些实施方式中,化合物具有约1.0μm至约2.0μm的粒径分布D(0.5)。
在[A]的某些实施方式中,化合物具有高于约99.5%的化学纯度;或高于约99.7%的化学纯度;或高于约99.8%的化学纯度。
在[A]的某些实施方式中,化合物具有少于约45ppm的5-氯-水杨酸;或少于约30ppm的5-氯-水杨酸。
在[A]的某些实施方式中,化合物具有少于约50ppm的2-氯-4硝基-苯胺;或少于约10ppm的2-氯-4硝基-苯胺。
在[A]的某些实施方式中,化合物具有少于约45ppm的5-氯-水杨酸和少于约50ppm的2-氯-4硝基-苯胺;或少于约30ppm的5-氯-水杨酸和少于约10ppm的2-氯-4硝基-苯胺。
在[A]的某些实施方式中,化合物具有少于约0.05%的水。
在[A]的某些实施方式中,化合物基本上不含水和氯硝柳胺固体形式。
在[A]的某些实施方式中,化合物是无水氯硝柳胺。
在[A]的某些实施方式中,化合物是晶体。
在[A]的某些实施方式中,化合物具有约5m2/g至约10m2/g的比表面积。
氯硝柳胺化合物的共结晶
概述
在一些实施方式中,氯硝柳胺化合物(例如,氯硝柳胺)可以是共结晶的形式,其包含(i)氯硝柳胺化合物(例如,氯硝柳胺)或其药学上可接受的盐;和(ii)一种或多种药学上可接受的共形成物。如本文所用,术语“共结晶”是指由两种或多种在室温下以化学计量或非化学计量比的独特固体组成的结晶材料,它们通过一种或多种非共价相互作用在晶格中保持在一起(例如,氢键、pi堆叠、客体-主体络合和范德华相互作用)。
在一些实施方式中,一种或多种非共价相互作用中的至少一种是氢键。在这些实施方式中的某些实施方式中,化学实体是氢键供体,并且一种或多种共形成物之一是氢键受体。在其他实施方式中,化学实体是氢键受体,并且一种或多种共形成物之一是氢键供体。
本文所述的共结晶可以在晶格中包括一种或多种溶剂化物(例如,水或含有一个或多个羟基的有机溶剂,例如C1-C6醇或二醇,例如C1-C6醇或二醇,例如乙醇或丙二醇)分子。然而,不进一步包含共形成物(例如,固体构象异构体)的化学实体的溶剂化物不包括在本公开中阐述的共结晶定义中。
在一些实施方式中,共结晶包括超过一种共形成物。例如,两种、三种、四种、五种或更多种共形成物可以与化学实体结合在共结晶中。化学实体与一种或多种药学上可接受的共形成物中的每一种的比率可以是化学计量的或非化学计量的。作为一个非限制性的实例,1:1、1:1.5和1:2的化学实体:共形成物的比例是可以考虑的。
氯硝柳胺化合物(例如,氯硝柳胺)和一种或多种药学上可接受的共形成物中的每一种可以各自独立地指定为:游离形式,或更具体地,游离酸、游离碱或两性离子;盐,或更具体地,例如无机碱加成盐如钠、钾、锂、钙、镁、铵、铝盐或有机碱加成盐,或无机酸加成盐如HBr、HCl、硫酸、硝酸或磷酸加成盐,或有机酸加成盐如乙酸、丙酸、丙酮酸、苹果酸、琥珀酸、苹果酸、马来酸、富马酸、酒石酸、柠檬酸、苯甲酸、甲磺酸、乙磺酸、硬脂酸或乳酸加成盐;游离形式或盐的无水物或水合物,或更具体地,例如,半水合物、一水合物、二水合物、三水合物、四水合物、五水合物;或游离形式或盐的溶剂化物。
共形成物
在一些实施方式中,一种或多种药学上可接受的共形成物中的至少一种可以与共结晶中的化学实体形成一个或多个氢键。在一些实施方式中,一种或多种药学上可接受的共形成物中的至少一种可以接受来自共结晶中的化学实体的一个或多个氢键。在一些实施方式中,一种或多种药学上可接受的共形成物中的至少一种可以与共结晶中的化学实体形成一个或多个氢键,并且一种或多种药学上可接受的共形成物中的至少一种可以接受来自共结晶中的化学实体的一个或多个氢键。
在一些实施方式中,一种或多种药学上可接受的共形成物中的至少一种包含一种或多种选自下组的官能团:醚、硫醚、羟基、巯基、醛、酮、硫酮、硝酸酯、磷酸酯、硫代磷酸酯、酯、硫酯、硫酸酯、羧酸、膦酸、次膦酸、磺酸、酰胺、伯胺、仲胺、氨、叔氨基、sp2氨基、硫氰酸酯、氰胺、肟、腈、重氮、卤代烷基、硝基、杂环、杂芳基环、环氧化物、过氧化物和异羟肟酸。
在某些实施方式中,一种或多种药学上可接受的共形成物中的每一种独立地选自乙酰胺、苯甲酰胺、(+/-)-柠檬烯、1-(苯偶氮)-2-萘胺、1,2,6-己三醇、1,2-二肉豆蔻酰-sn-甘油-3-(磷酸化-s-(1-甘油))、1,2-二肉豆蔻酰-sn-甘油-3-磷酸胆碱、1,2-二油酰基-sn-甘油-3-磷酸胆碱、1,2-二棕榈酰-sn-甘油-3-(磷酸化-rac-(1-甘油))、1,2-二硬脂酰基-sn-甘油-3-(磷酸化-rac-(1-甘油))、1,2-二硬脂酰基-sn-甘油-3-磷酸胆碱、1,5-萘-二磺酸、1-羟基-2-萘酸、1-o-甲苯基双胍、2-乙基-1,6-己二醇、4-氨基苯甲酸、4-氨基吡啶、4-氨基水杨酸、4-氯苯-磺酸、4-乙氧基苯基脲、7-氧代-脱氢酶、金合欢、洋槐胶、金合欢糖浆、安赛蜜、安赛蜜钾、乙酰氧肟酸、丙酮亚硫酸氢钠、乙酰化羊毛脂醇、乙酰化甘油单酯、乙酰半胱氨酸、乙酰柠檬酸三丁酯、丙烯酸酯共聚物、丙烯酸-丙烯酸异辛酯共聚物、腺嘌呤、己二酸、丙氨酸、白蛋白聚集、白蛋白胶体、人白蛋白、白蛋白、海藻酸、烷基磺酸铵甜菜碱、烷基芳基磺酸钠、尿囊素、别嘌醇、烯丙基α-紫罗兰酮、α-松油醇、α-生育酚、α-生育酚乙酸酯、氨基苯甲酸钠、乙酸戊酯、茴香脑、柠檬酸酐、无水葡萄糖、无水乳糖、无水磷酸三钠、无水三柠檬酸钠、精氨酸、失水山梨醇酯、阿魏胶、抗坏血酸、抗坏血酸棕榈酸酯、天冬酰胺、阿斯巴甜、天冬氨酸、抑菌氯化钠注射液、硫酸钡、苯扎氯铵、苯磺酸、苄索氯铵、苯并十二溴铵、苯甲酸、乙酸苄酯、苯甲醇、苯甲酸苄酯、苄基氯、β-胡萝卜素、倍萘酚、甜菜、比巴西肽、碱式碳酸铋、次没食子酸铋、硼酸、溴克利那、硬脂酸丁酯、丁基羟基茴香醚、丁基化羟基甲苯、对羟基苯甲酸丁酯、丁酸、C-11-1-氨基环己烷甲酸、C12-15烷基乳酸、咖啡因、考布醇、钙胺钠、钙塞酸三钠、卡特利多鈣、樟脑酸、羊蜡酸、克菌丹、磺丁基环糊精、羧基聚亚甲基、胭脂红、巴西棕榈蜡、巴西棕榈黄蜡、角叉菜胶、卡拉胶钙、卡拉胶盐、角叉菜胶钠、地蜡、鲸蜡硬脂醇聚醚-12、鲸蜡硬脂醇聚醚-15、鲸蜡硬脂醇聚醚-30、鲸蜡硬脂醇/鲸蜡硬脂醇聚醚-20、鲸蜡硬脂基乙基己酸酯、鲸蜡醇聚醚-10、鲸蜡醇聚醚-2、鲸蜡醇聚醚-20、鲸蜡醇聚醚-23、鲸蜡硬脂醇、西曲氯铵、鲸蜡醇、十六烷基酯蜡、十六烷基棕榈酸酯、十六烷基氯化吡啶、氯甲酚、氯二甲酚、胆固醇、白杨素、肉桂醛、肉桂酸、柠檬酸盐、柠檬酸、柠檬酸一水合物、克立咪唑、椰油酰胺醚硫酸盐、氧化椰油胺、椰油甜菜碱、椰油二乙醇酰胺、椰油单乙醇酰胺、椰油辛酸酯、椰油甘油酯、肌酸、肌酸酐、甲酚、硫酸铜、环聚氨基甲酸、环甲硅油、环甲硅油5、半胱氨酸、达伐吡啶、癸基甲基亚砜、脱氢乙酸、苯甲酸地那铵、脱氧胆酸、葡聚糖、葡聚糖40、葡聚糖、糊精、葡萄糖、葡萄糖一水合物、二乙酰化甘油单酯、泛影酸、无水磷酸氢二钠、磷酸氢二钠、磷酸氢二钠二水合物、磷酸氢二钠十二水合物、磷酸氢二钠七水合物、邻苯二甲酸二丁酯、癸二酸二丁酯、邻苯二甲酸二乙酯、焦碳酸二乙酯、癸二酸二乙酯、磷酸二乙氨基乙基硬脂酰胺、二甘醇单乙醚、二甘醇单甲醚、邻苯二甲酸二乙基己酯、己二酸二异丙酯、二亚油酸二异丙酯、二异丙基苯并噻唑-2-亚磺酰胺、聚二甲基硅氧烷药液360、二甲基异山梨醇、邻苯二甲酸二甲酯、二甲基亚砜、二甲基二十八烷基铵膨润土、二甲基甘氨酸、二甲基硅氧烷/甲基乙烯基硅氧烷共聚物、地诺乙铵、二丙二醇、椰油两性二乙酸二钠、柠檬酸氢二钠、月桂基磺基琥珀酸二钠、月桂基磺基琥珀酸二钠、油酰胺基单乙醇胺磺基琥珀酸二钠、磺基水杨酸二钠、地索芬宁、dl-a350乳酸、dl-乙酰色氨酸、dl-α-生育酚、dl-α-生育酚乙酸酯、dl-二棕榈酰磷脂酰甘油、dl-二硬脂酰基磷脂酰胆碱、dl-谷氨酸、dl-酒石酸、d-甘露糖、dmdm乙内酰脲、二十二烷醇、多库酯钠、d-核糖、依地酸钙二钠、依地酸二钠、依地酸钠、依地酸、鸡蛋磷脂酰甘油、鸡蛋磷脂、恩妥磺隆、恩妥磺隆钠、脱乳糖、表四环素盐酸盐、异抗坏血酸、赤藓糖醇、乙醇胺盐酸盐、乙基麦芽酚、油酸乙酯、香草酸乙酯、乙基香草醛、乙二胺二盐酸盐、乙基己基羟基硬脂酸酯、对羟基苯甲酸乙酯、桉叶油素、丁香酚、艾司他嗪、脂肪酸酯、脂肪酸甘油酯、脂肪酸季戊四醇酯、脂肪酸、柠檬酸脂肪醇、脂肪醇、氯化铁、氧化铁、氧化亚铁、富马酸亚铁、氧化亚铁、荧光素、果糖、富马酸、富马酰二酮哌嗪、氧化钆、半乳糖酸、半乳糖、γ环糊精、染料木黄酮、龙胆酸、龙胆酸乙醇酰胺、龙胆酸乙醇胺、葡萄糖酸钠、葡萄糖酸、葡萄糖酸内酯、葡萄糖胺、葡萄糖、葡萄糖醛酸、谷氨酸、谷氨酸盐酸盐、谷氨酰胺、戊二酸、谷胱甘肽、辛酸甘油酯、二山嵛酸甘油酯、二硬脂酸甘油酯、异硬脂酸甘油酯、月桂酸甘油酯、单硬脂酸甘油酯、油酸甘油酯、棕榈酸甘油酯、棕榈硬脂酸甘油酯、蓖麻油酸甘油酯、硬脂酸甘油酯、硬脂酸甘油酯-月桂醇聚醚-23、硬脂酸甘油酯/硬脂酸甘油酯、硬脂酸甘油酯/peg-100硬脂酸酯、硬脂酸甘油酯/peg-40硬脂酸酯、硬脂酸甘油酯-硬脂酰胺乙基二乙胺、甘油三油酸酯、甘氨酸、盐酸甘氨酸、二硬脂酸乙二醇酯、硬脂酸乙二醇酯、乙醇酸、甘草甜素、盐酸胍、己基间苯二酚、马尿酸、组氨酸、透明质酸钠、氢化可的松、对苯二酚、含水柠檬酸、羟乙基哌嗪乙磺酸、羟基八十八烷基羟基硬脂酸酯、己酸羟孕酮、羟丙基β-环糊精、hystrene、八角茴香、咪唑、咪脲、靛蓝二磺酸钠、碘肟酸、盐酸异丙苯胺、异丙黄酮、异亮氨酸、异硬脂酸异丙酯、肉豆蔻酸异丙酯、肉豆蔻酸异丙酯-肉豆蔻醇、棕榈酸异丙酯、硬脂酸异丙酯、异硬脂酸、异硬脂醇、乳酸、乳糖醇一水合物、乳糖酸、乳糖、兰达精、羊毛脂、氯化月桂铵、氧化月桂胺、硫酸月桂醇醚、月桂酸、月桂酸二乙醇酰胺、月桂酸肉豆蔻二乙醇酰胺、月桂酰肌氨酸、乳酸月桂酯、硫酸月桂酯、卵磷脂、亮氨酸、左薄荷脑、乙酰丙酸、利多芬宁、L-乳酸钠、赖氨酸、马来酸、苹果酸、丙二酸、麦芽糖醇、麦芽糖糊精、麦芽糖醇、无水麦芽糖、扁桃酸、甘露醇、磺化脂肪醇、甲溴芬宁、中链甘油三酯、甲羟戊酸二钠、甲羟戊酸、薄荷醇、间甲酚、蛋氨酸、水杨酸甲酯、硬脂酸甲酯、甲基氯异噻唑啉酮、甲基异噻唑啉酮、对羟基苯甲酸甲酯、对羟基苯甲酸甲酯钠、氯化米里吡铵、甘油单酯和甘油二酯、磷酸二氢钠、无水磷酸二氢钠、磷酸二氢钠二水合物、磷酸二氢钠一水合物、柠檬酸单甘油酯、单甘油酯、单柠檬酸钠、味精、柠檬酸单硬脂酸酯、单硫代甘油、肉豆蔻酸、肉豆蔻醇、乳酸肉豆蔻酯、尼克酰胺、烟酰胺、烟酸、N-甲基葡糖胺、辛酸、油醇聚醚-20、油醇、油酸油酸酯、乳清酸、草酸、氧化二钠、羟喹啉、棕榈胺氧化物、棕榈酸、棕榈酸、十五内酯、季戊四醇椰油酸酯、戊酸五钠、戊酸钙三钠、戊酸、苯酚、苯醌、苯氧乙醇、苯基氨酸、苯乙醇、磷脂、哌嗪、哌嗪六水合物、普鲁卡因、产品水合物(product wat)、脯氨酸、丙烯基愈创木酚、没食子酸丙酯、碳酸亚丙酯、丙二醇、丙二醇-卵磷脂、海藻酸丙二醇酯、二乙酸丙二醇酯、二辛酸丙二醇酯、单月桂酸丙二醇酯、单棕榈硬脂酸丙二醇酯、棕榈硬脂酸丙二醇酯、蓖麻油酸丙二醇酯、丙二醇/二唑烷基脲/对羟基苯甲酸甲酯/对羟基苯甲酸丙酯、对羟基苯甲酸丙酯、对羟基苯甲酸丙酯钠、对甲苯磺酸、吡哆胺、吡哆醇(4-吡哆酸)、槲皮素(quercetin)、白藜芦醇、核黄素、糖精、糖精钙、糖精钠、无水糖精钠、水杨酸、饱和脂肪酸酯、癸二酸、丝氨酸、1,2-乙二磺酸钠、2-萘磺酸钠、乙酸钠、无水乙酸钠、海藻酸钠、烷基硫酸钠、硅酸铝钠、抗坏血酸钠、苯甲酸钠、碳酸氢钠、硫酸氢钠、硫酸氢钠丙酮、亚硫酸氢钠、酒石酸氢钠、硼酸钠、十水硼酸钠、碳酸钠、十水碳酸钠、一水碳酸钠、羧甲基β-葡聚糖钠(ds 065-085)、酪蛋白酸钠、纤维素钠、鲸蜡硬脂基硫酸钠、氯酸钠、氯化钠、氯化钠注射液、胆固醇硫酸钠、柠檬酸钠、柠檬酸钠水合物、椰油酰肌氨酸钠、甜蜜素钠、脱氧胆酸钠、连二亚硫酸钠、十二烷基苯磺酸钠、对羟基苯甲酸乙酯钠、甲醛次硫酸钠、葡萄糖酸钠、氢氧化钠、次氯酸钠、碘化钠、乳酸钠、月桂基聚醚-2硫酸钠、月桂醇聚醚-3硫酸钠、月桂醇聚醚-5硫酸钠、月桂酰肌氨酸钠、月桂基硫酸钠、月桂基磺基乙酸钠、焦亚硫酸钠、硝酸钠、油酸钠、磷酸钠、二水合磷酸钠、亚磷酸钠、聚丙烯酸钠、聚丙烯酸钠(2500000MW)、聚偏磷酸钠、丙酸钠、焦磷酸钠、吡咯烷酮羧酸钠、羟基乙酸淀粉钠、A型玉米羟基乙酸淀粉钠、A型马铃薯羟基乙酸淀粉钠、B型马铃薯羟基乙酸淀粉钠、硬脂酸钠、硬脂富马酸钠、丁二酸钠六水合物、硫酸钠、无水硫酸钠、十水硫酸钠、亚硫酸钠、磺基琥珀酸十一烷醇酰胺钠、酒石酸钠、硫代乙醇酸钠、硫代苹果酸钠、硫代硫酸钠、无水硫代硫酸钠、三偏磷酸钠、三聚磷酸钠、二甲苯磺酸钠、山梨酸、山梨聚糖、山梨聚糖异硬脂酸酯、山梨聚糖单月桂酸酯、山梨聚糖单油酸酯、山梨聚糖单棕榈酸酯、山梨聚糖单硬脂酸酯、山梨聚糖倍半油酸酯、山梨聚糖三油酸酯、山梨聚糖三硬脂酸酯、山梨糖醇、角鲨烷、2-乙基己酸亚锡、硬脂氯化铵、硬脂锂蒙脱石/碳酸亚丙酯、硬脂酰氨基乙基二乙胺、硬脂酸盐、硬脂酸、硬脂酸二乙醇酰胺、硬脂氧基三甲基硅烷、硬脂醇、琥珀酸、三氯蔗糖、蔗糖、蔗糖二硬脂酸酯、蔗糖月桂酸酯、蔗糖棕榈酸酯、蔗糖聚酯、蔗糖硬脂酸酯、蔗糖糖浆、磺胺乙酰胺钠、磺丁基醚β-环糊精、塔格糖、酒石酸、tegacid、叔丁基对苯二酚、替曲磷、茶碱、硫柳汞、苏氨酸、百里酚、生育酚、生育酚、黄蓍胶、甘油三乙酸酯、磷酸三钠、磷酸三钠一水合物、三苯酚、三辛精、三鲸蜡硬脂醇聚醚-4磷酸盐、三乙醇胺月桂基硫酸盐、柠檬酸三乙酯、三羟基硬脂精、三羊毛醇聚醚-4磷酸盐、月桂醇聚醚-4磷酸盐、三肉豆蔻精、tris、柠檬酸三钠二水合物、羟乙基二胺四乙酸三钠盐、三硬脂精、三乙醇胺、曲金刚烷胺、氨丁三醇、色氨酸、泰洛沙泊、酪氨酸、十一碳烯酸、尿素、氨基甲酸乙酯、熊二醇、缬氨酸、香草醛、维塞他胺、维斯卡林、维生素E、醋酸维生素E、维生素K5、木糖醇、和硫酸锌。还参见美国专利7,927,613,其以引用方式全文纳入本文。其他药学上可接受的共形成物包括“一般认为安全”(“GRAS”)和/或美国FDA“美国食品中添加的所有物质”(“EAFUS”)列表中描述的那些。
在某些实施方式中,一种或多种药学上可接受的共形成物中的至少一种选自下组:咖啡因、尿素、对氨基苯甲酸、茶碱、苯甲酸苄酯、和烟酰胺。在某些实施方式中,一种或多种药学上可接受的共形成物中的至少一种不是选自下组的那些:咖啡因、尿素、对氨基苯甲酸、茶碱、苯甲酸苄酯、和烟酰胺。在其他实施方式中,一种或多种药学上可接受的共形成物中的至少一种不是选自下组的那些:乙酰胺、苯甲酰胺、2-氨基噻唑、和异烟肼。在其它实施方式中,一种或多种药学上可接受的共形成物是氨基酸(例如脯氨酸,例如D-脯氨酸或L-脯氨酸,或外消旋脯氨酸)。在另一个实施方式中,一种或多种药学上可接受的共形成物是5-10(例如5-9、5-6或5)元杂芳基,例如含氮杂芳基,例如咪唑。
在某些实施方式中,一种或多种药学上可接受的共形成物中的至少一种是第二API。在这些实施方式中的某些实施方式中,第二API独立地选自(-)-氨氯地平、(-)-卤芬酯、(R)-沙丁胺醇、(R)-沙丁胺醇、(R,R)-福莫特罗、(S)-多沙唑嗪、(S)-氟西汀、(S)-奥昔布宁、1,2-萘醌、17-甲基睾酮、17α-羟基孕酮、195mPt-顺铂、1-萘基水杨酸酯、1-萘胺-4-、1-可可碱乙酸、1α-羟基胆钙化醇、2,4,6-三溴间甲酚、2,6-二氨基-2'-丁氧基-3,5'-偶氮吡啶、2-[[[(1r)-2-(1h-咪唑-4-基)-1-甲基乙基]亚氨基]苯甲基]-苯酚、21-乙酰氧基孕烯醇酮、2-氨基-4-甲基吡啶、2-氨基噻唑、2-乙氧基苯甲酸、2-萘酚、2-苯甲酸萘酯、2-乳酸萘酯、2-水杨酸萘酯、2-对磺基苯胺乙醇、2-硫尿嘧啶、3′,3″,5′,5″-四溴酚酞、3-氨基-4-羟基丁酸、3-溴-D-樟脑、3-羟基樟脑、3-O-月桂酰吡哆醇二乙酸酯、3-十五烷基儿茶酚、3-奎宁环醇、4,4'-氧化二-2-丁醇、4,4'-亚磺酰二苯胺、4-氨基-3-羟基丁酸、4-氨基-3-苯基丁酸、4-氨基水杨酸、4-氯间甲酚、4-己基间苯二酚、4-水杨酰吗啉、5'-硝基-2'-丙氧基乙酰苯胺、5-氨基乙酰丙酸、5-阿扎胞苷、5-溴水杨酰异羟肟酸、5F-DF-203、5-FU、5-HT3拮抗剂、6-氮杂尿苷、6-巯基嘌呤、8-羟基喹啉、9-氨基喜树碱、A-151892、A-5021、阿巴卡韦、阿巴哌酮、阿巴瑞克、阿昔单抗、阿贝卡尼、阿比莫司、阿比特龙、ABLC、ABT-751、AC-5216、阿卡地辛、阿坎酸、阿坎酸、阿卡波糖、醋氨茶碱、醋丁洛尔、醋卡胺、醋卡溴胺、醋氯芬酸、安定松、醋二砜、醋茶碱、乙酰谷酰胺、乙酰谷酰胺、阿西美辛、醋硝香豆素、乙酰氨基酚、乙缩醛、乙酰氨基丁香酚、对乙酰氨基酚、对乙酰氨基酚、乙酰苯胺、乙酰松、乙酰唑胺、乙胺、乙酰己酰胺、乙酰氧肟酸、乙酰吩嗪、乙酰苯胺、苯乙酮、乙酰砜、乙酰唑酮、醋曲唑、乙酰、乙酰肉碱、乙酰胆碱、乙酰胆碱、乙酰半胱氨酸、乙酰亮氨酸、乙酰苯乙脲、乙酰水杨酸盐、乙酰水杨酸、阿昔洛韦、阿西弗兰、阿西莫司、阿司匹林、阿维A、阿柔比星、阿克拉铵、乌头碱、acranil吖啶黄、茴香霉素、阿克伐斯汀、阿克伐斯汀、阿塔加定衍生物、阿克他利、ACTH、阿昔洛韦、阿达帕林、ADCON-L、阿德福韦、阿德福韦酯、腺苷、三磷酸腺苷、ADEPT、阿地唑仑、地芬宁、ADL-10-0101、阿屈非尼、肾上腺酮、肾上腺素红、阿德罗内酯、AEOL-10150、炔诺酮、AET、AF-2259、阿氟喹酮、AG-041R、AG-2037、AGN-194310、阿戈美拉汀、阿希斯坦、AHL-157、AIT-034、AIT-202、AJ-9677、AJG-049、阿吉马林、阿克苏去氧孕烯、阿拉普利、阿拉哌唑、阿巴康唑、阿苯达唑、沙丁胺醇、沙丁胺醇、阿氯芬酸、阿氯米松、阿库溴铵、尿囊素铝、醛醇、醛固酮、阿仑膦酸盐、阿仑膦酸、阿来昔定、阿法骨化醇、阿法多龙、阿法沙龙、阿芬太尼、阿非美拉酶、阿夫唑嗪、阿夫唑嗪、海藻石、海藻石、海藻精、糖苷酶、阿利苯多、阿利吉仑、阿立替丁、阿利扎必利、紫草素、氨磺苯、尿囊素、阿洛巴比妥、别嘌醇、异硫氰酸烯丙酯、烯丙基雌烯醇、海藻酸盐,铝镁加、阿米洛芬、阿米特林、阿莫曲坦、芦荟大黄素、芦荟素、阿洛司琼、阿洛夫定、阿洛西林、α-、α-1蛋白酶、阿法罗定、阿尔吡登、阿吡必利、阿普唑仑、阿普洛尔、阿沙克肽、ALT-711、阿尔噻嗪、阿替克林、六甲密胺、六水氯化铝、铝、醋酸铝溶液、氯酸铝、羟基氯化铝、硫酸铝钾、硫酸铝钠、铝硫复、阿尔维林、爱维莫潘、阿伏西地、ALX-0646、AM-24、AM-36、AM-477、金刚烷胺、金刚溴铵、安巴宗、安倍铵、安立生坦、氨溴索、安布卡因、安布茶碱、安布西德、溴化铵、安西宁、AMD-3100、氨苄青霉素、氨苄西林匹酯、阿多索韦、阿美卢班、苯佐卡因、氨甲氧苯嗪、安芬酸、氨肾上腺素、脒霉素、氨磷汀、阿米鲁胺、阿米卡星、阿米洛利、胺吖啶、阿尼普汀、氨硝唑、氨基酸制剂、氨基己酸、氨基谷氨酰胺、氨基胍、氨基马尿酸盐、氨基美特拉定、氨基戊酰胺、氨茶碱、氨基丙嗪、氨基比林、氨基奎脲、氨基雷克斯、胺碘酮、胺碘地平、阿米芬唑、阿米普利糖、氨磺必利、阿米替林、阿米替林+氯胺酮、阿米替林氧化物、氨来诺、氨水、氨化氯化汞、苯甲酸铵、扁桃酸铵、水杨酸铵、戊酸铵、阿莫巴比妥、阿莫卡津、阿莫地喹、阿莫罗芬、阿莫斯卡纳、阿莫舒洛尔、阿莫替林、阿莫沙平、阿莫西林、阿莫西林+克拉维兰钾、AMPAlex、安非他明、安非他明、两性霉素B、氨苄青霉素、氨吡昔康、安普利健、安普那韦、氨糖、氨柔比星、安吖啶、安托美汀、胺卡因、AN-152、合成代谢类固醇、阿那格石、阿那格雷、阿那曲唑、阿那佐林、安西他滨、蛇毒去纤维酶、安多司特、雄异恶唑、雄烯二醇、阿奈可他、茴香脑、茴香脑三硫酮、血管生成素、血管紧张素、脱水长春碱、阿尼芬净、阿尼乐定、阿尼西坦、茴茚二酮、茴香霉素、各异托品、阿尼替普酶、安他唑啉、安锑锂明、蒽三酚、安曲霉素、脱氧茜素、炭疽抑制剂、抗血管生成剂、抗皮质激素、抗抑郁药、抗侵袭素、酒石酸锑钾、硫乙醇酸锑钠、硫乙醇胺锑、抗孕激素、安替比林、水杨酸安替比林、抗凝血酶III、抗焦虑药、AP-521、AP-5280、阿帕西林、阿帕齐醌、阿帕松、阿扑可待因、阿扑明、阿扑吗啡、阿普乐定、阿瑞匹坦、阿普林定、阿普罗巴比妥、阿普罗奈特、抑肽酶、阿替加奈、AQ4N、磷丙泊酚二钠、AR-116081、AR-A2、花生四烯酸、阿尼地平、阿贝卡星、阿比朵尔、阿布他明、阿西单抗、阿地肝素、槟榔碱、阿加曲班、精氨酸、Ariflo/>阿立哌唑、阿洛茶碱、阿罗替洛尔、阿塞西丁、三氧化二砷、阿斯芬明、蒿乙醚、阿替夫林、蒿甲醚、青蒿素、蒿乙醚、青蒿琥酯、阿佐昔芬、AS-3201、ASA、蛔虫醇、抗坏血酸、阿塞那平、阿西马多林、阿索卡波肼、阿索普利、阿肟、天冬氨酸、阿司匹丁、天冬氨醇、、阿司匹林、阿司匹林双嘧达莫、阿扑西林、AST-120、阿司咪唑、舒拉克林、AT-1015、阿他美坦、阿扎那韦、阿替洛尔、阿替洛尔+氯噻酮、阿替洛尔+硝苯地平、阿替韦定、阿替美唑、阿替莫德双马来酸酯、ATL-146e、阿托西汀、阿托伐他汀、阿托西班、阿托伐醌、阿托伐醌+氯胍、阿曲库铵、阿曲生坦、心钠素、阿曲内酰胺、阿托品、奥格门汀、金诺芬、金硫葡萄糖、阿瓦西米贝、阿伏苯宗、AWD-12-281、阿扎胞苷、氮杂环醇、氮杂硝唑、氮杂普酮、氮杂色林、阿扎司琼、阿扎他定、硫唑嘌呤、AZD-4282、AZD-6140、壬二酸、氮卓斯汀、阿齐地平、阿齐达芬尼考、阿齐多西林、阿齐利特、阿齐胺、阿奇霉素、阿洛西林、阿佐塞米、氨曲南、薁、巴卡西林、杆菌肽、巴氯芬、黄芩素、巴洛沙星、巴柳氮、班布特罗、巴米坦、巴可可碱、巴米平、巴比妥、巴尼地平、BAS-118、碱性氧化铝、巴利昔单抗、巴马司他、巴曲酶、Bay-41-2272、Bay-41-8543、BAY-43-9006、BAY-57-1293、巴多昔芬、BBR-3464、BBR-3576、BBR-3610、BCH-1868、贝比林、倍草胺、倍氯米松、贝氟沙酮、贝福洛尔、贝美格瑞、苯那替嗪、苯那普利、苯环烷、苯达扎克、苯氟噻嗪、苯甲奈德、苯奈沙、苯氟噻胺、苯氟硫胺、苯呋地尔、苯地平、苯诺酯、苯诺沙洛芬、苯诺昔酯、苯哌利多、苯丙哌林、苄丝肼、苯他西泮、苯替罗米特、苯托夸坦、苯扎贝特、苯扎氯铵、苯扎隆、苄星、苯溴马隆、苄索铵、苯甲亚胺、苯齐氯铵、苯并碘酮、苯并硝唑、苯佐卡因、苯甲胺、苯佐那酯、苯氧氯铵、过氧化苯甲酰、苯甲酰帕斯、苯丙胺、苯并哌啶、苯喹酰胺、苯并噻嗪、苯托品、苄达明、苯甲酸苄酯、苄基氢氯噻嗪、苄基吗啡、苄酚宁、贝他斯汀、贝普利地尔、贝前列素、小檗碱、佛手柑、贝莫洛芬、贝西匹定、倍他司汀、甜菜碱、倍他米松、倍他米普龙、甜菜碱、倍他洛尔、倍他唑、倍他胆碱、倍他尼定、贝托卡因、贝万洛尔、贝伐铵、贝沙罗汀、苯甲酰胺、BG-9928、BIA-2-024、BIA-2-093、BIA-3-202、比拉米考、比阿培南、联苯铵、比溴乙醇、比卡鲁胺、比西发定、比西沙、双环、比二咪胺、比他米林、比他诺汀、比他丝平、比弗美兰、联氟醚醇、联苯苄唑、比马前列素、比莫氯酚、比莫西莫糖、比尼贝特、比诺地松、biomed-101、生物素、比哌立登、比立哌酮、birlcodar、比沙可啶、比生群、双苯二胺、地喹氯铵、铋、铋、铋、铝酸铋、乙基铋、铋钠、三乙醇酸铋钠、碱式碳酸铋、碱式没食子酸铋、碱式硝酸铋、碱式水杨酸铋、比索洛尔、比索洛尔+HCTZ、比索洛尔+三氯噻嗪、比沙丁、比硫醇、比托特罗、比托斯卡纳、BL-3875、博来霉素、布南色林、BMS-184476、BMS-387032、BN-82451、BNP-7787、BO-653、硼兰二醇、勃拉睾酮、勃地酮、苯丙洛尔、冰片基氯、水杨酸冰片酯、硼替佐米、波生坦、泊拉得可、脑钠素、布洛巴比妥、布拉索芬辛、布雷奎那、溴乙炔、亮绿色、溴莫尼定、布林佐胺、布立夫定、溴地莫林、溴西泮、溴芬酸、溴己新、溴二酮、溴米索伐、溴隐亭、溴苯海拉明、溴仿、溴必利、溴水杨酰氯苯胺、溴哌啶醇、溴苯那敏、溴苯雌酚、溴匹利明、溴林霉素、溴替唑仑、溴长春胺、溴喹啉、溴尿苷、布鲁辛、布西汀、布西拉明、布欣多洛尔、布克拉地新、布克利嗪、布氯沙胺、布可隆、丁吖卡因、布库洛尔、布地奈德、布地奈德+福莫特罗、布地平、布德拉嗪、布非碘、布非洛尔、布非昔单抗、布洛地尔、丁双胍、布呋洛尔、布马地松、布美他尼、布那芬、布那芬钠、布那唑嗪、布尼洛尔、布比卡因、布匹洛尔、丁丙诺啡、安非他酮、布丁胺、布舍瑞林、丁螺环酮、白消安、白消安、丁巴比妥、丁卡因、布他西丁、布他拉胺、布他比妥、丁溴比妥、氨苯丁酯、丁胺氧酯、布坦卡因、布他拉嗪、丁弗林、丁唑胺、丁膦酸、布替萘芬、丁苯乙胺、丁苯胺、丁他明、丁他利、布噻嗪、布替巴芬、布丁胺、布托苯丁、布康唑、丁辛酰胺、布托洛尔、布托啡诺、丁氧卡因、布曲替林、布托溴铵、硫代月桂酸丁酯、丙酸丁酸酯、布西匹特、BVT-5182、BXT-51072、C-1311、卡麦角林、卡麦角林、二甲双胍酸、放线菌素、卡地美碘、水杨酸镉、卡德拉嗪、咖啡胺醇、咖啡因、骨化二醇、卡泊三烯、卡泊三醇、卡泊三醇+倍氯米松、骨化三醇、3-金硫-2-丙醇-1-磺酸钙、乙酰水杨酸钙、溴乳酸钙、碳酸钙、葡萄糖酸钙、甘油磷酸钙、泛酸钙、碘山嵛酸钙、碘硬脂酸钙、乳酸钙、乙酰丙酸钙、中草酸钙、N-氨基甲酰天冬氨酸钙、聚卡波非钙、丙酸钙、琥珀酸钙、caldaret、月见草酮、卡西泮、卡莫司他、樟脑、樟脑酸盐、樟脑酰胺、喜树碱、坎地沙坦、坎地沙坦酯、坎多沙曲、卡纳替尼、坎利酮、斑蝥素、莫坎妥珠单抗、卡培他滨、卡本酸、卡普韦林、卡罗单抗、辣椒素乳膏、卡托二胺、卡托普利、卡托普利+HCTZ、卡布利特、卡巴沙、卡米芬、咔唑醇、卡巴胆碱、卡马西平、过氧化脲、卡巴松、甲萘威、咔唑铬、多菌灵、羧苄青霉素、生胃酮、维静宁、carbicarb、卡比多巴、卡比多巴+左旋多巴-1、卡比马唑、羧甲胺、氯醛、羧半胱氨酸、四氯化碳、碳酸盐凝胶、卡铂、卡前列素、卡前列素、卡波醌、卡布罗姆、卡巴巴、卡丁酰胺、卡布特罗、卡非氨酯、甘草酸、卡古缩宫素、卡林达西林、卡立普瑞特、卡立普瑞、卡立普多、卡莫氟、卡莫昔罗、卡莫司汀、肉碱、胡萝卜素、卡洛沙宗、卡芬那嗪、卡匹帕明、卡洛芬、卡萨拉姆、卡替洛尔、卡替卡因、卡比星、香豆素、香芹酚、卡维地洛、香芹酮、卡卡里林、卡泊芬净、儿茶素、组织蛋白酶K抑制剂、组织蛋白酶S抑制剂、CC-401、CCI-779、CCR5拮抗剂、CDC-394、CDC-801、CEE-03-310、西华克乐、头孢羟氨苄、头孢氨苄、头孢氨苄酯、头孢孟多、头孢曲嗪、头孢西酮、头孢唑啉、头孢哌酮、头孢卡宾酯、头孢克定、头孢地尼、头孢托仑酯、头孢吡肟、头孢他美、头孢他美酯、头孢克肟、头孢甲肟、头孢美唑、头孢米诺、头孢地嗪、头孢尼西、头孢哌酮、头孢哌酮+舒巴坦、头孢尼特、头孢塞利斯、头孢他啶、头孢替坦、头孢替安、头孢替安、头孢西丁、头孢唑啉、头孢匹唑、头孢匹胺、头孢匹罗、头孢泊肟、头孢丙烯、头孢沙定、头孢磺胺、头孢他啶、头孢特仑、头孢唑啉、头孢替布烯、头孢唑肟、头孢唑肟、头孢曲松、头孢呋辛、头孢呋辛酯、头孢唑南、塞来昔布、西戈西韦、西利洛尔、乙基纤维素、CEP-1347、CEP-701、头孢氨苄、头孢氨苄、头孢氨苄、头孢霉素、头孢洛定、头孢菌素C、头孢噻吩、头孢匹林、头孢拉定、西立伐他汀、西罗那普利、西托肝素、西乐肽、西替前列素、西他氯铵、西他莫洛尔、西塞氯铵、赛红霉素、西替地尔、西替利嗪、西替利嗪、西替利嗪+伪麻黄碱、西托硫胺、西妥昔、西曲沙、西曲铵、西曲瑞克、鲸蜡基二甲基乙基铵、鲸蜡基吡啶鎓、西维美林、CG-1521、芍药酸鹅二醇、CHF-3381、氯苯达诺、氯西嗪、氯醛、苯丁酸氮芥、氯胺-B、氯胺-T、氯氨基-氯霉素、氯氮卓、氯苯甲胺、氯贝他胺、氯环嗪、氯丹妥因、氯胍、氯己定、氯己定、氯氮平、氯异丹明、氯地黄酮、氯美罗定、氯美扎酮、氯咪唑、氯萘嗪、氯唑啉、叶绿素、氯泼尼松、氯普鲁卡因、氯吡胺、氯喹、氯霉素、氯噻嗪、氯三苯、氯辛、氯二甲苯酚、氯唑菌素、扑尔敏、氯苯那新、扑尔敏、扑尔敏、扑尔敏、扑尔敏、氯丙嗪、氯丙胍、氯丙胍+氨苯砜、氯丙嗪、氯丙胺、氯丙噻吩、氯喹诺醇、金霉素、氯噻酮、氯噻嗪(e)、氯唑沙宗、胆酸、胆碱、茶碱酸胆碱、L-甘磷酸胆碱、铬威威、克罗那、金黄素、CHS-828、CI-1031、CI-1040、西苯啉、环索奈德、环索坦、环氯酸盐、环吡酮、环西多明、环孢素A、西多福韦、西芬林、西兰司琼、西司他丁、西拉普利、西仑吉肽、西尼地平、西洛司特、西洛他唑、西咪替丁、西美托溴铵、西那卡塞、辛可尼定、辛可宁、金可芬、桂哌酯、桂哌齐特、桂哌齐特、西尼他必利、桂美新、肉桂碱、桂利嗪、西诺西泮、西诺沙星、西诺沙酯、桂溴胺、塞奥罗奈、西帕可林、西帕利桑、环丙贝特、环丙沙星、环丙沙星+西拉马多、西沙必利、西沙曲库铵、顺铂、西酞普兰、胞磷胆碱、西噻酮、柠檬酸盐、柠檬酸、瓜氨酸、西唑拉汀、CJ-13610、CKD-602、克拉屈滨、克拉诺布丁、克拉霉素、克拉维兰、克拉维酸二钠、克拉维酸、氯苯必利、氯马斯汀、克立咪唑、克仑特罗、克林特西姆、克维地平、克利夫定、克立达酸、克力溴铵、克林沙星、克林霉素、克林霉素、克林霉素+维甲酸、克林诺贝特、克林前列素、氯巴占、氯苯呋喃、氯苄葡甙、氯苯西泮、氯苄雷司、氯苯托品、氯倍他索、氯倍他松、氯丁替诺、氯卡帕明、可乐宁、氯康唑、氯可龙、氯膦酸盐、氯膦酸、氯法拉滨、氯法齐明、氯芬胺、氯贝特、氯贝酸、氯氟卡班、氯福克酚、氯福雷司、氯马克仑、氯甲睾酮、氯美辛、氯美噻唑、氯甲氧西林、克罗米芬、氯米帕明、氯霉素、氯硝西泮、可乐定、氯硝唑、氯硝基酯、氯尼辛、氯帕胺、氯哌噻吨、氯哌斯汀、氯吡格雷、氯吡拉克、氯泼诺、氯萘洛尔、氯拉西酸、氯雷索龙、氯克罗敏、氯茚二酮、氯丙肾上腺素、氯特明、氯吡嗪、氯司替勃、氯噻平、氯硫西泮、克霉唑、克霉唑+倍他米松、氯唑西林、氯沙唑仑、氯睾酮、氯氧喹、氯氮平、CMI-392、CMT-3、CNI-1493、CNS-5161、钴胺、可卡乙烯、可卡因、可待因、辅因子、秋水仙碱、考来维仑、考来替兰、考来替泊、考福辛达罗帕特、棕榈酸可夫色尔、collagraft、结肠素、双醋羟雌酮、考拉西坦、考布他汀A-4前药、化合物B、考尼伐汀缀合物、透明质酸钠、铃兰毒素、科帕腊芬内特、可的瑞林ovine、皮质酮、可的松、可的唑、促性腺激素、可他宁、可替宁、复方三嗪、香豆素、CP-248、CP-461、CPC-211、CPI-1189、CRA-0450、肌酸-O-磷酸、CRL-5861、克罗奈汀、克罗康唑、色甘酸、色甘酸钠、克罗丙酰胺、克罗米通、克罗他胺、克立他杀、CS-502、CS-758、CS-834、CT-052923、CT-32228、柠檬酸铜、铜克索林、CVT-2584、CX-659S、氰乙酰胺、氰胺嗪、花青素、CYC400、环西林、环烷烃、环佐辛、环克沙酮、环西塞林、环丙醇、细胞周期蛋白D1抑制剂、环利嗪、环巴比妥、环苯达唑、环苯扎林、环丁醇、环香豆素、环己酮、环苯胺、环胍、环甲卡因、环尼洛特、环戊胺、环戊噻嗪、环戊巴比妥、环戊酯、环磷酰胺、环吡咯烷胺、环丝氨酸、环噻嗪、环戊二烯酮、仙人掌素、仙人掌丝氨酸、洋蓟素、cyp26抑制剂、赛庚啶、环丙孕酮、半胱胺、囊性纤维化治疗剂、阿糖胞苷、D-24851、D-4418、DA-5018、DA-6034、DA-7867、DA-7911、DA-8159、达卡巴嗪、达珠单抗、放线菌素、达巴万星、达福普汀、达福普汀+奎奴普汀、达肝素、达曲班、达那帕罗、达那唑、丹松隆、丹曲林、达哌唑、达匹韦林、达泊西汀、氨苯砜、达托霉素、达贝泊汀阿尔法、达利那新、柔红霉素、DAX<SciClone、DB-67、D-樟脑羧基、DCF-987、DDT、脱氨催产素、脱醇、去甲喹、十甲铵、地西咪胺、地西他滨、地氯普胺、去铁酮、去铁胺、地氟沙可、去磷酰胺、地加瑞克、脱氢抗坏血酸、脱氢吐根碱、脱氢胆酸、地拉普利+地拉普利、地拉普利、地拉韦定、地尔麦地酮、地莫匹诺、地洛西泮、地西明、地曼尼、地麦草、地美环素、地美秋霉素、地甲孕酮、地美替林、地那维林、树枝状大分子、地尼介素、地诺巴胺、地诺蝶呤、脱氧胆酸、脱氧皮质酮、脱氧二氢链霉素、脱氧肾上腺素、去肽、去肽、去托品、地喹铵、德沙拉嗪、地塞匹定、去铁胺、地氟醚、地昔帕明、地斯拉诺苷、地氯雷他定、地氯瑞林、去氨加压素、去氧孕烯、去氧孕烯+雌二醇、去氧孕烯+炔雌醇(1)、地索吗啡、地奈德、地塞米松、去葡聚糖、devacade、地塞米松、地塞米诺、地塞多曲、地塞法罗生、地塞米特、右布洛芬、右酮洛芬、右西鲁米特、右美托咪定、右旋哌甲酯、右泛醇、右雷佐生、葡聚糖-1、右旋聚体、右旋安非他明、右美沙芬、右美胺、右丙氧芬、地佐辛、DF-1012、DFA-IV、D-茴香酮、D-葡萄糖醛酸内酯、Diab II、双醋瑞因、二安普胺、二咪唑、二百里砜、泛影酮、地西泮、二嗪酮、二氮嗪、地贝卡星、地苯西平、二溴丙脒、地布卡因、地氯苯那宗、二氯胺T、二氯松、二氯苯甲醇、二氯醇、二氯苯酚、二氯苯胂、二氯苯胺、双氯芬酸、双氯芬酸+HA、双氯西林、双香豆素、双香豆素、双环胺、去羟肌苷、去氧腺苷、地诺孕素、地诺孕素、地诺孕素、地诺孕素+雌二醇、二乙二酮、二乙嗪、二乙胺、二乙基溴乙酰胺、二乙基氨基甲酸酯、二乙基丙酸、己烯雌酚、二非美林、地芬那唑、地芬诺辛、地芬吡胺、二氟替康、地氟拉松、地氟沙星、地氟可龙、地氟尼柳、地氟泼尼酯、洋地黄素、地高辛、地高辛、地己维林、二肼、二氢可待因、二氢可待因烯醇、二氢麦角隐亭、二氢麦角隐亭、二氢麦角胺、二氢吗啡、二氢链霉素、二氢速甾醇、二羟基铝、二异丙胺、二异丙基对氧磷、二异丙胺、地拉西普、地尔瓦洛尔、地洛尼特、地尔硫卓、二麦角酸、二甲胺、二甲胺、二甲氧苯丙酸、二苯海明、二甲恶唑、二甲庚醇、二巯基丙醇、二甲克林、二甲二酮、二甲山、二甲茚、二甲异喹、二甲睾酮、地美卡因、二甲氧乙酯、二甲基亚砜、二甲基噻丁烯、二甲托福林、二吗啉、地诺前列酮、透钙石、地奥司明、二苯恶啶、二氧杂萘基、二恶塞碱、双氧苯宗、双苯胺、地芬那酮、苯丙氨酸、苯海拉明、地苯多酚、地芬诺酯、二苯吡咯啉、地芬他松、白喉和破伤风类毒素和无细胞百日咳疫苗吸附、地哌酮、地匹福林、双嘧达莫、双嘧达莫、双硫氰酸、安乃近、地夸磷索、地红霉素、帕米膦酸二钠、地索非宁、丙吡胺、地斯的明、双硫胺、双硫仑、地他唑、二噻嗪、地蒽酚、二硫威、双黄原、二恶嗪、DJ-927、DK-507k、DL-乳酸、DMDC、DMXAA、DNA Stealth、羟苯磺酸盐、多巴酚丁胺、多卡巴胺、多西他赛、二十二碳六烯酸、二十二烷醇、多库酯、多非利特、多拉司琼甲磺酸盐、多碘多、多米芬、多米曲班、多潘立酮、多奈哌齐、多尼曲坦、多巴胺、多培明、多拉匹莫德、多拉硝唑、多瑞培南、多佐胺、多佐胺+噻吗洛尔、多斯麦酯、多舒平、多他利嗪、多硫平、多沙库铵、多沙普仑、多沙唑嗪、多西西泮、多塞尼妥英、多塞平、多塞骨化醇、多西氟尿苷、多索茶碱、多柔比星、多西环素、多西拉敏、DPC-817、DPI-3290、DQ-113、屈洛芬、屈洛昔芬、屈美曲唑、屈莫司酮、屈大麻酚、屈奈达隆、氟哌利多、屈苯丙胺、屈丙嗪、屈螺酮、屈他维林、屈他巴诺、屈洛昔康、屈西多巴、屈西多巴、DU-125530、度洛西汀、耐久霉素、杜拉帕特、度他雄胺、DW-1141、DW-286a、DW-471、DX-9065a、DY-9760e、达克罗宁、地屈孕酮、达曼辛、达菲林、E-1010、E-2101、E2F拮抗剂、E-3620、E-5564、E-5842、E-6259、EAA-90、依巴斯汀、依伯康唑、依溴替丁、依布硒啉、依本胺、依卡巴派特、依卡贝特、依卡曲利、依哥宁定、依哥宁、依多舒定、益康唑、依可哌泮、依克拉前列素、依地脲、ED-71、依达拉奉、依达曲沙、依地酸钙二钠、依地酸二钠、依地酸钠、依地酸三钠、依地那坦、依多曲肽、依度舒定、依地可洛单抗、依德罗铵、依夫立特、依夫普罗、依非韦伦、依氟利嗪、依氟鸟氨酸、依氟沙特、氟西米贝、依氟地平、EGIS-7229、胃脘、乙呱仑、依拉非班、降钙素、二十碳五烯酸、章鱼毒素、依立曲坦、依高地平、鞣花酸、甲基羟基玫瑰树碱、依托拉嗪、艾夫他滨、苊烯、酸藤子酚、溴甲苯醇胺、依美司汀、依麻溴铵、依美汀、乙嘧替氟、EMM-210525、大黄素、依莫法宗、EMR-62203、恩曲他滨、异戊烯酸、依那普利、依那普利拉、烯丙基丙醛、恩卡尼、恩西拉嗪、恩曲拉嗪、恩芬那酸、恩氟醚、恩康唑、恩尿嘧啶、ENMD-0995、依西他滨、enol-3-IPA、依诺沙星、依诺肝素、依诺昔酮、依诺松、恩前列素、恩拉生坦、恩他卡朋、恩替卡韦、环霉素、依帕司他、依帕韦、EPC-K1、乙哌立松、依帕夫定、麻黄碱、表皮西林、吡美甾酮、依匹斯汀、依匹唑、表柔比星、表甾醇、依普利酮、依立凡色林、依前列醇、依波司坦、依普拉西酮、依普列特、依普罗沙坦、依普罗西诺、依他匹隆、依普铂、依普斯的明、依他佐辛、依替巴肽、马蹄莲素、马烯雌酮、ERA-923、厄多司坦、麦角角碱、麦角角碱、甲磺酸麦角素、麦角新碱、麦角甾醇、麦角胺、香菇嘌呤、厄洛替尼、厄他培南、四硝酸赤藓酯、红半胱氨酸、红霉素、红霉素、红霉素、红霉素葡庚糖酸盐、乳糖酸红霉素、丙酸红霉素、硬脂酸红霉素、斯诺普酸红霉素、依沙拉唑、依他普仑、七叶苷、艾司洛尔、埃索美拉唑、艾司唑仑、酯、雌二醇、雌二醇、雌莫司汀、雌三醇、雌激素、雌酮、右佐匹克隆、依他非林、依他酮、依那西普、依他硝唑、依喹酮、依他巴、依沙吖啶、依他利酸、乙氧嘧啶、乙胺丁醇、乙胺胺、乙胺磺酸盐、乙醇胺、依他维林、乙氯维诺、乙息胺、乙噻嗪、乙氨酰胺、乙炔雌二醇、乙炔雌二醇、乙炔雌二醇、乙硫异烟胺、乙炔酮、乙庚嗪、乙丙嗪、乙琥胺、乙妥英、乙恶唑胺、乙炔托品、乙醇、双香豆酸乙酯、氯乙烷、二丁二酸乙酯、乙醚、二十碳五烯酸乙酯、氯磺草酸乙酯、氯磺草酸乙酯、乙胺、乙烯、乙雌醇、亚乙基、乙基甲基噻丁烯、乙基吗啡、乙基去甲肾上腺素、炔二醇、乙炔基胞苷、依替卡因、依替膦酸盐、依替膦酸、依替福明、依替福辛、依替福林、依替伏多巴、依替泼诺、依替洛沙、依替唑仑、依托度酸、依托西嗪、乙托芬酯、乙托贝特、乙托茶碱、乙托茶碱氯贝特、乙托茶碱烟酸酯、乙托葡糖、依托咪酯、乙托美林、依托尼他烯、依托孕烯、依托哌酮、依托泊苷、磷酸依托泊苷、依托考昔、依托考昔、依托唑啉、依维甲酸酯、乙胺、乙丙嗪、优卡托品、丁香酚、EUK-134、EUK-189、埃文斯蓝、依维莫司、乙丙胺、埃塞他嗪、埃塞替康、依西美坦、埃西芬、依昔舒林、Exosurf/>依折麦布、IX因子、VIII因子、XIII因子、法多咪定、法曲唑、法替骨化三醇、泛昔洛韦、法莫替丁、泛吡啶、凡多沙星、凡托法隆、法罗培南、法罗培南达洛沙、法西多曲、法舒地尔、法扎溴铵、非巴氨酯、非布洛尔、非布司他、非多津、非尔氨酯、联苯乙酸、非洛地平、felypressin、非莫西汀、芬苯西林、芬布芬、芬布特、芬卡芬、芬卡明、芬氯酸、芬地林、芬多沙、芬乙酯、芬氟拉明、非尼喷妥、非诺贝特、非诺多泮、非诺洛芬、非诺特罗、非诺维林、非诺唑啉、非诺地尔、芬唑酮、芬戊二醇、芬哌烷、芬哌维铵、芬丙普瑞、芬喹酮、芬维A胺、芬司匹利、芬太尼、芬替扎克、芬替克罗、芬替康唑、溴化芬顿铵、非哌地醇、非拉宗、依地酸铁钠、亚铁胺B、亚铁胆碱酸盐、葡萄糖酸亚铁、阿魏醇、非索罗定、非索非那定、纤维抑菌剂、非达司他、非多糖、非那雄胺、芬罗唑、非哌西特、FK-960、黄酮哌啶醇、黄酮酯、氟卡尼、氟罗沙星、氟西诺生、氟班色林、氟他非宁、氟氧头孢、氟吡酮、氟蒽醌、氟喹南、氟西林、氟尿苷、氟西嗪、氟苯尼松、氟利嗪、氟拉酮、氟唑菌酯、氟氯奈德、氟氯西林、氟康唑、氟胞嘧啶、氟达拉滨、氟脱氧葡萄糖F18、氟地西泮、氟氢可的松、氟芬那酸、氟茚二酮、氟马西尼、氟美辛醇、氟甲喹、氟米松、氟噻嗪、氟尼缩松、氟硝西泮、氟诺沙洛芬、氟轻松、氟轻松SAL、氟轻松、氟可汀丁基、氟可龙、荧光素、氟松、氟米龙、氟沙仑、氟尿嘧啶、氟西汀、氟甲睾酮、氟哌噻吨、氟哌噻吨、氟奋乃静、氟吡汀、醋酸氟泼尼松、氟泼尼松龙、氟丙喹酮、氟瑞诺内酯、氟拉西泮、氟比洛芬、氟红霉素、氟孕酮、氟噻吩、氟乐生、氟螺环、氟他胺、氟他唑仑、氟替卡松、氟托拉西泮、氟虫唑、氟托溴铵、氟伐他汀、氟伏沙明、叶酸、亚叶酸、氟哌唑、福米诺苯、福米韦森、福莫卡因、氟那嗪、磺达肝素、福美隆、福美坦、福莫替罗、福莫特罗、磷沙那韦、膦甲酸、磷苯酚、磷氟康唑、磷霉素、磷霉素、磷苯妥钠、福辛普利、磷苯妥英、福莫司汀、弗罗培南、弗罗曲坦、果糖、1,6-二磷酸果糖、FTC、FTY-720、氟多司坦、氟维司群、氟马吉兰、氟马吉林、呋喃他酮、呋喃唑啉、呋喃唑酮、呋喃唑氯化物、呋喃嗪、呋塞米、呋硫胺、呋塞米、夫西地酸、G1、YM BioSciences、G25、GABA-A Alpha5、加巴喷丁、加贝沙、加波沙朵、钆贝纳、钆布醇、钆二胺、钆、钆喷酸、钆特醇、钆维西胺、钆塞酸、加兰他敏、加兰他敏、加拉比星、没食子酸三乙胺、没食子酸、麦芽糖酸镓、硝酸镓、没食子安定、加奈索酮、更昔洛韦、加尼瑞克、更斯的明、甘托非班、加瑞沙星、加诺西汀、加替沙星、吉法酯、吉非替尼、吉卡宾、吉西他滨、吉美前列素、吉非罗齐、吉米沙星、庆大霉素、龙胆紫、龙胆苦苷、龙胆酸、吉培芬、吉哌隆、孕二烯酮、孕二烯酮+乙炔酯、己酸孕酮、孕三烯酮、喜树碱、环乙酰胺、木霉毒素、GL-406349、格拉芬宁、格拉替雷、格列本脲、格列齐特、格列美脲、格列吡嗪、格列酮、格列索胺、格列索皮、球蛋白(人)、葡糖胺、葡庚糖酸、葡糖酸、葡糖胺、葡糖砜、葡磷酰胺、谷氨酸、戊二醛、格列本脲、格列本脲、格列丁噻唑(e)、格列丁唑、甘油、甘油磷酸酯、甘氨醇、水杨酸乙二醇酯、甘氨酰肼、格隆溴铵、格列己酰胺、甘氨嘧啶、格列吡脲、GMDP、金钠、戈舍瑞林、GPI-1485、GPI-5693、移植皮、格拉司琼、格瑞沙星、灰黄霉素、愈创木酚、愈创木酚酯、愈创木灵、愈创甘油醚、愈创木醚、愈创木酚磺酸盐、胍美环素、胍苄、胍那瑞、胍乙啶、胍法辛、胍沙苄、鸟氧生、古古脂、古斯皮莫司、GW-280430A、GW-320659、GYKI-16084、哈奇霉素、哈西泮、哈西奈德、卤倍他索、卤泛群、卤米松、氟哌啶醇、氟哌啶酮、卤丙甙、卤丙烷、氟烷、卤唑仑、拉科酰胺、HE-2000、healos、血卟啉、甲磺酸、七巴比妥、七氨基酚、赫他西林、羟乙基淀粉、己内酯、六氯酚、六甲氰胺、六氟鎓、六甲铵、六脒、六丙酸、己二胺、己烯雌酚、己二烯雌酚双(β-二乙氨基乙醚)、己乙缩醛、己二胺、己巴比妥、己苯胺、甲基硫酸己环铵、己丙肾上腺素、羟乙基淀粉、己卡因、HF-0299、HGP-2、HGP-6A、喜思明、组胺、组胺吡咯烷、组胺、组胺、HM-101、HMN-214、后马托品、高甘芬、高氯环利嗪、藿香酸、HP-228、石杉碱甲、透明质酸、海康酮、次氢果酸、肼屈嗪、肼屈嗪、肼屈嗪、氢氯噻嗪、氢可酮、氢可酮、氢化可的松、氢化可的松、氢氟噻嗪、氢吗啡酮、氢奎尼丁、氢奎宁、氢醌、氢氧化物、羟钴胺素、羟苯丙胺、羟氯喹、羟二酮、羟乙醚、羟萘甲酸酯、羟哌替啶、羟苯甲酸酯、羟丙基纤维素、羟芪脒、羟丁卡因、羟嗪、Hylan G-F 20、琼脂素、莨菪碱、金丝桃素、IACFT、伊班膦酸、异巴胺、异巴胺、依布妥单抗、布洛芬、布洛芬匹康醇、布洛沙姆、伊布利特、ICA-17043、艾考糊精、伊达比星、艾达唑生、IdB-1016、艾地苯醌、IDN-5109、艾多昔芬、伊德拉肝素、伊多西胺、艾芬地尔、异环磷酰胺、艾拉莫德、艾普拉唑、伊洛马他、伊潘立酮、伊洛前列素氨丁三醇、ILX23-7553、伊马替尼、咪达普利、咪唑水杨酸盐、亚胺培南、丙咪嗪、丙咪嗪N-氧化物、咪喹莫特、伊莫拉明、英普他匹特、丙磺舒、灭活、伊那哌酮、茚卡膦酸盐、茚卡膦酸、吲达平、吲唑啉、吲达帕胺、吲哚卡尼、吲哚洛芬、吲哚洛尔、茚地那韦、吲地普隆、吲地司琼、吲哚磺胺、吲哚布芬、吲哚菁绿、吲哚美辛、吲哚洛芬、吲哚拉明、诱导剂、英夫利昔单抗、抑制剂、抑制剂、异丙肌苷、肌醇、烟酸肌醇、反向激动剂Mer、碘苯胍、碘苯甲酸、碘比三醇、碘甲酸、碘乙酰胺、碘酰胺、碘化物、碘、碘二酰胺、碘克沙醇、碘代丙酸、碘氯羟喹、碘仿、碘吡喃酮、碘吡咯、碘喹啉、碘代次没食子酸酯、碘苯丙胺123I、碘甘酸、碘海醇、碘甲酸、碘美丙醇、碘帕醇、碘帕醇、碘戊醇、碘芬酯、碘苯氧酸、碘普罗胺、碘丙酸、碘吡醇、碘吡酮、碘酞酸、碘托兰、碘佛醇、碘草酸、碘西兰、IP-751、伊匹达克林、IPL-576092、伊泊苷、异烟肼、异丙托溴铵、异丙托溴铵、异丙托溴铵、异丙托溴铵、异丙托溴铵、异丙托溴铵、异丙托溴铵、异丙啶、异丙氯噻吩、艾普司隆、厄贝沙坦、IRFI-042、IRFI-165、伊立霉素、伊立替康、伊立替康、伊罗氟芬、山梨醇铁、伊索拉定、IS-741、艾格列酮、ISAtx-247、异博格雷、异帕霉素、异胺、对氨基苯甲酸异丁酯、异康唑、异乙肝素、异氟草醚、异氟醚、异氟磷酸酯、异拉多、异美沙酮、异美汀、异烟肼、异恶辛、异丙嗪、异丙酰胺碘化物、异丙醇、异丙醇前列酮、异丙肾上腺素、异山梨醇、异山梨醇二硝酸酯、异山梨醇单硝酸酯、异噻菌灵、异维A酸、异戊酰、异速派克、异昔康、异舒林、伊拉地平、伊拉帕凡、ISV-403、伊泰司琼、ITF-282、伊托必利、伊曲康唑、伊曲明、伊曲鲁胺、伊曲立克、伊伐布雷定、伊沙匹隆、J-104132、J-107088、J-113397、Janex-1、交沙霉素、JTV-519、K-777、红藻氨酸、卡利特、卡利丁、KB-130015、KCB-328、酮保泰松、氯胺酮、酮色林、酮唑仑、酮恶醛、酮贝米酮、酮康唑、酮洛芬、酮咯酸、酮咯酸、酮替芬、凯林、激动素、KNI-272、KP-103、KP-157、KP-544、KRN-5500、KT-136、KUL-7211、KW-2170、KW-6002、KW-7158、L-365260、L-5-羟色氨酸、L-745337、L-758298、L-826141、拉贝洛尔、拉西地平、乳酸、乳糖醇、乳果糖、拉夫替丁、拉米非班、拉米夫定、拉莫三嗪、兰地洛尔、拉尼西明、拉尼奎达、拉诺康唑、拉诺普酶、兰瑞肽、兰索拉唑、碳酸镧、拉帕替尼、拉喹莫德、拉索昔芬、拉莫昔芬、拉坦前列素、月桂胍、醋酸劳利铵、2-羟基-1,4-萘醌、LAX-111、拉扎米特、LB-30057、L-半胱氨酸、来苯丙胺、来氟米特、来氟米特、来吡咯、来氨苄西林、香菇多糖、来匹卢定、乐卡地平、来瑞司琼、来匹隆、来普利宁、来托司汀、来曲唑、无色花青素、亮丙瑞林、醋酸亮丙瑞林、亮丙瑞林、左丙洛芬、左旋咪唑、左克罗卡林、左乙拉西坦、左旋倍他乐、左巴布洛汀、左旋巴唑啉、左西替利嗪、左旋多巴、左旋丙嗪、左氧氟沙星、醋酸左美甲酯、左莫洛尔、左炔诺孕酮、左旋乙酰哌烷、左丙氧芬、左啡诺、左西孟旦、左舒必利、左甲状腺素、左维林、来西多南、来西帕芬、LF-15-0195、LF-16-0687、LGD-1550、LH、LH-RH、liarozote、利可氟龙、利考斯汀、利达膦酸盐、利达米定、利多卡因、利多芬宁、利多弗拉嗪、利马前列素、林可霉素、林丹、利奈唑胺、亚油酸、亚麻酸、碘塞罗宁、脂肪酶、脂-地塞米松、脂-氟比洛芬、Lipogel HA、LiquiVent、利拉夫酯、赖诺普利、异索福林、甘草胺、锂、柠檬酸锂、利西普坦、LJP-1082、LLUAlpha、LMP-160、LMP-420、洛氮平、洛铂、洛贝林、洛苄利特、洛多沙胺、洛芬太尼、洛非帕明、洛非西定、洛氟卡班、洛美沙星、洛美利嗪、洛米沙星、洛莫司汀、洛那法尼、洛那帕林、洛那唑酸、洛尼达明、洛哌丁胺、洛哌丁胺、洛哌唑仑、洛普林酮、劳拉卡福、劳拉吉明、氯雷他定、劳拉西泮、氯卡尼、氯美西泮、氯诺昔康、氯沙坦、洛替泼诺、洛曲非班、洛伐他汀、洛沙平、洛格鲁胺、洛索洛芬、Lu-35-138、鲁贝鲁唑、鲁比前列酮、硫蒽酮、硫蒽酮、苯芴醇、鲁美昔布、鲁托替康、镥特沙弗林(lutetium texaphyrin)、LV-216、LX-104、LY-156735、LY-293111、LY-293558、LY-355703、利阿波特、莱美环素、来烯雌醇、溶血素、赖氨酸乙酰水杨酸盐、赖氨酸水杨酸盐、溶血磷脂、M-40403、马布洛芬、马布特罗、巨噬细胞集落刺激因子、MADU、马芬尼、马磷酰胺、水化铝酸镁、品红色I、镁、碳酸镁、氯化镁、柠檬酸镁、葡萄糖酸镁、乳酸镁、水杨酸镁、马拉硫磷、苹果酸、扁桃酸、扁桃酸异戊酯、曼加福地吡、马尼地平、甘露莫司汀、6-磷酸甘露糖、马普替林、马利巴韦、马利马他、马沙骨化醇、马吲哚、马齐雷酮、MC-5723、MCC-478、MCI-154、醋酸间甲苯酯、MDAM、MDI-101、MDI-403、MDL-100907、甲苯咪唑、美贝维林、甲羟胺、甲溴芬宁、美丁酸、美加明、甲氯乙胺、氧化甲氯乙胺、美西林、美克利嗪、甲氯环素、甲氯芬那酯、甲氯芬那酸、甲氯芬那酯、甲氯喹、甲半胱氨酸、美西泮、甲氧氟沙明、美甲孕酮、甲羟孕酮、甲羟孕酮、甲地松、甲灭酸、甲非诺瑞斯、甲非沙胺、甲氟喹、甲氟司特、甲地孕酮、甲葡胺、美谷醇、美拉加群、黑皮质素-4激动剂、美拉索洛尔、美仑孕酮、美左旋多巴、美胺酰胺、美利曲辛、美洛昔康、美哌隆、美法仑、美卢阿君、美金刚、MEN-10700、MEN-10755、甲萘氢醌、甲萘醌、甲萘醌肟胺、孟布酮、甲诺加瑞、MENT、薄荷脑、戊酸薄荷酯、美苯汀、甲哌芬醇、美帕曲星、甲哌嗪、甲哌唑溴化物、哌替啶、美芬辛、美芬沙酮、美芬特明、美苯妥英、甲氧巴比妥、美哌洛尔、美皮司坦、甲哌卡因、美哌沙诺、甲泼尼松、甲丙氨酯、甲丙西林、美他嗪、甲喹他嗪、美乐林、美乐脲、汞溴胺、巯基美林、汞烯丙基酸、油酸汞、氰化汞、美美泊地布、美罗培南、美沙利尔、多糖肽、美沙拉嗪、美沙拉嗪、美司钠、美索拉嗪、美泰龙、美睾酮、美甾醇、美舒芬、甲拉西泮、甲氨苄青霉素、甲帕明、甲丙肾上腺素、间苯二甲胺醇、甲唑辛、美罗宁、二甲双胍、乙酰甲胆碱、甲环素、美沙酮、甲基呋喃、甲基苯丙胺、甲氨蝶呤、美雄烯龙、甲氧麻黄碱、安乃近、甲喹酮、美沙比妥、甲唑胺、甲地拉嗪、甲胺、美替诺龙、甲酚、美托因、甲氧西林、甲巯咪唑、甲硫醛、蛋氨酸、蛋氨酸、甲沙松、甲氧西林、甲氧西林、美索巴莫、甲氧己缩醛、甲氨蝶呤、甲氧苄啶、甲氧胺、甲氧沙林、甲氧肉桂酸酯、甲氧氟醚、甲氧苯那敏、甲氧丙嗪、甲莨菪碱、甲舒酰亚胺、甲基噻嗪、甲基蓝、烟酸甲酯、甲基丙醚、水杨酸甲酯、甲基叔丁基醚、甲基苄索氯铵、甲基溴、甲钴胺、甲基多巴、亚甲蓝、甲基麦角新碱、甲基己酰胺、哌醋甲酯、甲基强的松龙、甲基强的松龙、甲基强的松龙、甲基硫氧嘧啶、甲基三烯诺酮、甲氧苄啶、美麦角、甲噻嗪酸、甲哌洛尔、甲氧氯普胺、甲氧氯普胺、甲氧芬那酯、美托拉松、美托咪嗪、美托泮、美托洛尔、美曲吲哚、美利甲酰胺、甲唑酸、美敦力、美替拉酮、美罗新、美沙唑仑、美塞酮、美西律、美洛西林、MFH-244、米安色林、米贝拉地尔、米铂、米卡芬净、咪康唑、小诺霉素、咪达可可林、咪达唑仑、麦迪霉素、醋酸麦迪霉素、米德司坦、米多君、米多司他林、米非司酮、米格列醇、米格鲁司他、米膦酸盐、米那普仑、米洛沙星、米力农、米替福新、米那普利、米诺环素、米诺膦酸、米诺地尔、米奥卡霉素、米氮平、米索前列醇、螨胺、米格列奈、米托布罗尼醇、米托胍酮、米托拉克、丝裂霉素、米托坦、米托蒽醌、米托蒽醌、MIV-210、米瓦库铵、米伐罗尔、咪唑斯汀、咪唑立滨、MKC-733、MLN-519、MLN-576、吗氯贝胺、莫达非尼、莫昔普利、莫法罗汀、莫非他酮、莫非吉兰、莫非替尼、莫非唑酸、MOL-6131、吗啉酮、莫西多明、莫米松、莫那匹尔、单苯宗、单乙醇胺、单月桂酸甘油酯、单萜二醇、孟鲁司特、孟替普酶、莫哌隆、莫匹达莫、莫普洛尔、莫拉西嗪、莫拉宗、莫瑞西嗪、吗啡定、吗嗪酰胺、吗啡、吗啡-6-葡萄糖苷酸、莫沙帕明、莫沙必利、莫特沙芬、莫维A胺、莫维普利、莫沙内坦、莫斯汀、莫沙维林、莫雌醇、莫西沙星、莫西利特、莫索尼定、M-PGA、MPI-5010、MPI-5020、MPL、MRS-1754、MS-209、MS-275、MS-325、MS-377、莫匹罗星、毒蕈碱、莫唑胺、MX-1013、霉酚酸酯、霉酚酸、麦洛芬、N-(羟甲基)-烟酰胺、N,N,N′,N′-四乙基邻苯二甲酰胺、N-[4-[4-(2-甲氧基苯基)-1-哌嗪基]丁基]萘-2-甲酰胺、N2-甲酰基-亚磺胺、N4-磺胺基磺胺、N4-β-D-葡糖基磺胺、萘比隆、萘丁美酮、N-乙酰半胱氨酸、N-乙酰蛋氨酸、那地沙星、纳多洛尔、纳多洛尔、萘莫司他、那法林、萘夫西林、萘弗尼、萘替呋喃、萘替芬、萘托吡地、纳布啡、萘啶酸、纳美芬、纳洛啡、纳洛酮、纳曲酮、NAMI、纳米地尔、诺龙、萘帕地尔、萘甲唑啉、萘、萘普生、萘普生甜菜酸盐、那拉曲坦、那他因、那他霉素、那格列奈、N-丁基脱氧野尻霉素、N-丁基东莨菪碱、NC-503、NC-531、NCX-1000、NCX-4016、NCX-456、NCX-950、正二十二烷醇、NE-100、尼巴比妥、奈必洛尔、尼波司汀、奈布西坦、奈达铂、奈多罗米、奈法唑酮、奈非西坦、奈福泮、奈加霉素、奈非那韦、奈莫必利、新斯的明、奈帕度坦、奈拉美生、奈立膦酸、奈立福林、N-乙基安非他明、奈康唑、奈替米星、奈韦拉平、NGD-98-2、尼亚酰胺、尼拉嗪、尼康酸盐、尼卡拉温、尼卡地平、麦角林、烟三醇、氯硝柳胺、尼可洛酯、呋喃糖、尼可莫尔、尼可吗啡、尼可地尔、烟酰胺、尼古丁、烟酸、烟酸苄酯、烟醇、硝苯地平、硝苯卡兰、硝苯那洛、硝氟酸、硝呋太尔、硝呋呋喃、硝呋噻嗪、硝呋肟、硝呋匹林、硝呋拉嗪、硝呋替莫、硝呋妥诺、硝呋齐特、NIK-254、尼可沙胺、尼鲁米特、尼伐地平、尼美舒利、尼美西泮、尼莫地平、尼莫拉唑、尼莫司汀、尼喋呤、NIP-142、NIP-531、尼哌罗替丁、尼普地洛、尼硝唑、尼索地平、硝唑尼特、尼替西农、硝克宁、硝西泮、尼群地平、硝基氟比洛芬、呋喃妥因、呋喃酮、硝化甘油、硝基美醇、硝基萘普生、硝氮杂、硝唑啉、尼扎替丁、硝唑酮、NM-3、NM-702、N-甲基麻黄碱、N-甲基肾上腺素、N-甲基葡糖胺、NN-414、NNC-05-1869、诺贝尔、诺加霉素、诺拉曲塞、诺洛米罗、诺匹坦、诺地孕酮、诺米芬新、诺普磺胺、去甲波利酮、去甲西泮、去甲去甲肾上腺素、去甲二氢愈创木甲酸、去甲炔诺酮、去甲肾上腺素、去甲炔诺酮、炔诺酮、炔诺酮、去甲非芬、诺氟沙星、诺孕酮、诺孕酯、诺孕烯、诺孕三烯酮、去甲左啡诺、去甲美沙酮、去甲甲睾酮、去甲吗啡、去甲苯肾上腺素、去甲替林、去甲肾上腺素、去甲肾上腺素、去甲维尼斯特酮、诺斯卡品、新霉素、新霉素、诺西替林、诺西硫林、NS-1209、NS-1231、NS-126、NS-220、NS-2330、NS5A抑制剂、NS-7、NS-8、NSC-330507、NSC-619534、NSC-697726、N-磺胺基-3,4-木酰胺、NU-6027核苷、NV-07、NVP-SRA880、NW-1029、NXY-059、尼利德林、NZ-314、NZ-419、氯化奥比肟、OC-108、奥西普隆、辛苯酮、辛卡因、八氧嘧啶、八维林、奥替尼定、奥托君、章鱼胺、奥替尼定、奥曲肽、辛基、氧氟沙星、夹竹桃苷、油酸、奥美沙坦-酯、邻洛多马尿酸盐、奥洛他定、奥帕膦酸、奥沙拉嗪、奥替拉嗪、OM-294DP、omacor、奥帕曲拉、奥美拉唑、奥米洛西汀、奥康唑、奥那司酮、昂丹司琼、ONO-3403、ONO-4128、ONO-8815Ly、ONT-093、OPC-14523、OPC-31260、OPC-51803、OPC-6535、奥匹亚齐特、阿片类镇痛药、奥哌拉莫、奥拉扎胺、奥拉西酮、Org-12962、Org-24448、奥利万星、奥利司他、奥美洛昔芬、奥硝唑、奥尼加压素、鸟氨酸、奥诺前列素、乳清酸、奥芬那君、邻卡因、奥沙利米、奥沙尼坦、奥沙特龙、奥司他韦、OSI-7836、OSI-7904、欧司帕米芬、奥替溴铵、哇巴因、奥塞普洛、苯唑西林、恶唑烷、奥沙利铂、oxalyt-C、奥沙林、奥沙美辛、奥沙尼喹、奥雄龙、奥沙太尔、奥沙丙铵、奥沙普秦、奥沙托米、奥沙西泮、恶唑仑、奥卡西平、黄素、氧舒龙、氧噻嗪、氧唑仑、奥昔康唑、奥昔磷酸、氧烟酸、奥拉西坦、奥托溴铵、奥索拉明、恶喹酸、氧苯胂、氧丙烯洛尔、氧苯酮、奥昔布宁、奥辛可芬、羟考酮、氧合剂、羟甲睾酮、羟甲唑啉、羟甲烯龙、羟甲脲、羟吗啡酮、羟哌啶酮、羟哌丁胺、羟苯丁酮、羟苯环胺、羟苯哌丁、羟苯鎓、羟匹诺康酮、羟嘌呤醇、羟色胺、土霉素、奥扎格雷、对(苄基磺胺)-苯甲酸、P-100、P-1202、P32/98、PA-824、PACAP 38、紫杉醇、PADRE、pagoclone、PAI inhibs、palindore、帕利珠单抗、帕洛诺司琼、帕马溴、帕马喹、帕米格拉、帕米膦酸盐、对氨基苯甲酸、对氨基马尿酸、对氨基苯丙酮、对氨基水杨酸、帕那韦、泮库溴铵、帕尼培南、泛硫乙胺、泮托拉唑、泛酸、木瓜蛋白酶、罂粟碱、扑热息痛、对氟噻嗪、三聚乙醛、甲乙双酮、帕拉米松、帕拉尼林、甲状旁腺激素、帕瑞昔布、帕洛西卡因、帕吉林、帕立骨化醇、巴龙霉素、帕罗西汀、帕洛西酮、帕赛米、帕特林-2、帕唑仑、帕珠沙星、对溴乙酰苯胺、PC-NSAIDs、PD-0166285、青霉素、培氟沙星、培维索孟、培替林、培美曲塞、培米司特、匹莫林、哌匹啶、PEN-203、青霉素、喷丁洛尔、喷昔洛韦、喷培沙酯、喷氟利多、青霉素、青霉素G、青霉素G、普鲁卡因、青霉素N、青霉素O、青霉素V、青霉环素、pentuss、季戊四醇、季戊四醇、季戊四醇三氯乙醛、五胃泌素、五甲孕酮、pentalyte、喷他鎓、喷他脒、喷他佐辛、喷替酯、喷替酸、喷替曲肽、戊噻吩酯、喷替林、喷替盖肽、戊唑胺、戊巴比妥、喷托溴铵、喷妥昔、戊聚糖、喷司他丁、己酮可可碱、戊氧基、喷三硝唑、戊四唑、哌洛霉素、肽、肽、哌嗪、过氟霉素、氟溴磷、过环磷酰胺、培高利特、哌可昔林、哌嗪、哌替福辛、紫苏醇、哌利美嗪、培哚普利、高碘酮、过氧乙酸、哌拉平、高锰酸盐、氯菊酯、哌螺环酮、奋乃静、石油、石油精、PH-10、泛醌、药剂、制药项目编号6362、制药项目编号4994、制药项目编号5325、制药项目编号5972、制药项目编号6446、制药项目编号6590、制药项目编号6656、制药项目编号6691、制药项目编号6743、制药项目编号6748、非那卡因、非那西胺、非那西丁、苯那多酮、苯那唑、苯那美、苯那胺、芬那佐辛、非那吡啶、苯丁胺、苯环利定、苯二甲嗪、苯乙肼、苯那斯汀、苯哈比妥、苯乙西林、苯乙脲、苯乙双胍、苯戊二胺、苯茚满、苯茚二酮、苯哌嗪、苯那敏、苯甲嗪、苯巴比妥、苯丁地尔、苯酚、辛酚醛、酚酞、酚酞醇、酚磺酞、苯酚四氯酞、苯哌啶、苯磺胺嘧啶、苯氧苯甲胺、苯氧丙嗪、苯丙胺、苯丙香豆素、苯丙香豆素、苯乙嘧啶、苯丁胺、苯硫酞、苯妥拉明、乙酰水杨酸苯酯、氨基水杨酸苯酯、水杨酸苯酯、保泰松、去氧肾上腺素、苯乙醇胺、苯汞、苯甲基巴比妥酸、苯丙醇胺、苯丙甲胺、苯托洛沙明、苯胺、苯妥英、苯乙胺、间苯三酚、福尔可碱、苦胆碱、佛尔酰胺、磷酸盐、磷酸盐、磷酸肌酸、磷酸半胱胺、磷酰胆碱、邻苯二甲磺胺噻唑、邻苯二甲酰磺胺、对羟基麻黄碱、叶绿醌、毒扁豆碱、植酸、PI-88、哌洛林、哌波色罗、匹洛瑞克、匹洛昔定、匹哌林、匹可硫酸盐、匹莫胺、匹莫司特、匹多莫德、匹法宁、匹克托洛芬、匹拉嗪、匹罗卡品、匹罗普、匹西卡尼、匹美克隆、匹美莫司、匹美可林、匹米前列素、匹米诺定、匹莫苯坦、匹莫齐特、匹那地尔、匹维铵、匹西泮、吲哚洛尔、匹格列酮、匹帕环素、匹帕嗪、哌帕酮、哌嗪、哌丁酮、哌库铵、哌库溴铵、哌啶酸、哌唑溴铵、哌西嗪、哌拉西林、己二酸哌嗪、哌啶酮、哌啶醇、哌啶酸、哌啶类似物、哌罗卡因、胡椒醛、哌啶、哌啶酮、哌泊溴曼、哌泊硫烷、哌噻嗪、哌泊啶、哌拉唑、哌丙唑啉、吡拉西坦、吡柔比星、吡唑酸、吡布特罗、吡诺辛、哌仑西平、吡咯他尼、吡非尼酮、哌啶地尔、吡多卡因、吡瑞贝特、吡虫胺、吡曲昔、吡林多、吡美诺、吡罗克酮、吡罗庚丁、吡咯酸、吡罗昔康、吡罗昔康-Β-环糊精、吡罗昔康肉桂酸酯、吡罗扎地尔、吡洛芬、匹伐他汀、匹伐他滨、新戊酰氧基甲基、新戊酰苯肼、匹伐西林、匹伐西林/匹维西林、匹维替林、匹维西南、匹克蒽醌、匹唑替芬、匹唑啉、PKI-166、对拉克芬肽、普拉贝脲、纤溶酶原激活剂、纤溶酶、柏拉酮、PLD-118、PLD-147、普来可那立、普卡霉素、对甲基苯海拉明、PMS-601、肺炎球菌、PNU-288034、鬼臼毒素、波拉普锌、硫酸甲酯、聚甲酚磺草胺、波地昔德、聚多卡醇、脊髓灰质炎病毒疫苗、聚ADPRT抑制剂、聚雌二醇、聚苯酚E、聚噻嗪类、泊菲默、泊沙康唑、泊沙瑞林、钾、钾、钾、氯化钾、葡萄糖酸钾、对氨基苯甲酸钾、聚维酮、聚维酮碘、PP-117、PR-2699、PR-608、普萘洛尔、普乐美林、解磷定、普拉纳卡生、普拉克索、普拉西坦、普拉米维林、普兰林肽、普拉莫辛、普兰地平、普仑司特、普诺洛芬、普拉司酮、普拉托沙坦、普伐他汀、普拉西泮、吡喹酮、哌唑嗪、泼尼卡酯、泼尼莫司汀、泼尼松龙、泼尼松龙21-二乙氨基乙酸酯、泼尼松龙法尼、泼尼松龙钠、泼尼松、泼尼松龙戊酸酯、泼尼立定、普瑞巴林、孕烷醇酮、普瑞马林+曲孕酮、普瑞那特罗、普瑞诺二嗪、异戊二烯胺、普瑞卡因、普地诺、普瑞芬铵、丙胺卡因、伯氨喹、普立米酮、普立诺司他、PRO-2000、丙磺舒、普罗布考、普鲁卡因胺、普鲁卡因、丙卡巴肼、丙卡特罗、丙氯拉嗪、丙达唑、丙环利定、腐植酸、普罗地平、普罗黄素、普罗格比特、黄体酮、丙谷美辛、丙谷胺、丙庚嗪、催乳素、脯氨酰胺、丙溴铵、丙嗪、普罗多、普罗孕酮、普罗雌烯、异丙嗪、普萘洛尔、丙乙酰氨基酚、普罗帕酮、丙帕芬、丙丙炔醛、丙脒、丙烷-1,2-二醇、丙脒、丙太林、丙美卡因、丙炔、丙硝唑、丙茶碱、丙西林、丙嗪、丙酸、丙酰左旋肉碱、丙哌卡因、丙吡仑、丙哌维林、丙西平、丙泊酚、丙氧卡因、丙氧芬、普萘洛尔、丙己烯、丙碘酮、丙硫氧嘧啶、丙哌酮、丙喹酮、海葱次甙、前列环素、前列腺素E1、前列腺素E2、前列腺素F2α、丙磺胺、蛋白C、丙可可碱、丙噻菌胺、丙酸、丙硫异烟胺、质子酸、原白头翁素、原白菜素、原卟啉IX、丙替林、尿激酶原、丙恶唑、普塞基、丙羟巴比、丙帕锗、丙茶碱、丙氮平、普卡必利、普鲁利沙星、伪可卡因、伪麻黄碱、伪麻黄碱、伪麻黄碱+曲普利啶、裸盖菇素、PSK-3841、对磺胺苯甲胺、PT-141、蝶呤、嘌呤霉素、PX-12、吡喃太尔、吡嗪酰胺、吡啶酚氨基甲酸酯、吡啶斯的明、5-磷酸吡哆醛、吡哆醇、吡拉明、乙胺嘧啶、吡啉、嘧啶醇、吡硫酮、吡啶二酮、吡硫醇、邻苯二酚、邻苯三酚、吡咯啶、焦磷酸盐、吡咯戊酮、吡咯啉、吡咯丁胺、吡咯卡因、吡咯啉、吡喃双胍、夸西泮、槲皮素、喹硫平、喹那西林、喹那可林、喹那普利、喹那普利、喹那普利拉、喹那拉敏、喹勃龙、喹雌二醇、喹诺酮、喹沙松、喹灭胺、奎尼丁、奎宁、喹诺酮、奎奴帕明、奎奴普丁、R-107500、R-667、雷贝拉唑、消旋卡多曲、消旋美沙芬、雷洛昔芬、雷替曲塞、雷马曲班、雷米那宗、雷米普利、雷莫司琼、拉莫特项目1097号、雷莫司汀、雷尼替丁、雷尼替丁铋、雷诺嗪、伦匹那酶、雷帕库溴铵、雷沙吉兰、罗巴辛、雷乌康唑、雷索非拉特、雷佐生、RC-529、瑞巴派特、瑞比马他、瑞波西泰、瑞马西胺、瑞芬太尼、瑞纳坦、瑞莫西必利、伦扎必利、瑞格列奈、瑞帕他星L-赖氨酸盐、瑞匹诺坦、瑞匹司特、双环辛巴比妥、瑞丙特罗、瑞西美醇、利肉桂胺、利血平、利血平、树脂皂苷元、瑞喹莫特、间苯二酚、瑞替普酶、瑞替加滨、维甲酸、瑞维米德、R-氟比洛芬、ρ(D)免疫、ρ激酶抑制剂、利巴韦林、核黄素、核霉素、蓖麻油酸、利多格雷、利福布丁、利福拉齐、利福美坦、利福平、利福平+甲氧苄啶、利福平、利福霉素SV、利福喷丁、利福昔明、利福昔明乳膏、利马扎酮、利美尼定、利鲁唑、金刚乙胺、利马唑胺、利美索龙、利米特罗、利莫那班、利多索、利奥前列素、利塞膦酸盐、利塞膦酸、利培酮、利坦色林、利替培南、利托君、利托那韦、利妥昔单抗、利伐斯的明、利扎曲坦、RJR-2403、RNAStealth、Ro-0094889、Ro-61-1790、罗西维林、罗库溴铵、罗非昔布、罗氟司特、罗基霉素、咯利普兰、罗利四环素、罗莫肽、罗尼贝特、罗匹尼罗、罗哌卡因、罗奎尼美、罗沙前列醇、罗萨拉米星、孟加拉玫瑰、罗格列酮、罗沙星、罗他泊芬、罗苏伐他汀、罗替戈汀、罗曲沙特、罗沙松、罗沙替丁、罗昔非班、罗欣多、罗红霉素、RPR-109881A、RPR-130401、R-罗斯科维汀、RS-0406、RSR-13、红枣、鲁比替康、鲁布司司他林、卢非酰胺、卢氟沙星、卢帕他定、芦丁、RWJ-54428、S-0139、S-15535、S-18886、S-34730、S-3578、S-36496、S-36527、S-5751、S-8510、S-8921、沙贝美林、沙贝鲁唑、S-腺苷甲硫氨酸、沙芬胺、沙拉西酰胺、柳氮磺胺嘧啶、沙丁胺醇、水杨苷、水杨醇、水杨酰胺、水杨酰胺邻乙酸、水杨酰苯胺、水杨酸、水杨基硅酸、沙利肼、沙美特罗、水杨酸、沙维林、钐153Sm、山帕曲拉、山环素、沙康唑、沙丙蝶呤、沙奎那韦、萨拉辛、沙瑞度坦、沙瑞度坦、萨里佐坦、萨里佐坦、沙格雷酯、沙格雷酯、沙替格雷、沙替格雷、沙铂、沙铂、沙图单抗、沙图单抗、SB-237376、SB-237376、SB-238039、SB-238039、SB-277011、SB-277011、猩红色、SCH-00013、SCH-00013、Sch-23863、Sch-23863、Sch-57790、Sch-63390、莨菪碱、东莨菪碱、东莨菪碱、N-氧化东莨菪碱、SCS技术、司钙化醇、塞克硝唑、司可巴比妥、司来吉兰、硒代蛋氨酸、司马利特、司莫替地尔、西骨化醇、司匹司他、舍曲司特、舍他康唑、舍他康唑、舍吲哚、舍吲哚、舍曲林、舍曲林、塞司米比、司他汀、西斯汀、司维拉姆、司维拉姆、七氟醚、七氟醚、SG-210、西布曲明、西卡宁、西地那非、西洛多辛、西前列酮、乳酸银、苦味酸银、磺胺嘧啶银、西美特利、辛贝特、辛伐他汀、辛卡利特、溴化辛托溴铵、西索米星、西他沙星、西他喹、西他生坦、西维司他、SJA-6017、SL-65-1498、SLV-306、SLV-308、Sm153来西多南、S-甲基蛋氨酸、SMP-300、SN-38、SNAP-7941、SOA-132、索比洛汀、索布雷罗、索布唑烷、阿磺酸钠、阿斯芬钠、氯化钠、丁二酸钠、叶酸钠、甲醛次硫酸钠、透明质酸钠、碘甲酸钠、亚硝酸钠、硝普钠、羟丁酸钠、苯酚磺酸钠、苯丁酸钠、磷酸钠、普拉甾酮硫酸钠、丙酸钠、水杨酸钠、十四烷基硫酸钠、索法酮、索拉砜、索利那新、山梨酸、山梨糖醇、索利夫定、索他洛尔、索特瑞诺、索托洛尔酸、谷氨酸、司帕沙星、斯巴丁、SPA-S-843、解痉醇、SPD-754、大观霉素、SPI-339、螺哌酮、螺普利、螺锗、螺内酯、SR-121463、SR-144190、SR-146131、SR-271425、SR-27897、SR-31747、SR-58611、SS732、SS-750、SSR-149415、SSR-180575、SSR-181507、SSR-591813、SST-101、SSY-726、ST-200、司司他林、史利霉素、司他丁、亚锡、锡泊芬、司他龙、司坦唑醇、金黄色葡萄球菌、STAT4抑制剂、司他夫定、司腾勃龙、司腾宁、噻唑啉、司替波芬、芪脒、司替戊醇、链多糖酶、链霉素、链霉素、链霉菌素、链脲佐菌素、雷奈酸锶、氯化锶89、丁二酸、丁二酰亚胺、丁二酰胆碱、丁二酰胆碱、丁二酰磺胺噻唑、丁二砜、磺胺、硫糖铝、舒芬太尼、舒巴坦、舒巴坦+氨苄西林、舒苄西林、舒本汀、舒布硫胺、舒康唑、舒普坦、舒来索单抗、磺胺苯甲酰胺、磺胺乙酰胺、磺胺氯哒嗪、磺胺柯定、磺胺西汀、磺胺哒嗪、磺胺戊烯、磺胺二甲氧嘧啶、磺胺多辛、磺胺乙二唑、磺胺胍、磺胺胖二甲唑、环丁砜、次磺酸、磺胺甲基嘧啶、磺胺对甲氧嘧啶、磺胺二甲基嘧啶、磺胺甲基硫代二嗪、磺胺托嘧啶、磺胺甲恶唑、磺胺甲氧嗪、长效磺胺、磺胺美曲、磺胺柯衣定、磺胺二甲唑、磺胺、磺胺酸、磺胺酰脲、磺胺哌啶、磺胺苯唑、磺胺丙氧嘧啶、磺胺吡嗪、磺胺吡啶、磺胺苷、磺胺苯磺胺、柳氮磺胺吡啶、磺胺甲基异噻唑、磺胺均三嗪、磺胺塞唑、磺胺硫脲、磺胺醇、磺吡酮、硫磺隆、磺胺嘧啶、磺胺异恶唑、磺基溴酞、磺乙基甲烷、磺酰肼、磺酸、磺基甲烷、磺胺嘧啶、砜、舒林酸、舒利司汀、舒利苯宗、苏尔马林、舒尔马唑、舒洛地尔、磺胺蓝、舒必利、舒他西林、磺胺嘧啶、舒托必利、硫代硅酸、舒马尼罗、舒马曲坦、SUN-N8075、甲磺司特、舒洛芬、苏拉明、表面活性剂TA、舒利克酮、舒布松、SYM-1010、SYM-2081、SYM-2207、symclosene、Syn-1253、Syn-2190、Syn-2869、辛弗林、昔洛金平、T-1095、T-1249、T-3912、T-588、T-67、T-82、TA-2005、TA-2005、TA-993、他比莫林、他骨化醇、他西地林、他克林、他克莫司、他达拉非、他非诺喹、他氟泊苷、TAK-375、TAK-427、TAK-559、taka-淀粉酶、他兰帕奈、他氨苄西林、他拉泊芬、他司汀、他布丁、他利洛尔、他利克索、他尼坦、他尼氟酯、他替瑞林、他莫昔芬、坦洛新、坦多螺酮、鞣酸、前列素、他立喹达、TAS-103、他索沙坦、牛磺胆酸、牛磺罗定、他扎司特、他扎罗汀、他唑巴坦、他唑巴坦+哌拉西林、TBC-3711、TCH-346、替比培南、替硼肟、替卡松松、替卡咪唑、锝99Tc、替氯噻嗪、替氯占、替地沙米、替氟醚、替加氟、替加氟+尿嘧啶、替加色罗、替考拉宁、替比夫定、替尼西平、泰利霉素、替美司坦、替米沙坦、端粒酶抑制剂、替马西泮、替米维林、替莫普利、替莫西林、替莫泊芬、替莫唑胺、替那拉唑、替奈普酶、替尼达普、替尼泊苷、替诺福韦、替诺福韦酯、替诺福韦酯、替诺硝唑、替诺昔康、替诺唑酸、替普瑞酮、特拉唑嗪、特比萘芬、特布他林、特康唑、特非那定、特古利特、特利加压素、特罗地林、特洛芬酯、萜品、特他洛尔、叔戊醇、特格列扎、地斯米利芬、睾酮内酯、睾酮、丁氨酯、四巴比妥、丁苯那嗪、丁卡因、四氯乙烯、丁辛辛、四环素、四氢唑啉、防己碱、丁妥因、四西泮、替曲磷、替托普林、Tevenel/>替扎他滨、替佐生坦、沙利度胺、那尔定、噻二胺、可可碱、西奥贝特、茶碱、噻苯达唑、噻唑酮、噻菌丝氨酸、硫巴比妥、硫胺素、硫胺嘧啶、甲砜霉素、噻菌灵、噻嗪、噻嗪铵、噻唑啉酮、噻唑啉酮、噻唑啉、噻菌灵、噻吩嗪、硫柳汞、硫柳汞、硫代巴比妥、硫代巴比妥、硫代卡巴肼、硫代卡巴松、硫代秋水仙碱、硫代甲酚、硫辛酸、硫代甘油、硫代鸟嘌呤、硫代戊二烯、硫代戊二烯、硫代丙唑啉、硫代丙嗪、硫利达嗪、硫代硫酸盐、硫噻吩、硫代韦、噻吩那米、福美双、消炎痛、噻唑啉酮、凝血酶、烟酸噻吩酯、百里香霉素、百里香酚、胸腺五肽、N-异戊基氨基甲酸百里香酯、甲硫丙酸、甲状腺素、噻腺醇、噻加宾、噻菌灵、噻奈普汀、噻匹必利、噻洛芬酸、噻唑胺、噻唑呋林、替贝唑铵、替勃龙、替卡西林、噻氯匹定、替克萘芬、替莫铵、替加环素、替格莫南、替格罗定、替立啶、替利索洛尔、替马考昔、替鲁膦酸、替莫汀、替哌啶、替米哌隆、噻吗洛尔、替莫那酸、锡乙基硫紫嘌呤、替唑啉、替硝唑、替诺定、替卡利特、替氯马洛、噻康唑、硫普罗宁、噻托溴铵、噻唑啉酮、替哌啶、替比法尼、替拉那韦、替克西姆、替拉扎明、替拉曲考、替拉扎德、替罗非班、替罗普胺、硫酸钛、替西坦、替考可尔、替扎尼定、TLK-199、TLK-286、TNF-β类似物、TNP-470、TO-186、妥布霉素、妥卡尼、妥卡芬、妥卡地辛、妥考替酯、托拉嗪、托非那新、托非司特、托非索泮、托拉唑胺、托拉唑林、甲苯磺丁脲、托卡朋、托拉西林、托环酰胺、托来福、托芬那酸、托林酯、托普洛尔、托美汀、托萘酯、托洛尼定、托洛铵、托洛沙通、托哌酮、托丙胺、托瑞他、托丝林、托特罗定、托伐普坦、托卡因、托吡酯、拓扑异构酶、托泊替康、托拉塞米、托西他比、托西他滨、托瑞米芬、托拉塞米、托西图马、磺胺嘧啶、曲马多、曲马唑啉、群多普利、氨甲环酸、曲尼司特、反式维甲酸、反苯环丙胺、曲匹地尔、曲妥珠单抗、曲伏前列素、曲沙诺、曲索地尔、曲唑酮、曲美康、群勃龙、群孕酮、曲硫丹、曲吡酮、曲前列醇、维甲酸、曲托喹诺、TRH、TRI-50b、曲醋精、曲安奈德、曲安西龙、曲安西龙、曲安奈德、曲安泰、曲氯平、曲唑酮、曲唑仑、曲苯醌、三溴苯酚、三氯噻嗪、三氯甲基、三氯乙烯、三氯比溴铵、三氯卡班、三氯苯酚哌嗪、三氯磷、三氯生、三氯苯甲酰、三己基碘、曲恩汀、三乙醇胺、三乙烯三聚氰胺、三氟拉嗪、三氟哌啶醇、三氟丙嗪、三氟尿嘧啶、三氟磺脲、三氟甲磺酸酯、苯三唑、三唑嗪、曲美布汀、曲美卡因、曲美拉嗪、曲美他嗪、曲美二酮、曲美沙芬、曲美苯甲酰胺、甲氧苄啶、曲美唑嗪、曲美沙、曲米帕明、曲前列素、三羟甲基苯丙胺、曲沙林、曲酰胺、曲帕诺、曲来那敏、曲丙立定、曲普瑞林、曲硫嗪、曲喹啉、TRK-530、TRK-820、曲氯辛、曲磷酰胺、曲格列酮、曲安多霉素、曲硝酸酯、曲金刚烷胺、氨丁三醇、氨丁三醇、氨丁三醇、氨丁三醇、托帕辛、托帕辛、托品酰胺、托品、托司琼、托普霉素、托司铵、曲伐沙星、曲沙他滨、曲克芦丁、托西派特、台盼红、锥虫胺、色氨酸、TSH、TSN-09、TU-2100、三氨基庚烷、结核菌素、管霉素氯化物、妥洛特罗、TV-3326、TY-11223、TY-12533、TYB-3215、泰巴氨酯、泰洛沙泊、泰马唑啉、酪胺、酪氨酸、乌苯美司、氟芬那酸丁酯、十一碳烯酸、乌诺前列酮、UR-8880、尿嘧啶、尿嘧啶-U、乌拉地尔、尿素、乌地帕、尿烷、尿苷5′-三磷酸、尿司他丁、熊去氧胆酸、熊二醇、先导细胞、乌札拉苷、疫苗、白喉疫苗、多价疫苗、伐昔洛韦、伐地昔布、伐地他胺、缬草胺、缬更昔洛韦、伐诺克胺、伐昔洛韦、丙戊酸盐、丙戊酸、丙戊酸、伐罗塞米、缬柔比星、缬沙坦、伐泊达、伐地那非、伐瑞拉迪、水痘病毒、伐他地平、VEA、维库溴铵、维纳克林、文拉法辛、维拉必利、维拉帕米、维替泊芬、维沙利酮、维曲布汀、VF-233、VI-0134、阿糖腺苷、氨己烯酸、维拉佐酮、维恶嗪、维米诺、长春巴比妥、长春碱、长春碱、长春胺、长春新碱、长春新碱、长春地辛、长春氟宁、长春瑞滨、长春西汀、乙烯基醚、乙烯基比妥、维奎地尔、维里定、维那定、维生素A、维生素B12、维生素C、维生素D2、维生素D3、维生素K5、产前维生素、VLA-4拮抗剂、VNP-4010M、伏格列波糖、伏立康唑、伏拉唑、VUF-K-8788、华法林、WF-10、WMC-79、伤口愈合基质、WP-170、沙利普罗登、沙莫特罗、沙诺美林、烟酸黄嘌呤醇、西米非班、新布星、西苯洛尔、西冰片醇、西美加群、昔莫洛芬、西帕特、氧吗啡酚、XR-5118、XR-5944、木甲唑啉、木糖、YH-1885、YM-511、YM-598、育亨宾、YT-146、Z-321、Z-335、扎鲁司特、扎西他滨、扎达利特、扎来普隆、扎托洛芬、扎那米韦、扎那哌齐、扎替布雷定、ZD-0473、ZD-0947、ZD-6126、ZD-9331、泽布林、西兰多泮、泽纳司他、齐考诺肽、齐多夫定、齐留通、齐美定、醋酸锌、醋氨酸锌、布洛芬酸锌、对苯酚磺酸锌、水杨酸锌、抑菌素、抑菌素刺激物、齐培丙醇、齐拉西酮、佐芬普利、佐芬普利+HCTZ、唑来膦酸、唑咪定、佐米曲坦、唑吡坦、佐美拉克、佐南帕奈、佐尼泊利、唑尼沙胺、佐匹克隆、唑泊司他、佐柔比星、唑舒达、佐替平、ZP-123、Z-他莫昔芬、珠氯噻醇、α1-抗胰蛋白酶、α-红没药醇、α-氯醛糖、α-乙基苯甲醇、α-1-磷酸葡萄糖、α-苯基丁酰胺、α-桑托宁、α-松油醇、α-生育酚、β-丙炔、β-苯扎丁酰胺、β-胡萝卜素、β-尤卡因、β-丙内酯、β-谷甾醇、γ-氨基丁酸、γ-羟基丁酸、γ-亚麻酸、δ-氨基乙酰丙酸、ε-乙酰氨基己酸和ε-氨基己酸。还参见美国专利7,927,613,其以引用方式全文纳入本文。其他药学上可接受的共形成物包括“一般认为安全”(“GRAS”)和/或美国FDA“美国食品中添加的所有物质”(“EAFUS”)列表中描述的那些。
在这些实施方式中的一些实施方式中,一种或多种药学上可接受的共形成物中的至少一种可以是如美国专利第10,292,951所述的具有式(I)、(XVIII)-(XXV)、和XXVII中任一种(例如,式XXIV或XXV)的化合物,其以引用方式全文纳入本文;或上述任何一种化合物。在这些实施方式中的某些实施方式中,一种或多种药学上可接受的共形成物中的至少一种可以是如美国专利第10,292,951所述的具有式(I)、(XVIII)-(XXV)、和XXVII中任一种(例如,式XXIV或XXV;或XXVI)的氯硝柳胺类似物,其以引用方式全文纳入本文;或上述具体的任何一种化合物。
在一些实施方式中,共形成物可以是任意一种或多种其他治疗剂,如本文所述。
在一些实施方式中,共形成物选自下组:1-磷酸鞘氨醇(S1P)受体调节剂;甾体抗炎药;非甾体抗炎药;受体相互作用蛋白激酶1(RIPK1)抑制剂;EP4调节剂;Toll样受体(例如,TLR4、TLR9)调节剂;Janus激酶(JAK)抑制剂;羊毛硫氨酸合成酶C样2(LANCL2)调节剂;磷脂酰胆碱;整合素(例如,α4整合素)调节剂;a Smad7调节剂;磷酸二酯酶4(PDE4)调节剂;肿瘤进展位点2(TPL2)抑制剂;酪氨酸激酶2(TYK2)抑制剂;和TEC激酶抑制剂。
在某些实施方式中,共形成物是1-磷酸鞘氨醇(S1P)受体调节剂。
在某些实施方式中,共形成物是艾曲莫德(etrasimod)或奥扎莫德(ozanimod)。
在某些实施方式中,共形成物是甾体抗炎药。作为一个非限制性实例,共形成物可以是倍氯米松(beclomethasone)17或布地奈德(budesonide)。
在某些实施方式中,共形成物是非甾体抗炎药如5-ASA。
在某些实施方式中,共形成物是受体相互作用蛋白激酶1(RIPK1)抑制剂如GSK2982772。
在某些实施方式中,共形成物是EP4调节剂,如KAG-308。
在某些实施方式中,共形成物是Toll样受体(例如,TLR4,TLR9)调节剂。在这些实施方式中的某些实施方式中,共形成物是TLR4调节剂如JKB-122。在某些实施方式中,共形成物是TLR9调节剂如可比托莫德(cobitolimod)。
在某些实施方式中,共形成物是Janus激酶(JAK)抑制剂。在这些实施方式中的某些实施方式中,共形成物选自下组:TD-1473、托法替尼(tofacitinib)、乌帕替尼(upadacitinib)、非戈替尼(filgotinib)、PF-06651600、和PF-06700841。
在某些实施方式中,共形成物是羊毛硫氨酸合成酶C样2(LANCL2)调节剂如BT-11。
在某些实施方式中,共形成物是磷脂酰胆碱如LT-02。
在某些实施方式中,共形成物是整合素调节剂。在这些实施方式的某些实施方式中,共形成物是α4整合素调节剂如AJM-300(卡泰司特(carotegrast))。
在某些实施方式中,共形成物是Smad7反义寡核苷酸如蒙格生(mongersen)。
在某些实施方式中,共形成物是磷酸二酯酶4(PDE4)调节剂如阿普斯特(apremilast)。
在某些实施方式中,共形成物是肿瘤进展位点2(TPL2)抑制剂如GS-4875。
在某些实施方式中,共形成物是酪氨酸激酶2(TYK2)抑制剂。
在这些实施方式中的某些实施方式中,共形成物是BMS-986165,PF-06700841,或PF-06826647。
在某些实施方式中,共形成物是TEC激酶抑制剂如PF-06651600.
非限制性组合
在一些实施方式中,共结晶包含(i)氯硝柳胺;和(ii)氯硝柳胺的药学上可接受的盐;或氯硝柳胺类似物的氯硝柳胺的药学上可接受的盐和/或水合物。
在一些实施方式中,共结晶包含(i)氯硝柳胺;和(ii)第二API。
在一些实施方式中,共结晶包含(i)氯硝柳胺的药学上可接受的盐;和(ii)第二API。
在一些实施方式中,共结晶包含(i)氯硝柳胺;和(ii)第二API。
在一些实施方式中,共结晶包含(i)氯硝柳胺的药学上可接受的盐;和(ii)氨基酸(例如脯氨酸,例如D-脯氨酸或L-脯氨酸,或外消旋脯氨酸)。
在一些实施方式中,共结晶包含(i)氯硝柳胺;和(ii)氨基酸(例如,脯氨酸,例如,D-脯氨酸,或L-脯氨酸,或外消旋脯氨酸)。
在一些实施方式中,共结晶包含(i)氯硝柳胺的药学上可接受的盐;和(ii)5-10(例如,5-9,5-6,或5)元杂芳基,例如,含氮杂芳基,例如,咪唑。
在一些实施方式中,共结晶包含(i)氯硝柳胺;和(ii)5-10(例如,5-9,5-6,或5)元杂芳基,例如,含氮杂芳基,例如,咪唑。
例如,参见Sanphui,P.Cryst.Growth Des.2012,12,4588;Imramovsky,A.Crystals 2012,2,349-361;和Grifasi,F.Cryst.Growth Des.2015,15,4588。
共结晶的氯硝柳胺化合物
在一些实施方式中,氯硝柳胺化合物的化学纯度可以如本文任何地方所定义。
共结晶的粒径
在一些实施方式中,共结晶可具有如本文任何地方所定义的针对氯硝柳胺化合物的降低的粒径。
在一些实施方式中,可通过喷射研磨制备具有降低的粒径的共结晶,例如,使用由Sturtevant制造的CMTI设备NGMP-Mill-A,一种2英寸的薄饼微粉机。
粒度分布(PSD)可以通过激光衍射技术测定,例如,使用“MALVERN MASTERSIZER2000”(标准范围在0.020和2000.0微米之间),型号“APA2000”,配备“Hydro 2000sm”作为分散单元。
在一些实施方式中,共结晶具有减小的粒径范围。
在一些实施方式中,共结晶具有约0.1μm至约30μm的粒径范围。在某些实施方式中,共结晶具有约0.1μm至约20μm的粒径范围。在某些实施方式中,共结晶具有约0.1μm至约10μm的粒径范围。
在一些实施方式中,共结晶具有约1.0μm至约15.0μm的粒径分布D(0.9)。在某些实施方式中,共结晶具有约1.0μm至约10.0μm的粒径分布D(0.9)。在某些实施方式中,共结晶具有约6.0μm至约8.0μm的粒径分布D(0.9)。在某些实施方式中,共结晶具有约2.2μm至约3.2μm的粒径分布D(0.9)。
在一些实施方式中,共结晶具有约0.1μm至约1.5μm的粒径分布D(0.1)。在某些实施方式中,共结晶具有约0.1μm至约1.0μm的粒径分布D(0.1)。在某些实施方式中,共结晶具有约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,共结晶具有约0.5μm至约6.0μm的粒径分布D(0.5)。在某些实施方式中,共结晶具有约1.0μm至约4.0μm的粒径分布D(0.5)。在某些实施方式中,共结晶具有约1.0μm至约2.0μm的粒径分布D(0.5)。在某些实施方式中,共结晶具有约2.5μm至约3.5μm的粒径分布D(0.5)。
在一些实施方式中,共结晶具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
在一些实施方式中,共结晶具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,共结晶具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,氯硝柳胺化合物具有高于约99.0%的化学纯度;且共结晶具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
在一些实施方式中,氯硝柳胺化合物具有高于约99.0%的化学纯度;且共结晶具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,氯硝柳胺化合物具有高于约99.0%的化学纯度;且共结晶具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,氯硝柳胺化合物具有高于约99.0%的化学纯度;且共结晶具有约0.1μm至约30μm的粒径范围,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
在一些实施方式中,氯硝柳胺化合物具有高于约99.0%的化学纯度;且共结晶具有约0.1μm至约30μm的粒径范围,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在一些实施方式中,氯硝柳胺化合物具有高于约99.0%的化学纯度;且共结晶具有约0.1μm至约30μm的粒径范围,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
在前述实施方式的某些实施方式中,共结晶具有约2.5μm至约3.5μm的粒径分布D(0.5)。
在前述实施方式的某些其他实施方式中,共结晶具有约1.0μm至约2.0μm的粒径分布D(0.5)。
药物组合物和给予
概述
通过使化合物具有生物利用度(例如,局部生物利用度)的任何途径,将氯硝柳胺化合物,或其药学上可接受的盐和/或共结晶;例如,化合物,如氯硝柳胺,或其药学上可接受的盐和/或共结晶给予有需要的对象。在某些实施方式中,途径是口服给予。
在一些实施方式中,将氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶作为药学组合物给予,该药学组合物包括化学实体和一种或多种药学上可接受的赋形剂、和任选的一种或多种其他治疗剂,如本文所述。
在一些实施方式中,氯硝柳胺化合物可以与一种或多种常规药用赋形剂联合给予。药学上可接受的赋形剂包括但不限于:离子交换剂、氧化铝、硬脂酸铝、卵磷脂、自乳化药物递送系统(SEDDS)、例如d-α-生育酚聚乙二醇1000琥珀酸酯、药物剂型中使用的表面活性剂、例如吐温(Tweens)、泊洛沙姆或其它类似的聚合物递送基质、血清蛋白、例如人血清白蛋白、缓冲物质、例如磷酸盐、三羟甲基氨基甲烷、丙三醇、山梨酸、山梨酸钾、饱和植物脂肪酸的部分甘油酯混合物、水、盐或电解质、例如硫酸鱼精蛋白、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐、胶体二氧化硅、三硅酸镁、聚乙烯基吡咯烷酮、基于纤维素的物质、聚乙二醇、羧甲基纤维素钠、聚丙烯酸酯、蜡、聚乙烯-聚氧化丙烯-嵌段聚合物、以及羊毛脂。环糊精如α-、β和γ-环糊精,或化学改性的衍生物如羟烷基环糊精,包括2-和3-羟丙基-b-环糊精,或其它溶液化的衍生物也可用于提高文中所述的通式的化合物的递送。可以制备包含0.005%至100%范围内的如本文所述的化学实体的剂型或组合物,余量由无毒赋形剂构成。预期的组合物可包含0.001%-100%的本文提供的化学实体,在一个实施方式中为0.1-95%,在另一个实施方式中为75-85%,在进一步的实施方式中为20-80%。制备这种剂型的实际方法是已知的,或是本领域技术人员所明白的;例如参见雷明登药物科学和实践(Remington:The Science and Practice of Pharmacy),第22版(英国伦敦的药物出版社(Pharmaceutical Press),2012)。
在一些实施方式中,本文所述的氯硝柳胺化合物或其药物组合物可以通过任何可接受的给予途径给予有需要的对象。可接受的给予途径包括但不限于,口腔、皮肤、颈内、鼻窦、气管内、肠内、硬膜外、间质、腹内、动脉内、支气管内、滑囊内、脑内、脑池内、冠状动脉内、皮内、导管内、十二指肠内、硬膜内、表皮内、食道内、胃内、牙龈内、回肠内、淋巴管内、髓内、脑膜内、肌肉内、卵巢内、腹膜内、前列腺内、肺内、窦内、脊柱内、滑膜内、睾丸内、鞘内、管内、肿瘤内、宫内、血管内、静脉内、鼻内、鼻胃内、口服、肠外、经皮、硬膜外、直肠、呼吸(吸入)、皮下、舌下、粘膜下、局部、透皮、透粘膜、经气管、输尿管、尿道和阴道。
局部给予
本文所述的氯硝柳胺化合物或其药物组合物适用于局部给予,例如,通过在特定治疗部位(例如,消化道、胃肠道(“GI”),例如结肠)给予氯硝柳胺化合物或其组合物的局部给予,从而将化学实体局部给予至需要治疗的区域(例如,口腔;胃肠道,例如,结肠;眼睛;皮肤;或关节)。在某些实施方式中,在所述局部给予期间,氯硝柳胺化合物的全身暴露相对较低。这样组合物的实例包括例如口服给予。
在一些实施方式中,本文所述的氯硝柳胺化合物或其药物组合物适合于局部施用至胃肠道,例如结肠。在某些实施方式中,给予后,氯硝柳胺化合物在胃肠道中的局部浓度高于血浆室中化学实体的浓度(例如,约2倍高至约1,000倍高;约2倍高至约900倍高;约2倍高至约800倍高;约2倍高至约700倍高;约2倍高至约500倍高;约2倍高至约400倍高;约2倍高至约300倍高;约2倍高至约200倍高;约2倍高至约100倍高;约2倍高至约50倍高,约5倍高至约1,000倍高;约5倍高至约900倍高;约5倍高至约800倍高;约2倍高至约700倍高;约5倍高至约500倍高;约5倍高至约400倍高;约5倍高至约300倍高;约5倍高至约200倍高;约5倍高至约100倍高;约5倍高至约50倍高;约5倍高至约25倍高;约5倍高至约15倍高;例如、约1,000倍高、约900倍高、约800倍高、约700倍高、约600倍高、约500倍高、约400倍高、约300倍高、约200倍高、约100倍高、约50倍高、约25倍高、约20倍高、约15倍高、约10倍高、约5倍高)。在这些实施方式中的某些实施方式中,血浆室中的化学实体经过首过代谢。
在一些实施方式中,本文所述的氯硝柳胺化合物或其药物组合物适合于局部施用至消化道或胃肠道内的一个或多个特定位置,例如结肠。例如,至少一些氯硝柳胺化合物存在于上胃肠道(例如,胃);或至少一些氯硝柳胺化合物存在于下胃肠道(例如,大肠,例如,结肠,例如,升结肠和/或横结肠和/或远端结肠;或小肠)。作为另一个实例,至少一些氯硝柳胺化合物存在于升结肠和/或横结肠和/或远端结肠和/或小肠和/或胃。所述局部给予的方法可包括但不限于口服给予。
在一个方面,提供了一种组合物,其包含如本文任何地方所述的氯硝柳胺化合物或共结晶和一种或多种药学上可接受的赋形剂,其中组合物适于口服给予。
在一些实施方式中,向对象给予单剂的组合物在对象的胃肠道(例如,结肠)中产生高于对象的血浆室中化合物的浓度的氯硝柳胺化合物的局部浓度。
在一些实施方式中,向对象给予单剂的组合物在对象的胃肠道(例如,结肠)中产生高于对象的血浆室中化合物的浓度至少约200倍的氯硝柳胺化合物的局部浓度。
在一些实施方式中,向对象给予单剂的组合物在对象的胃肠道(例如,结肠)中产生高于对象的血浆室中化合物的浓度至少约300倍的氯硝柳胺化合物的局部浓度。
在一些实施方式中,向对象给予单剂的组合物在对象的胃肠道(例如,结肠)中产生高于对象的血浆室中化合物的浓度至少约500倍的氯硝柳胺化合物的局部浓度。
在一些实施方式中,向对象给予单剂的组合物在对象的胃肠道(例如,结肠)中产生高于对象的血浆室中化合物的浓度至少约700倍的氯硝柳胺化合物的局部浓度。
在一些实施方式中,对象的胃肠道(例如,结肠)中的氯硝柳胺化合物的局部浓度高于单剂的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
在一些实施方式中,对象的胃肠道(例如,结肠)中的氯硝柳胺化合物的局部浓度高于单剂的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度至少约100倍,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
在一些实施方式中,对象的胃肠道(例如,结肠)中的氯硝柳胺化合物的局部浓度高于单剂的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度至少约100倍,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
在一些实施方式中,第二氯硝柳胺化合物具有约25.0μm至约65.0μm的粒径分布D(0.9)。
在一些实施方式中,第二氯硝柳胺化合物具有约4.0μm至约10.0μm的粒径分布D(0.1)。
在另一个方面,本文提供包含如本文任何地方所述的组合物的剂型(例如,单位剂型),其中剂型适于口服给予。
在一些实施方式中,剂型进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至升结肠的组分。
在一些实施方式中,剂型进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至横结肠的组分。
在一些实施方式中,剂型进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至远端结肠的组分。
在一些实施方式中,剂型进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至小肠的组分。
其他实施方式包括在权利要求168-178和/或179-183中任一项或多项中描述的那些。
口服递送
在其他实施方式中,本文所述化学实体或其药学组合物适于通过口服给予的方式局部递送至消化道或胃肠道(例如,固体或液体剂型)。
用于口服给予的固体剂型包括胶囊、片剂、丸剂、粉剂和颗粒剂。在这样的固体剂型中,化学实体与一种或多种药学上可接受的赋形剂混合,如柠檬酸钠或磷酸二钙和/或:a)填充剂或增量剂如淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;b)粘合剂如羧甲基纤维素、藻酸盐、明胶、聚乙烯吡咯烷酮、蔗糖和阿拉伯胶;c)保湿剂如甘油;d)崩解剂如琼脂、碳酸钙、马铃薯或木薯淀粉、海藻酸、某些硅酸盐和碳酸钠,e)溶液阻滞剂如石蜡;f)吸收促进剂如季铵化合物;g)润湿剂如鲸蜡醇和单硬脂酸甘油酯;h)吸收剂,例如高岭土和膨润土;i)润滑剂如滑石粉、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠;及其混合物。在胶囊、片剂和丸剂的情况下,剂型中也可含有缓冲剂。亦可使用诸如乳糖和高分子量聚乙二醇等聚合物作为赋形剂,将类型相似的固体组合物填充到软和硬填充明胶胶囊中。
在一个实施方式中,组合物将采用单位剂型如丸剂或片剂的形式,并且因此组合物可以与本文提供的化学实体一起包含:稀释剂如乳糖、蔗糖、磷酸二钙等;润滑剂如硬脂酸镁等;以及粘合剂如淀粉、阿拉伯树胶、聚乙烯吡咯烷、明胶、纤维素、纤维素衍生物等。在另一种固体剂型中,粉末、药丸、溶液或混悬液(例如在碳酸亚丙酯、植物油、PEG、泊洛沙姆124或甘油三酸酯中)被包封在胶囊(明胶或纤维素基胶囊)内。还考虑了其中一种或多种本文提供的化学实体或另外的活性剂物理分离的单位剂型;例如,每种药物的颗粒胶囊(或胶囊中的片剂);两层片剂;两室凝胶帽等。肠溶包衣或延迟释放口服剂型也被考虑。
其他生理上可接受的化合物包括润湿剂、乳化剂、分散剂、或防腐剂,防腐剂对于避免微生物生长或作用特别有用。熟知各种防腐剂,例如包括苯酚和抗坏血酸。
在某些实施方式中,赋形剂是无菌的并且通常不含不良物质。这些组合物可通过常规、熟知的灭菌技术消毒。对于各种口服剂型赋形剂,例如片剂和胶囊剂,不需要无菌。USP/NF标准通常是足够的。
在某些实施方式中,固体口服剂型可以进一步包括一种或多种组分,其在化学和/或结构上使组合物易于将化学实体递送至胃或下胃肠道;例如,升结肠和/或横结肠和/或远端结肠和/或小肠。例如,Filipski,K.J.等人Current Topics in MedicinalChemistry,2013,13,776-802描述了示例性的配制技术,其以引用方式全文纳入本文。
实例包括上胃肠道靶向技术,例如Accordion Pill(Intec Pharma)、浮动胶囊和能够粘附到粘膜壁的材料。
其他实例包括下胃肠道靶向技术。为了靶向肠道中的各个区域,有几种肠溶/pH响应包衣和赋形剂可供选择。这些材料通常是聚合物,设计用于在特定的pH范围内溶解或腐蚀,根据所需药物释放的胃肠区域进行选择。这些材料还具有保护酸不稳定药物免受胃液影响或在活性成分可能刺激上胃肠道的情况下限制暴露的作用(例如,邻苯二甲酸羟丙基甲基纤维素系列、Coateric(聚乙酸邻苯二甲酸乙烯酯)、乙酸邻苯二甲酸纤维素、乙酸羟丙基甲基纤维素琥珀酸盐、Eudragit系列(甲基丙烯酸-甲基丙烯酸甲酯共聚物)和Marcoat)。其他技术包括响应胃肠道局部菌群的剂型、压力控制的结肠递送胶囊和脉冲塞囊(Pulsincap)。
口服给予的液体剂型包括药学上可接受的乳剂、微乳剂、溶液剂、混悬剂、糖浆剂和酏剂。除本文所述的化学实体外,液体剂型可含有本领域常用的惰性稀释剂,例如水或其它溶剂,增溶剂和乳化剂,例如乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苄醇、苯甲酸苄酯、丙二醇、1,3-丁二醇、二甲基甲酰胺、油类(尤其棉籽油、花生油、玉米油、胚芽油、橄榄油、蓖麻油和芝麻油)、甘油、四氢呋喃醇、聚乙二醇和失水山梨糖醇脂肪酸酯和它们的混合物。除惰性稀释剂外,这些口服组合物亦可包含诸如湿润剂、乳化及悬浮剂、甜味剂、调味剂和芳香剂等辅助试剂。在某些实施方式中,液体剂型是漱口剂。在某些实施方式中,这样的液体口服剂型可用于对消化道或胃肠道,例如消化道,例如口腔进行局部和外用给予。
其他形式的递送
在一些实施方式中,本文所述的化学实体或其药学组合物适合于局部和外用给予眼部(例如,滴眼液)。眼部组合物可以包括但不限于以下任何一种或多种:粘胶原(例如、羧甲基纤维素、甘油、聚乙烯吡咯烷酮、聚乙二醇);稳定剂(例如、普流罗尼克(Pluronic)(三嵌段共聚物)、环糊精);防腐剂(例如、苯扎氯铵、ETDA、SofZia(硼酸、丙二醇、山梨糖醇、和氯化锌;Alcon Laboratories公司)、Purite(稳定的氧氯络合物;Allergan公司))。
在一些实施方式中,本文所述的化学实体或其药学组合物适合于局部和外用给予皮肤(例如,软膏剂和乳膏剂)。软膏剂是半固体制剂,通常基于凡士林或其他石油衍生物。含有所选活性剂的乳膏剂通常是粘性液体或半固体乳液,通常为水包油或油包水。乳膏剂基质通常是可水洗的,并且包含油相、乳化剂和水相。油相,有时也称为“内”相,通常由凡士林和脂肪醇如鲸蜡醇或硬脂醇组成;水相通常(尽管不是必须的)体积超过油相,并且通常含有保湿剂。乳膏剂制剂中的乳化剂通常是非离子、阴离子、阳离子或两性表面活性剂。与其他运载体或载剂一样,软膏剂基质应该是惰性的、稳定的、无刺激性和无致敏性的。
剂量
剂量可以根据患者的需要、正在治疗的病症的严重程度和所使用的特定化合物而变化。特定情况下合适剂量的确定可由医学领域的技术人员确定。每日总剂量可以在一天中分成几部分或通过提供连续递送的方式给予。
在一些实施方式中,氯硝柳胺化合物以约0.01mg/Kg至约200mg/Kg(例如,约0.01mg/Kg至约150mg/Kg;约0.01mg/Kg至约100mg/Kg;约0.01mg/Kg至约50mg/Kg;约0.01mg/Kg至约10mg/Kg;约0.01mg/Kg至约5mg/Kg;约0.1mg/Kg至约200mg/Kg;约0.1mg/Kg至约150mg/Kg;约0.1mg/Kg至约100mg/Kg;约0.1mg/Kg至约50mg/Kg;约0.1mg/Kg至约10mg/Kg;约0.1mg/Kg至约5mg/Kg)的剂量给予。
在某些实施方式中,氯硝柳胺化合物以约15mg/Kg至约100mg/Kg(例如,约15mg/Kg至约90mg/Kg,约20mg/Kg至约100mg/Kg;约20mg/Kg至约90mg/Kg;约20mg/Kg至约80mg/Kg;约30mg/Kg至约90mg/Kg;约30mg/Kg至约80mg/Kg;约35mg/Kg至约75mg/Kg;约10mg/Kg至约50mg/Kg;约15mg/Kg至约45mg/Kg;例如,约35mg/Kg或约75mg/Kg)的剂量给予。在其他实施方式中,化学实体以约0.1mg/Kg至约10mg/Kg(例如,约0.1mg/Kg至约5mg/Kg;约1mg/Kg至约10mg/Kg;约1mg/Kg至约5mg/Kg)的剂量给予。
在一些实施方式中,制剂包括约0.5mg至约2500mg(例如,约0.5mg至约2000mg、约0.5mg至约1000mg、约0.5mg至约750mg、约0.5mg至约600mg、约0.5mg至约500mg、约0.5mg至约400mg、约0.5mg至约300mg、约0.5mg至约200mg;例如、约5mg至约2500mg、约5mg至约2000mg、约5mg至约1000mg;约5mg至约750mg;约5mg至约600mg;约5mg至约500mg;约5mg至约400mg;约5mg至约300mg;约5mg至约200mg;例如、约50mg至约2000mg、约50mg至约1000mg、约50mg至约750mg、约50mg至约600mg、约50mg至约500mg、约50mg至约400mg、约50mg至约300mg、约50mg至约200mg;例如、约100mg至约2500mg、约100mg至约2000mg、约100mg至约1000mg、约100mg至约750mg、约100mg至约700mg、约100mg至约600mg、约100mg至约500mg、约100mg至约400mg、约100mg至约300mg、约100mg至约200mg;例如、约150mg至约2500mg、约150mg至约2000mg、约150mg至约1000mg、约150mg至约750mg、约150mg至约700mg、约150mg至约600mg、约150mg至约500mg、约150mg至约400mg、约150mg至约300mg、约150mg至约200mg;例如、约150mg至约500mg;例如、约300mg至约2500mg、约300mg至约2000mg、约300mg至约1000mg、约300mg至约750mg、约300mg至约700mg、约300mg至约600mg;例如、约400mg至约2500mg、约400mg至约2000mg、约400mg至约1000mg、约400mg至约750mg、约400mg至约700mg、约400mg至约600约400mg至约500mg;例如、150mg或450mg)的氯硝柳胺化合物。
在某些实施方式中,制剂包括约50mg至约250mg(例如,约100mg至约200;例如,约150mg)的氯硝柳胺化合物。在某些实施方式中,所述剂量适于通过直肠给予(例如,通过灌肠)来给予的制剂。
在某些实施方式中,灌肠制剂包括约350mg至约550mg(例如,约400mg至约500;例如,约450mg)的氯硝柳胺化合物。在某些实施方式中,所述剂量适于通过直肠给予(例如,通过灌肠)来给予的制剂。
前述剂量可以是每天(例如,每天单剂;或每天两或更多个分拆的剂量;或两或更多个剂量;例如,每天两剂、每天三剂)或非每天(例如,每隔一天、每两天、每三天、每周一次、每周两次、每两周一次、每月一次)给予。在某些实施方式中,剂量可以给予约1周、约2周、约3周、约4周、约5周、约6周、约7周、约8周、约3个月、约6个月、约1年、或超过。例如,液体运载体中化学实体的剂量(例如,约2.5mg/mL或约7.5mg/mL)可以每天给予两次,持续约6周。在这些实施方式中的某些实施方式中,化学实体是氯硝柳胺、或其药学上可接受的盐和/或水合物和/或共结晶。例如,液体运载体中约2.5mg/mL或约7.5mg/mL的氯硝柳胺可以每天给予两次,持续约6周。代表性的液体运载体包括,例如,先前结合组分(ii)描述的那些。
在一些实施方式中,制剂包括约500mg至约2500mg(例如、约600mg至约1800mg、约700mg至约1700mg、约800mg至约1600mg、约900mg至约1500mg、约1000mg至约1400mg、约1100mg至约1300mg、例如、约1200mg。在某些实施方式中,所述剂量适于制剂通过口服给予(例如,通过片剂或丸剂)来给予的制剂。
在某些实施方式中,制剂包括约100mg至约700mg(例如、约200mg至约600mg;例如、约300mg至约500mg;例如、约350mg至约450mg;例如、约400mg)的氯硝柳胺化合物。在某些实施方式中,所述剂量适于通过口服给予(例如,通过片剂或丸剂)来给予的制剂。
前述剂量可以是每天(例如,每天单剂;或每天两或更多个分拆的剂量;或两或更多个剂量;例如,两剂每天;或三剂每天;或四剂每天;或五剂每天;例如,三剂每天)或非每天(例如,每隔一天、每两天、每三天、每周一次、每周两次、每两周一次、每月一次)给予。在某些实施方式中,剂量可以给予约1周、约2周、约3周、约4周、约5周、约6周、约7周、约8周、约3个月、约6个月、约1年、或超过;例如2周。
在某些实施方式中,制剂包括约100mg至约700mg(例如、约200mg至约600mg;例如、约300mg至约500mg;例如、约350mg至约450mg;例如、约400mg)的氯硝柳胺化合物,并且上述剂量每天给予。在某些实施方式中,前述剂量以单剂每天给予(例如,持续14天)。在某些实施方式中,所述剂量适于通过口服给予(例如,通过片剂或丸剂)来给予的制剂。
在一些实施方式中,制剂包括约500mg至约2500mg(例如、约600mg至约1800mg、约700mg至约1700mg、约800mg至约1600mg、约900mg至约1500mg、约1000mg至约1400mg、约1100mg至约1300mg、例如、约1200mg。在某些实施方式中,前述剂量每天给予。在某些实施方式中,前述剂量以每天两或更多个分拆的剂量;或两或更多个剂量;例如,每天两剂;例如,每天三剂;例如,每天四剂;例如,每天五剂;例如,三剂每天);例如,持续14天给予。在某些实施方式中,所述剂量适于通过口服给予(例如,通过片剂或丸剂)来给予的制剂。在某些实施方式中,前述剂量以每天两或更多个分拆的剂量,例如,每天三剂;例如,每天三剂400mg;例如,持续14天给予。
治疗方法
在一些实施方式中,提供了用于诱导对象的(例如消化道和/或胃肠道(GI)、皮肤、眼睛或关节中的)一种或多种T细胞的细胞死亡的方法。该方法包括使一种或多种T细胞与有效量的氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶接触;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶,如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的接触步骤组成。
在一些实施方式中,提供了用于治疗患有与对象的(例如消化道和/或胃肠道(GI),例如结肠,例如皮肤、眼睛或关节中的)一种或多种T细胞的不受调节的(异常的、升高的)募集和/或滞留相关的病症的对象的方法。该方法包括使一种或多种T细胞与有效量的氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶接触;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶,如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的接触步骤组成。
在一些实施方式中,提供了用于治疗患有与对象的(例如消化道和/或胃肠道(GI),例如结肠中的)一种或多种T细胞的不受调节的(异常的、升高的)活化相关的病症的对象的方法。该方法包括使一种或多种活化的T细胞与有效量的共结晶接触,该共结晶包含(i)氯硝柳胺化合物、或其药学上可接受的盐;例如,化合物,如氯硝柳胺、或药学上可接受的盐;和(ii)一种或多种药学上可接受的共形成物,如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的接触步骤组成。
在一些实施方式中,诱导一种或多种T细胞的细胞死亡包括一种或多种以下途径:程序性细胞死亡、坏死性凋亡(Necroptosis)、细胞凋亡、坏死、细胞焦亡(Pyroptosis)、铁死亡(Ferroptosis)、失巢凋亡(Anoikis)、有丝分裂风暴(Mitotic cathastrophe)、类凋亡(Paraptosis)、焦坏死(Pyronecrosis)、侵入性细胞死亡(entosis)、中性粒细胞的炎性细胞死亡(NETosis)、PARP-1依赖性细胞死亡(Parthanatos)、自噬性细胞死亡、RGD:调节的细胞死亡、非凋亡程序性细胞死亡、诱导一种或多种T细胞的坏死或凋亡(例如一种或多种T细胞的坏死或凋亡)的不依赖半胱天冬酶的程序性细胞死亡。在某些实施方式中,有效量是足以诱导一种或多种T细胞中的至少一种细胞死亡(例如,通过上述任何一种或多种途径,例如一种或多种T细胞的坏死或凋亡)的量。
在一些实施方式中,一种或多种T细胞包括一种或多种活化的T细胞,例如,一种或多种活化的T细胞独立地选自下组:
CD45+CD3+TCRαβ+CD62L-;
CD45+CD3+TCRαβ+CD62L-CCR7-;
CD45+CD3+TCRαβ+CD62L-CD69+;
CD45+CD3+TCRαβ+CD62L-CD69+PD-1+;
CD45+CD3+TCRαβ+CD62L-CTLA4+;
CD45+CD3+TCRαβ+CD62L-PD-1++CTLA4+;
CD45+CD3+TCRγδ+CD62L-;
CD45+CD3+TCRγδ+CD62L-CCR7-;
CD45+CD3+TCRγδ+CD62L-CD69+;
CD45+CD3+TCRγδ+CD62L-CD69+PD-1+;
CD45+CD3+CD62L-TCRγδ+CTLA4+;和
CD45+CD3+TCRγδ+CD62L-PD-1++CTLA4+。
在某些实施方式中,有效量是足以诱导一种或多种活化的T细胞中的至少一种细胞死亡(例如,通过上述任何一种或多种途径,例如一种或多种活化的T细胞的坏死或凋亡)的量。
在一些实施方式中,一种或多种T细胞存在于肠上皮细胞内和/或固有层内和/或派尔氏斑(PP)内和/或GALT(肠道相关淋巴组织)内和/或肠黏膜内和/或肠黏膜下层内和/或肠肌层内和/或肠浆膜内。
在一些实施方式中,一种或多种T细胞包括一种或多种肠道嗜性T细胞。在某些实施方式中,一种或多种肠道嗜性T细胞中的每一种独立地表达一种或多种选自下组的肠道归巢受体:
(CD3+CCR9+;
CD3+α4+或CD3+β7+;
CD3+α4+β7+;
CD3+β1+;
CD3+α4+β1+;
CD3+LFA1;
CD3+CCR4+;和
CD3+CCR10+。
在一些实施方式中,提供了在有需要的对象中治疗以异常炎症反应为特征的病症(或其一种或多种症状)的方法(例如,自身免疫性疾病,例如,结肠炎,例如,自身免疫性结肠炎,例如,炎症性肠病,例如,克罗恩病、溃疡性结肠炎)。该方法包括给予对象有效量的化学实体(例如氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶),如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的给予步骤组成。
在一些实施方式中,提供了在有需要的对象中治疗以异常炎症反应为特征的病症(或其一种或多种症状)的方法(例如,自身免疫性疾病,例如,结肠炎,例如,自身免疫性结肠炎,例如,炎症性肠病,例如,克罗恩病、溃疡性结肠炎)。该方法包括外用或局部给予对象有效量的化学实体(例如氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶),如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的给予步骤组成。
在这些实施方式中的某些实施方式中,所述病症是自身免疫疾病。自身免疫疾病的非限制性实例包括:关节炎(包括类风湿性关节炎、青少年类风湿性关节炎、骨关节炎、银屑病关节炎)、多发性硬化症、重症肌无力、系统性红斑狼疮、自身免疫性甲状腺炎(例如桥本氏甲状腺炎)、皮炎(包括特应性皮炎和湿疹性皮炎)、牛皮癣、干燥综合征、包括继发于干燥综合征的干燥性角膜结膜炎、斑秃、节肢动物叮咬反应引起的过敏反应、克罗恩病、口疮性溃疡、虹膜炎、结膜炎、角膜结膜炎、溃疡性结肠炎、哮喘、过敏性哮喘、皮肤性红斑狼疮、硬皮病、阴道炎、结直肠炎、药疹、麻风逆转反应、麻风性结节性红斑、自身免疫性葡萄膜炎、过敏性脑脊髓炎、急性坏死性出血性脑病、特发性双侧进行性感觉神经性听力减退、再生障碍性贫血、纯红细胞性贫血、特发性血小板减少症、多发性软骨炎、韦格纳肉芽肿病、慢性活动性肝炎、史蒂文斯·约翰逊综合征、特发性注药、扁平苔藓、克罗恩病、格雷夫斯氏病、结节病、原发性胆汁性肝硬化、后葡萄膜炎、和间质性肺纤维化。
在一些实施方式中,用于治疗结肠炎例如自身免疫性结肠炎例如炎性肠病的方法;例如,提供了对象的克罗恩病或溃疡性结肠炎(或其一种或多种症状)。该方法包括给予对象有效量的化学实体(例如氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶),如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的给予步骤组成。
在一些实施方式中,提供了用于治疗对象的选自下组的病症(或其一种或多种症状)的方法:乳糜泻、肠易激综合征、粘膜炎、葡萄膜炎、胶原性结肠炎、淋巴细胞性结肠炎、显微结肠炎、放射性肠炎、类风湿关节炎、狼疮、硬皮病、银屑病、皮肤T细胞淋巴瘤、急性移植物抗宿主病和慢性移植物抗宿主病。该方法包括给予对象有效量的化学实体(例如氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶),如本文任何地方所定义。在某些实施方式中,该方法基本上由或由本段中上述的给予步骤组成。
在一些实施方式中,病症是结肠炎,例如,自身免疫性结肠炎。例如,自身免疫性结肠炎可以是炎症性肠病。炎症性肠病可以是克罗恩病。炎症性肠病可以是溃疡性结肠炎。结肠炎(例如,自身免疫性结肠炎)可以是医源性自身免疫性结肠炎,例如,一种或多种化疗剂诱导的结肠炎,用过继细胞疗法诱导的结肠炎,与一种或多种同种免疫疾病相关的结肠炎(如移植物抗宿主病,例如,急性移植物抗宿主病和慢性移植物抗宿主病)。在其他实施方式中,医源性自身免疫性结肠炎可由艰难梭菌(Clostridium difficile)感染引起,其是工业化世界中医院内腹泻和结肠炎的主要原因,并且通常发生在服用广谱抗生素的对象中。结肠炎可以是胶原性结肠炎、淋巴细胞性结肠炎或显微镜下结肠炎。
在这些实施方式中的某些实施方式中,病症是自身免疫疾病。在某些实施方式中,病症是自身免疫性结肠炎,例如,炎症性肠病(例如,克罗恩病或溃疡性结肠炎)。在某些实施方式中,病症是克罗恩病、自身免疫性结肠炎、医源性自身免疫性结肠炎、溃疡性结肠炎、一种或多种化疗剂诱导的结肠炎、用过继细胞疗法治疗诱导的结肠炎、与一种或多种同种免疫疾病(如移植物抗宿主病,例如,急性移植物抗宿主病和慢性移植物抗宿主病)相关的结肠炎、放射性肠炎、胶原性结肠炎、淋巴细胞性结肠炎、显微结肠炎、和放射性肠炎。
在这些实施方式中的某些实施方式中,病症是同种免疫疾病(如移植物抗宿主病,例如,急性移植物抗宿主病和慢性移植物抗宿主病)、乳糜泻、肠易激综合征、类风湿关节炎、狼疮、硬皮病、银屑病、皮肤T细胞淋巴瘤、葡萄膜炎、和粘膜炎(例如,口腔粘膜炎、食管粘膜炎或肠粘膜炎)。
在某些实施方式中,病症是自身免疫性结肠炎。
在这些实施方式中的某些实施方式中,自身免疫性结肠炎诱导自一种或多种化疗剂,例如,化疗免疫调节剂,例如,免疫检查点抑制剂。在这些实施方式中的某些实施方式中,免疫检查点抑制剂靶向选自下组的免疫检查点受体:CTLA-4、PD-1、PD-L1、PD-1–PD-L1、PD-1–PD-L2、白细胞介素-2(IL-2)、吲哚胺2,3-双加氧酶(IDO)、IL-10、转化生长因子-β(TGFβ)、T细胞免疫球蛋白和粘蛋白3(TIM3或HAVCR2)、半乳糖凝集素9–TIM3、磷脂酰丝氨酸–TIM3、淋巴细胞激活基因3蛋白(LAG3)、MHC II类–LAG3、4-1BB–4-1BB配体、OX40–OX40配体、GITR、GITR配体-GITR、CD27、CD70-CD27、TNFRSF25、TNFRSF25–TL1A、CD40L、CD40–CD40配体、HVEM–LIGHT–LTA、HVEM、HVEM-BTLA、HVEM-CD160、HVEM-LIGHT、HVEM–BTLA–CD160、CD80、CD80-PDL-1、PDL2-CD80、CD244、CD48-CD244、CD244、ICOS、ICOS–ICOS配体、B7-H3、B7-H4、VISTA、TMIGD2、HHLA2–TMIGD2、丁酰肌醇、包括BTNL2、Siglec家族、TIGIT和PVR家族成员、KIR、ILT和LIR、NKG2D和NKG2A、MICA和MICB、CD244、CD28、CD86-CD28、CD86-CTLA、CD80-CD28、CD39、CD73腺苷–CD39–CD73、CXCR4–CXCL12、磷脂酰丝氨酸、TIM3、磷脂酰丝氨酸–TIM3、SIRPA–CD47、VEGF、神经纤毛蛋白、CD160、CD30、和CD155;例如,CTLA-4或PD1或PD-L1。参见例如Postow,M.J.Clin.Oncol.2015,33,1。
在这些实施方式中的某些实施方式中,免疫检查点抑制剂选自下组:乌瑞芦单抗(Urelumab)、PF-05082566、MEDI6469、TRX518、伐立鲁单抗(Varlilumab)、CP-870893、帕博利珠单抗(Pembrolizumab)(PD1)、纳武单抗(Nivolumab)(PD1)、阿替利珠单抗(Atezolizumab)(原称MPDL3280A)(PDL1)、MEDI4736(PD-L1)、阿维鲁单抗(Avelumab)(PD-L1)、PDR001(PD1)、BMS-986016、MGA271、利瑞鲁单抗(Lirilumab)、IPH2201、依米妥珠单抗(Emactuzumab)、INCB024360、Galunisertib、乌洛鲁单抗(Ulocuplumab)、BKT140、巴维妥昔单抗(Bavituximab)、CC-90002、贝伐珠单抗(Bevacizumab)、和MNRP1685A、和MGA271。
在这些实施方式中的某些实施方式中,免疫检查点抑制剂靶向CTLA-4,例如,抗体,例如,伊皮木单抗(ipilimumab)或曲美木单抗(tremelimumab)。
在这些实施方式中的某些实施方式中,免疫检查点抑制剂靶向PD1或PD-L1,例如,纳武单抗(Nivolumab),兰布罗珠单抗(lambroizumab),或BMS-936559。
在某些实施方式中,病症是这种情况是粘膜炎,也称为口腔炎,可能由于化疗或放疗(单独或联合使用)以及在放疗范围之外暴露于辐射造成的损害而发生。单独或联合使用时可诱发粘膜炎的化疗剂包括但不限于铂、顺铂、卡铂、奥沙利铂、甲氯乙胺、环磷酰胺、苯丁酸氮芥、硫唑嘌呤、巯基嘌呤、长春新碱、长春碱、长春瑞滨、长春地辛、依托泊苷和替尼泊苷、紫杉醇、多西他赛、伊立替康、拓扑替康、安吖啶、依托泊苷、磷酸依托泊苷、替尼泊苷、5-氟尿嘧啶、亚叶酸、甲氨蝶呤、吉西他滨、紫杉烷、亚叶酸、丝裂霉素C、优福定(tegafur-uracil)、伊达比星、氟达拉滨、米托蒽醌、异环磷酰胺和多柔比星。其他药剂包括mTOR(雷帕霉素(rapamycin)的哺乳动物靶标)抑制剂,包括但不限于雷帕霉素(rapamycin),依维莫司(everolimus),替西罗莫司(temsirolimus)和德福莫司(deforolimus)。
在某些实施方式中,病症是葡萄膜炎,其是葡萄膜的炎症(例如,前葡萄膜炎,例如,虹膜睫状体炎或虹膜炎;中间葡萄膜炎(也称为平坦部炎);后葡萄膜炎;或脉络膜视网膜炎,例如,全葡萄膜炎)。
在一些实施方式中,病症是癌症。癌症的非限制性实例包括:多发性骨髓瘤、白血病(HTLV-1依赖性、红白血病、急性髓性白血病(AML)、慢性髓性白血病(CML)和大颗粒淋巴细胞白血病(LGL))、淋巴瘤(EBV相关/伯基特和伯基特样型、蕈样肉芽肿、皮肤T细胞淋巴瘤、非霍奇金淋巴瘤(NHL)、间变性大细胞淋巴瘤(ALCL)、乳腺癌、三阴性乳腺癌、头颈癌、黑色素瘤、卵巢癌、肺癌、胰腺癌、前列腺癌、肉瘤、骨肉瘤、卡波西肉瘤、尤文肉瘤、肝细胞癌、神经胶质瘤、神经母细胞瘤、星形细胞瘤、结直肠癌、威尔姆氏肿瘤、肾癌、膀胱癌、子宫内膜癌、宫颈癌、食道癌、皮肤鳞状细胞癌、基底细胞癌和转移性癌。
在一些实施方式中,病症是代谢紊乱。如本文所用,术语“代谢紊乱”是指由对象的异常代谢(即为重要过程和活动提供能量的活细胞中的化学变化)引起或表征的紊乱、疾病或病症。代谢紊乱包括与异常产热或异常脂肪细胞(例如棕色或白色脂肪细胞)含量或功能相关的疾病、障碍或病症。代谢紊乱的特征可以是PGC-1活性的失调(例如下调或上调)。代谢紊乱会对细胞功能产生不利影响,例如细胞增殖、生长、分化或迁移、细胞内稳态调节、细胞间或细胞内通讯;组织功能,例如肝功能、肌肉功能或脂肪细胞功能;生物体的全身反应,例如激素反应(例如,胰岛素反应)。代谢紊乱的例子包括肥胖症,包括胰岛素抵抗性肥胖症、糖尿病、食欲过盛、内分泌异常、甘油三酯贮积病、Bardet-Biedl综合征、Lawrence-Moon综合征、Prader-Labhart-Willi综合征、厌食症和恶病质。代谢紊乱的非限制性实例包括肥胖、代谢综合征、胰岛素抵抗、血脂异常(例如糖尿病血脂异常)、高脂血症、高血压、糖尿病(例如、2型糖尿病、1型糖尿病、小儿糖尿病)、高血糖、痛风、LADA、餐时高血糖、高脂蛋白血症、微量/大量白蛋白尿、葡萄糖耐量受损(IGT)、空腹血糖受损(IFG)、肝葡萄糖生成增加、高胰岛素血症、非酒精性脂肪肝(NAFD)、非酒精性脂肪性肝炎(NASH)、肾病、视网膜病、神经病和糖尿病并发症(包括心血管疾病、心血管疾病、脂质代谢疾病、神经退行性和精神疾病、眼压失调、包括青光眼、动脉粥样硬化、高血压、冠心病、胆囊疾病、肾病、视网膜病或糖尿病溃疡)。
在一些实施方式中,所述病症是心血管疾病,例如心肌梗塞和心脏肥大。心血管疾病可进一步包括冠心病(包括心脏病发作和心绞痛或胸痛);中风;充血性心力衰竭;高血压(例如肺动脉高压),高血压;心脏衰竭;风湿热/风湿性心脏病;先天性心血管缺陷;心律不齐(心率病况);动脉、微血管和毛细血管疾病(包括动脉粥样硬化和川崎病);细菌性心内膜炎;心肌病;瓣膜心脏病;肺循环疾病;静脉和淋巴小血管疾病;和其它循环系统疾病。在一些实施方式中,本文中的一种或多种方法导致对梗塞愈合、增加的血管生成和/或减弱的心脏肥大反应的有益作用。
在一些实施方式中,病症是与微生物感染(例如,病毒、细菌、真菌和/或寄生虫感染)相关的病症。非限制性例子包括:肺结核(如肺结核、非肺结核(如淋巴结结核、泌尿生殖系统结核、骨关节结核、结核性脑膜炎)和粟粒性结核)、炭疽、脓肿、寻常痤疮、放线菌病、哮喘、杆菌性痢疾、细菌性结膜炎、细菌性角膜炎、细菌性阴道病、肉毒杆菌中毒、布鲁里溃疡、骨和关节感染、支气管炎(急性或慢性)、布鲁氏菌病、烧伤、猫抓热、蜂窝组织炎、软下疳、胆管炎、胆囊炎、皮肤白喉、囊性纤维化、膀胱炎、弥漫性全细支气管炎、白喉、龋齿、上呼吸道疾病、湿疹、脓胸、心内膜炎、子宫内膜炎、肠热、肠炎,附睾炎,会厌炎,丹毒,丹毒,丹毒,红癣,眼部感染,疖,加德纳菌阴道炎,胃肠道感染(肠胃炎),生殖器感染,牙龈炎,淋病,腹股沟肉芽肿,黑弗里尔热,感染的烧伤,牙科手术后感染、口腔感染、假肢相关感染、腹腔脓肿、军团病、麻风病、钩端螺旋体病、李斯特菌病、肝脓肿、莱姆病、性病性淋巴肉芽肿、乳腺炎、乳突炎、脑膜炎和神经系统感染、足菌肿,诺卡菌病(例如马杜拉足),非特异性尿道炎、眼病(如新生儿眼病)、骨髓炎、中耳炎(如外耳炎和中耳炎)、睾丸炎、胰腺炎、甲沟炎、盆腔腹膜炎、腹膜炎、腹膜炎伴阑尾炎、咽炎、痰、斑疹伤寒、鼠疫、胸腔积液、肺炎、术后伤口感染、术后气性坏疽、前列腺炎、伪膜性结肠炎、鹦鹉热、肺气肿、肾盂肾炎、脓皮病(如脓疱病)、Q热、鼠咬热、网织菌病、蓖麻毒素中毒、里特氏病、沙门氏菌病、输卵管炎、脓毒性关节炎、脓毒性感染、败血症、鼻窦炎、皮肤感染(如皮肤肉芽肿、脓疱疮、毛囊炎和疖病)、梅毒、全身感染、扁桃体炎、中毒性休克综合征、沙眼、土拉菌病、伤寒、斑疹伤寒(例如流行性斑疹伤寒、鼠斑疹伤寒、恙虫病和斑疹伤寒),尿道炎、伤口感染、雅司病、曲霉病、念珠菌病(例如口咽念珠菌病、阴道念珠菌病或龟头炎)、隐球菌病、favus、组织胞浆菌病、擦伤、毛霉菌病、癣(例如体癣、头癣、股癣、足癣和甲癣),甲癣,花斑癣,癣和孢子丝菌病;或MSSA,MRSA,表皮葡萄球菌(Staph.epidermidis),无乳链球菌(Strept.agalactiae),化脓性链球菌(Strept.pyogenes),大肠杆菌(Escherichia coli),肺炎克雷伯菌(Klebs.pneumoniae),催产克氏菌(Klebs.oxytoca),奇异变杆菌(Pr.mirabilis),雷氏普罗威登菌(Pr.rettgeri),普通变形杆菌(Pr.vulgaris),嗜血杆菌流感(Haemophilis injluenzae),粪肠球菌(Enterococcus faecalis)和乳酸肠球菌(Enterococcus faecium)感染。非限制性实例还包括由感染引起的DNA和RNA病毒性疾病,例如由以下引起的:正粘病毒(A型和B型流感病毒)、副粘病毒(呼吸道合胞病毒(RSV)、亚急性硬化性全脑炎(SSPE)病毒)麻疹和3型副流感病毒)、疱疹病毒(HSV-1、HSV-2、HHV-6、HHV-7、HHV-8、爱泼斯坦巴尔病毒(EBV)、巨细胞病毒(HCMV)和水痘带状疱疹病毒(VZV)),逆转录病毒(HIV-1、HIV-2、HTLV-1、HTLV-2)、黄病毒和瘟病毒(黄热病病毒(YFV)、丙型肝炎病毒(HCV)、登革热病毒、牛病毒性腹泻病毒(BVDV)、肝营养病毒(甲型肝炎病毒(HAV)、乙型肝炎病毒(HBV)、HCV、丁型肝炎病毒(HDV)、戊型肝炎病毒(HEV)、庚型肝炎病毒(HGV)、克里米亚-刚果出血热病毒(CCHF)),布尼亚病毒(蓬塔托罗病毒、裂谷热病毒(RVFV)和白蛉热西西里病毒)、汉坦病毒、卡拉帕鲁病毒)、人乳头瘤病毒、脑炎病毒(拉克罗斯病毒)、竞技场病毒(朱宁和塔卡里贝病毒)、呼肠孤病毒,水泡性口炎病毒,鼻病毒,肠道病毒(脊髓灰质炎病毒,柯萨奇病毒,脑心肌炎病毒(EMC))、拉沙热病毒、披膜病毒(Sindbis和Semliki森林病毒)和痘病毒。其他非限制性实例包括真菌感染,例如念珠菌属、申基孢子丝菌、组织胞浆菌属、副球孢子菌属、曲霉属等;或寄生虫,如利什曼原虫、疟疾、棘阿米巴原虫、绦虫等。
在一些实施方式中,病症是过敏性疾病。非限制性实例包括荨麻疹、食物过敏、过敏性休克、嗜酸性粒细胞增多症、哮喘、过敏性鼻炎、过敏性结膜炎、和特应性皮炎。
在一些实施方式中,病症是与NF-κB活化相关的病症和/或提供了炎性细胞因子产生。非限制性实例包括自身免疫疾病如慢性风湿病、骨关节炎、系统性红斑狼疮、系统性硬皮病、多发性肌炎、干燥综合征、血管炎综合征、抗磷脂综合征、斯蒂尔病、白塞病、结节性动脉周围炎、溃疡性结肠炎、克罗恩病、活动性慢性肝炎、肾小球肾炎、慢性肾炎、慢性胰腺炎、痛风、动脉粥样硬化、多发性硬化、动脉硬化、内皮肥大、银屑病、银屑病关节炎、接触性皮炎、特应性皮炎、过敏性疾病如花粉病、哮喘、支气管炎、间质性肺炎、肉芽肿肺病、慢性阻塞性肺病、慢性肺血栓栓塞症、炎症性结肠炎、胰岛素抵抗、肥胖症、糖尿病及其并发症(肾病、视网膜病、神经症、高胰岛素血症、动脉硬化、肥大、外周血管阻塞等)涉及异常血管增殖的疾病、如高脂血症、视网膜病和肺炎、阿尔茨海默病、脑脊髓炎、急性肝炎、慢性肝炎、药物性中毒性肝病、酒精性肝炎、病毒性肝炎、黄疸、肝硬化、肝功能不全、心房粘液瘤、卡斯勒曼综合征、系膜肾炎、肾癌、肺癌、肝癌、乳腺癌、子宫癌、胰腺癌、其他实体癌、肉瘤、骨肉瘤、转移性癌症侵袭、炎性病灶的癌化、癌性恶病质、癌症转移、白血病、例如急性成髓细胞白血病、多发性骨髓瘤、伦纳特氏淋巴瘤、恶性淋巴瘤、癌症的抗癌性发展、病毒性肝炎和肝硬化等病灶的癌化、结肠息肉的癌、脑肿瘤、神经肿瘤、内毒素休克、败血症、细胞组、病毒性肺炎、巨细胞病毒性视网膜病、腺病毒性感冒、腺病毒池热、腺病毒性眼炎、结膜炎、艾滋病、葡萄膜炎、其他细菌、病毒和真菌感染引起的疾病或并发症、手术后的并发症、如全身性炎症症状、经皮输卵管冠状动脉整形手术后的再狭窄、血管闭塞开放后的再灌注障碍、例如缺血再灌注障碍、器官移植排斥和心脏、肝脏、肾脏等的灌注障碍、瘙痒、厌食、不适、慢性疲劳综合症等。
在一些实施方式中,病症是由水通道蛋白介导的病症,例如,水不平衡的疾病或病症。非限制性例子包括:脑或脊髓水肿(例如,脑水肿,例如头部外伤引起的脑水肿)、缺血性中风、神经胶质瘤、脑膜炎、急性高山病、癫痫发作、感染、代谢紊乱、缺氧(包括全身性缺氧和心脏骤停引起的缺氧)、水中毒、肝功能衰竭、肝性脑病、糖尿病酮症酸中毒、脓肿、子痫、克雅氏病、狼疮性脑炎或侵入性中枢神经系统手术(例如,神经外科手术、血管内血栓清除术、脊椎穿刺、动脉瘤修复或深部脑刺激,或例如,脊髓损伤(例如脊髓压迫)引起的脊髓水肿),或因微重力和/或辐射暴露引起的脑和/或视神经水肿;视网膜水肿;低钠血症过多的液体潴留,例如,心力衰竭(HF)、肝硬化、肾病疾病或抗利尿激素分泌不当综合征(SIADH)所致;癫痫、视网膜缺血或与眼压异常和/或组织水合异常、心肌缺血、心肌缺血/再灌注损伤相关的其他眼部疾病,心肌梗塞、心肌缺氧、充血性心力衰竭、败血症或视神经脊髓炎;和偏头痛。
在一些实施方式中,病症是神经退行性疾病或精神疾病。神经退行性疾病或精神疾病的非限制性实例包括:肌萎缩侧索硬化症、帕金森病、阿尔茨海默病、神经元死亡、认知功能受损、抑郁、焦虑、饮食失调、食欲调节、偏头痛、癫痫和化学物质成瘾。
在一些实施方式中,所述病症是勃起功能障碍(男性或女性)、肌病、肌肉组织损失、肌肉消瘦、肌肉分解代谢、骨质疏松症或线性生长减少。在一些实施方式中,病症是全身性硬化症。
本公开内容涵盖了单一疗法方案以及联合疗法方案。
在一些实施方式中,单一疗法包括向对象给予(例如,外用和局部)有效量的本文任何地方定义的化学实体(例如,氯硝柳胺化合物、或其药学上可接受的盐和/或共结晶;例如,化合物如氯硝柳胺、或其药学上可接受的盐和/或共结晶),但不包括给予其他治疗剂(例如,在美国专利8,148,328中公开的活性化合物,例如肽,其通过引用整体并入本文)。
在一些实施方式中,本文所述的方法可进一步包括给予第二治疗剂或方案。
在某些实施方式中,在接触或给予化学实体之前将第二治疗剂或方案给予对象(例如,约1小时前,或约6小时前,或约12小时前,或约24小时前,或约48小时前,或约1周前,或约1个月前)。
在其他实施方式中,第二治疗剂或方案在与接触或给予化学实体大约相同的时间给予对象。例如,第二治疗剂或方案和化学实体以相同的剂型同时提供给对象。作为另一个实例,第二治疗剂或方案和化学实体以单独的剂型同时提供给对象。
在其他实施方式中,第二治疗剂或方案在接触或给予化学实体后给予对象(例如,约1小时后,或约6小时后,或约12小时后,或约24小时后,或约48小时后,或约1周后,或约1个月后)。
在某些实施方式中,第二治疗剂是化疗免疫调节剂,例如免疫检查点抑制剂,其可以如本文任何地方所定义。在其他实施方式中,第二治疗剂或方案是一种或多种在胃肠道中局部作用的抗炎剂或免疫调节剂。在其他实施方式中,第二治疗剂或方案是5-ASA(和相关的递送系统)、抗SMAD7反义物、口服配制的抗-TNF、抗整合素、柳氮磺吡啶、巴柳氮、类固醇、硫唑嘌呤、和甲氨蝶呤。在进一步的实施方式中,第二治疗剂或方案是放射或手术。
在某些实施方式中,第二治疗剂是铂、顺铂、卡铂、奥沙利铂、甲氯乙胺、环磷酰胺、苯丁酸氮芥、硫唑嘌呤、巯基嘌呤、长春新碱、长春碱、长春瑞滨、长春地辛、依托泊苷和替尼泊苷、紫杉醇、多西他赛、伊立替康、拓扑替康、安吖啶、依托泊苷、磷酸依托泊苷、替尼泊苷、5-氟尿嘧啶、亚叶酸、甲氨蝶呤、吉西他滨、紫杉烷、亚叶酸、丝裂霉素C、优福定(tegafur-uracil)、伊达比星、氟达拉滨、米托蒽醌、异环磷酰胺和多柔比星。其他药剂包括mTOR(雷帕霉素(rapamycin)的哺乳动物靶标)抑制剂,包括但不限于雷帕霉素(rapamycin),依维莫司(everolimus),替西罗莫司(temsirolimus)和德福莫司(deforolimus)。
联合治疗
在一些实施方式中,本文所述的方法和组合物适合用于与各种其他治疗方案(例如,化学疗法和/或放射疗法)的联合疗法。在某些实施方式中,本文所述的化学实体和方法可用于治疗由此类治疗方案产生的副作用,例如由化学治疗性免疫调节剂(例如检查点抑制剂)诱导的炎症性肠病,其在一些情况下可能非常严重。
在一些实施方式中,本文所述的方法和组合物适合用于与一种或多种其他治疗剂的联合治疗。
在某些实施方式中,在接触或给予化学实体之前将一种或多种其他治疗剂给予对象(例如,约1小时前,或约6小时前,或约12小时前,或约24小时前,或约48小时前,或约1周前,或约1个月前)。
在其他实施方式中,一种或多种其他治疗剂在与接触或给予化学实体大约相同的时间给予对象。例如,第二治疗剂或方案和化学实体以相同的剂型同时提供给对象。作为另一个实例,第二治疗剂或方案和化学实体以单独的剂型同时提供给对象。
在其他实施方式中,一种或多种其他治疗剂在接触或给予化学实体后给予对象(例如,约1小时后,或约6小时后,或约12小时后,或约24小时后,或约48小时后,或约1周后,或约1个月后)。
作为另一个实例,该一种或多种治疗剂可以是:布地奈德;表皮生长因子;皮质类固醇;环孢素;柳氮磺吡啶;氨基水杨酸盐;6-巯基嘌呤;硫唑嘌呤;甲硝唑;脂肪氧合酶抑制剂;美沙拉秦;奥沙拉嗪;巴柳氮;抗氧化剂;血栓烷抑制剂;IL-1受体拮抗剂;抗IL-1单克隆抗体;抗IL-6单克隆抗体(例如,抗IL-6受体抗体和抗IL-6抗体);生长因子;弹性蛋白酶抑制剂;吡啶-咪唑化合物;如本文所述的TNF拮抗剂;IL-4,IL-10,IL-13和/或TGF beta,细胞因子或其激动剂(例如,激动剂抗体);IL-11;葡糖苷酸或右旋糖苷偶联的泼尼松龙的前药,地塞米松或布地奈德(budesonide);ICAM-1反义硫代磷酸寡核苷酸(ISIS 2302;伊希斯制药公司);可溶性补体受体1(TP10;T细胞科学公司);缓释美沙拉秦;甲氨蝶呤;血小板活化因子(PAF)的拮抗剂;环丙沙星;和/或利多卡因。
在一些实施方式中,本文所述的方法和组合物适合用于与一种或多种用于治疗或预防炎症性肠病(IBS)(例如,克罗恩病、溃疡性结肠炎)的其他治疗剂的联合治疗。其他的治疗剂的非限制性实例包括:1-磷酸鞘氨醇(S1P)受体调节剂(例如,艾曲莫德(etrasimod)或奥扎莫德(ozanimod));甾体抗炎药(例如,倍氯米松(beclomethasone)17或布地奈德(budesonide));非甾体抗炎药(例如,5-ASA);受体相互作用蛋白激酶1(RIPK1)抑制剂(例如,GSK2982772);EP4调节剂(例如,KAG-308);toll样受体(例如,TLR4,TLR9)调节剂(例如,JKB-122,可比托莫德(cobitolimod));Janus激酶(JAK)抑制剂(例如,TD-1473,托法替尼(tofacitinib),乌帕替尼(upadacitinib),非戈替尼(filgotinib),PF-06651600,和PF-06700841);羊毛硫氨酸合成酶C样2(LANCL2)调节剂(例如,BT-11);磷脂酰胆碱(例如,LT-02);整合素(例如,α4整合素)调节剂(例如,AJM-300(卡泰司特(carotegrast)));Smad7调节剂(例如,蒙格生(mongersen));磷酸二酯酶4(PDE4)调节剂(例如,阿普斯特(apremilast));肿瘤进展位点2(TPL2)抑制剂(例如,GS-4875);酪氨酸激酶2(TYK2)抑制剂(例如,BMS-986165,PF-06700841,和PF-06826647);和TEC激酶抑制剂(例如,PF-06651600)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗类风湿关节炎的药剂/方案。非限制性实例包括非甾体抗炎药(NSAIDs;例如,布洛芬和萘普生),皮质类固醇(例如,强的松),改善疾病的抗风湿药(DMARDs;例如,甲氨蝶呤来氟米特(leflunomide)羟氯喹(hydroxychloroquine)(赛能(Plaquenil)),PF-06650833,艾拉莫德(iguratimod),托法替尼(tofacitinib)/>ABBV-599,埃沃布替尼(evobrutinib),和柳氮磺吡啶/>),和生物制品(例如,阿巴西普(Abatacept)/>阿达木单抗(adalimumab)/>阿那白滞素(anakinra)赛妥珠单抗(certolizumab)/>依那西普(etanercept)戈利木单抗(golimumab)/>英夫利昔单抗/>利妥昔单抗(rituximab)/>托珠单抗(tocilizumab)/>沃巴利珠单抗(vobarilizumab),沙立芦单抗(sarilumab)/>苏金单抗(secukinumab),ABP501,CHS-0214,ABC-3373,和托珠单抗(tocilizumab)/>
在一些实施方式中,一种或多种其他治疗剂选自用于治疗狼疮的药剂/方案。非限制性实例包括类固醇、外用免疫调节剂(例如、他克莫司(tacrolimus)软膏剂和匹美克莫司(pimecrolimus)乳膏剂/>)、沙利度胺(thalidomide)/>非甾体抗炎药(NSAIDs;例如、布洛芬和萘普生)、抗疟药(例如、羟氯喹(hydroxychloroquine)(赛能(Plaquenil)))、皮质类固醇(例如、强的松)和免疫调节剂(例如、埃沃布替尼(evobrutinib)、伊伯多胺(iberdomide)、伏环孢素(voclosporin)、西尼莫德(cenerimod)、硫唑嘌呤/>环磷酰胺(cyclophosphamide)/>和环孢素(Neoral、)、和麦考酚酸酯(mycophenolate mofetil))巴瑞克替尼(baricitinb)、艾拉莫德(iguratimod)、非洛替尼(filogotinib)、GS-9876、雷帕霉素(rapamycin)、和PF-06650833)、和生物制品(例如、贝利单抗(belimumab)/>阿尼弗鲁单抗(anifrolumab)、普瑞鲁单抗(prezalumab)、MEDI0700、奥比妥珠单抗(obinutuzumab)、沃巴利珠单抗(vobarilizumab)、培罗利组单抗(lulizumab)、阿他西普(atacicept)、PF-06823859、和鲁皮唑尔(lupizor)、利妥昔单抗(rituximab)、BT063、BI655064、BIIB059、阿地白介素(aldesleukin)/>达匹罗珠单抗(dapirolizumab)、依地雷肽(edratide)、IFN-α-kinoid、OMS721、RC18、RSLV-132、西拉利珠单抗(theralizumab)、XmAb5871、和乌司奴单抗(ustekinumab)/>)。例如、全身性红斑狼疮的非限制性治疗包括非甾体抗炎药(NSAIDs;例如、布洛芬和萘普生)、抗疟药(例如、羟氯喹(hydroxychloroquine)(赛能(Plaquenil)))、皮质类固醇(例如、强的松)和免疫调节剂(例如、伊伯多胺(iberdomide)、伏环孢素(voclosporin)、硫唑嘌呤/>环磷酰胺(cyclophosphamide)/>和环孢素(Neoral、 )、和麦考酚酸酯(mycophenolate mofetil)、巴瑞克替尼(baricitinb)、非洛替尼(filogotinib)、和PF-06650833)、和生物制品(例如、贝利单抗(belimumab)/>阿尼弗鲁单抗(anifrolumab)、普瑞鲁单抗(prezalumab)、MEDI0700、沃巴利珠单抗(vobarilizumab)、培罗利组单抗(lulizumab)、阿他西普(atacicept)、PF-06823859、鲁皮唑尔(lupizor)、利妥昔单抗(rituximab)、BT063、BI655064、BIIB059、阿地白介素(aldesleukin)/>达匹罗珠单抗(dapirolizumab)、依地雷肽(edratide)、IFN-α-kinoid、RC18、RSLV-132、西拉利珠单抗(theralizumab)、XmAb5871、和乌司奴单抗(ustekinumab)/>)。作为另一个实例,皮肤狼疮的治疗的非限制性实例包括类固醇、免疫调节剂(例如、他克莫司(tacrolimus)软膏剂/>和匹美克莫司(pimecrolimus)乳膏剂/>)、GS-9876、非洛替尼(filogotinib)、和沙利度胺(thalidomide)/>也可以给予用于治疗药物诱导的和/或新生儿狼疮的药剂和方案。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗IBD的药剂/方案。非限制性实例包括6-巯基嘌呤、AbGn-168H、ABX464、ABT-494、阿达木单抗(adalimumab)、AJM300、阿利福生(alicaforsen)、AMG139、安芦珠单抗(anrukinzumab)、阿普斯特(apremilast)、ATR-107(PF0530900)、自体CD34选择的外周血干细胞移植、硫唑嘌呤、柏替木单抗(bertilimumab)、BI 655066、BMS-936557、赛妥珠单抗聚乙二醇(certolizumabpegol)可比托莫德(cobitolimod)、皮质类固醇(例如、强的松、Methyl泼尼松龙、强的松)、CP-690,550、CT-P13、环孢素、DIMS0150、E6007、E6011、艾曲莫德(etrasimod)、依曲利珠单抗(Etrolizumab)、粪便微生物移植、非戈替尼(figlotinib)、芬戈莫德(fingolimod)、非拉司特(firategrast)(SB-683699)(formerly T-0047)、GED0301、GLPG0634、GLPG0974、古塞奇尤单抗(guselkumab)、戈利木单抗(golimumab)、GSK1399686、HMPL-004(Andrographis paniculata extract)、IMU-838、英夫利昔单抗、白细胞介素2(IL-2)、Janus激酶(JAK)抑制剂、拉喹莫德(laquinimod)、马赛替尼(masitinib)(AB1010)、基质金属蛋白酶9(MMP 9)抑制剂(例如、GS-5745)、MEDI2070、美沙拉秦、甲氨蝶呤、米吉珠单抗(mirikizumab)(LY3074828)、那他珠单抗(natalizumab)、NNC 0142-0000-0002、NNC0114-0006、奥扎莫德(ozanimod)、吡西替尼(peficitinib)(JNJ-54781532)、PF-00547659、PF-04236921、PF-06687234、QAX576、RHB-104、利福昔明(rifaximin)、瑞莎珠单抗(risankizumab)、RPC1063、SB012、SHP647、柳氮磺吡啶、TD-1473、沙利度胺(thalidomide)、替拉珠单抗(tildrakizumab)(MK3222)、TJ301、TNF-/>托法替尼(tofacitinib)、曲罗芦单抗(tralokinumab)、TRK-170、乌帕替尼(upadacitinib)、乌司奴单抗(ustekinumab)、UTTR1147A、V565、vatelizumab、VB-201、维得利珠单抗(vedolizumab)、和维多氟拉迪莫(vidofludimus)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗肠易激综合征的药剂/方案。非限制性实例包括阿洛司琼(alosetron)、胆汁酸螯合剂(bileacid sequesterants)(例如、消胆胺、考来替泊(ColestiPol)、考来维仑(colesevelam))、氯离子通道激活剂(例如、鲁比前列酮(lubiprostone))、包衣薄荷油胶囊、地昔帕明(desipramine)、双环胺(dicyclomine)、依巴斯汀(ebastine)、艾沙度林(eluxadoline)、法尼醇X受体激动剂(例如、奥贝胆酸(Obeticholic Acid))、粪便微生物群移植、氟西汀(fluoxetine)、加巴喷丁(gabapentin)、鸟苷酸环化酶-C激动剂(例如、利那洛肽(linaclotide)、普卡那肽(plecanatide))、伊布杜坦(ibodutant)、丙咪嗪(imipramine)、JCM-16021、洛哌丁胺、鲁比前列酮(lubiprostone)、去甲替林(nortriptyline)、昂丹司琼(ondansetron)、阿片类(opioids)、帕罗西汀(paroxetine)、pinaverium、聚乙二醇、普瑞巴林(pregabalin)、益生菌(probiotics)、雷莫司琼(ramosetron)、利福昔明(rifaximin)、和坦帕诺(tanpanor)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗硬皮病的药剂/方案。非限制性实例包括非甾体抗炎药(NSAIDs;例如、布洛芬和萘普生)、皮质类固醇(例如,强的松)、免疫调节剂(例如、硫唑嘌呤、甲氨蝶呤环磷酰胺(cyclophosphamide)/>和环孢素抗胸腺细胞球蛋白、麦考酚酸酯(mycophenolate mofetil)、静脉注射免疫球蛋白、利妥昔单抗(rituximab)、西罗莫司(sirolimus)、和阿法赛特(alefacept))、钙通道阻滞剂(例如、硝苯地平(nifedipine))、α受体阻滞剂、血清素受体拮抗剂、血管紧张素II受体抑制剂、他汀类、局部硝酸盐、伊洛前列素(iloprost)、磷酸二酯酶5抑制剂(例如,西地那非(sildenafil))、波生坦(bosentan)、四环素类抗生素、内皮素受体拮抗剂、前列腺素、和酪氨酸激酶抑制剂(例如、伊马替尼(imatinib)、尼罗替尼(nilotinib)达沙替尼(dasatinib))。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗克罗恩病(CD)的药剂/方案。非限制性实例包括阿达木单抗(adalimumab)、自体CD34选择的外周血干细胞移植、6-巯基嘌呤、硫唑嘌呤、赛妥珠单抗聚乙二醇(certolizumab pegol)皮质类固醇(例如、强的松)、依曲利珠单抗(Etrolizumab)、E6011、粪便微生物移植、非戈替尼(figlotinib)、古塞奇尤单抗(guselkumab)、英夫利昔单抗、IL-2、JAK抑制剂、基质金属蛋白酶9(MMP 9)抑制剂(例如、GS-5745)、MEDI2070、美沙拉秦、甲氨蝶呤、那他珠单抗(natalizumab)、奥扎莫德(ozanimod)、RHB-104、利福昔明(rifaximin)、瑞莎珠单抗(risankizumab)、SHP647、柳氮磺吡啶、沙利度胺(thalidomide)、乌帕替尼(upadacitinib)、V565、和维得利珠单抗(vedolizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗UC的药剂/方案。非限制性实例包括AbGn-168H、ABT-494、ABX464、阿普斯特(apremilast)、PF-00547659、PF-06687234、6-巯基嘌呤、阿达木单抗(adalimumab)、硫唑嘌呤、柏替木单抗(bertilimumab)、布雷库单抗(brazikumab)(MEDI2070)、可比托莫德(cobitolimod)、赛妥珠单抗聚乙二醇(赛妥珠单抗(certolizumab)pegol)CP-690,550、皮质类固醇(例如、multimax布地奈德(budesonide)、Methyl泼尼松龙)、环孢素、E6007、艾曲莫德(etrasimod)、依曲利珠单抗(Etrolizumab)、粪便微生物移植、非戈替尼(figlotinib)、古塞奇尤单抗(guselkumab)、戈利木单抗(golimumab)、IL-2、IMU-838、英夫利昔单抗、基质金属蛋白酶9(MMP9)抑制剂(例如、GS-5745)、美沙拉秦、美沙拉秦、米吉珠单抗(mirikizumab)(LY3074828)、RPC1063、瑞莎珠单抗(risankizumab)(BI6555066)、SHP647、柳氮磺吡啶、TD-1473、TJ301、替拉珠单抗(tildrakizumab)(MK 3222)、托法替尼(tofacitinib)、托法替尼(tofacitinib)、乌司奴单抗(ustekinumab)、UTTR1147A、和维得利珠单抗(vedolizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗自身免疫性结肠炎的药剂/方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、美沙拉秦、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗医源性自身免疫性结肠炎的药剂/方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗一种或多种化疗剂诱导的结肠炎的药剂/方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、美沙拉秦、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗用过继细胞疗法治疗引起的结肠炎的治疗剂和/或方案。非限制性实例包括皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、地芬诺酯/阿托品、英夫利昔单抗、洛哌丁胺、TIP60抑制剂(参见、例如、美国专利申请公开第2012/0202848))、和维得利珠单抗(vedolizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗与一种或多种同种免疫疾病相关的结肠炎的药剂/方案。非限制性实例包括皮质类固醇(例如,布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、柳氮磺吡啶、和二十碳烯酸。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗放射性肠炎的药剂/方案。非限制性实例包括替度鲁肽(teduglutide)、氨磷汀(amifostine)、血管紧张素转换酶(ACE)抑制剂(例如、贝那普利(benazepril)、卡托普利(captopril)、依那普利(enalapril)、福辛普利(fosinopril)、赖诺普利(lisinopril)、莫西普利(moexipril)、培哚普利(perindopril)、喹那普利(quinapril)、雷米普利(ramipril)、和泉多普利(trandolapril))、益生菌(probiotics)、硒补充剂、他汀类(例如、阿托伐他汀(atorvastatin)、氟伐他汀(fluvastatin)、洛伐他汀(lovastatin)、普伐他汀(pravastatin)、瑞舒伐他汀(rosuvastatin)、辛伐他汀(simvastatin)、和匹伐他汀(pitavastatin))、硫糖铝、和维生素E。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗胶原性结肠炎的药剂/方案。非限制性实例包括6-巯基嘌呤、硫唑嘌呤、次水杨酸铋、消胆胺、考来替泊(ColestiPol)、皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、洛哌丁胺、美沙拉秦、甲氨蝶呤、和柳氮磺吡啶。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗淋巴细胞性结肠炎的药剂/方案。非限制性实例包括6-巯基嘌呤、硫唑嘌呤、次水杨酸铋、齿叶乳香(Boswelliaserrata)提取物、消胆胺、考来替泊(ColestiPol)、皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、粪便微生物移植、洛哌丁胺、美沙拉秦、甲氨蝶呤、益生菌(probiotics)、和柳氮磺吡啶。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗显微结肠炎的药剂/方案。非限制性实例包括6-巯基嘌呤、硫唑嘌呤、次水杨酸铋、齿叶乳香(Boswellia serrata)提取物、消胆胺、考来替泊(ColestiPol)、皮质类固醇(例如、布地奈德(budesonide)、强的松、泼尼松龙、丙酸倍氯米松)、粪便微生物移植、洛哌丁胺、美沙拉秦、甲氨蝶呤、益生菌(probiotics)、和柳氮磺吡啶。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗同种免疫疾病的药剂/方案。非限制性实例包括宫内血小板输注、静脉注射免疫球蛋白、母体类固醇、阿巴西普(abatacept)、阿仑单抗(alemtuzumab)、α1-抗胰蛋白酶、AMG592、抗胸腺细胞球蛋白、抗胸腺细胞球蛋白、巴西替尼(barcitinib)、巴利昔单抗(basiliximab)、硼替佐米(bortezomib)、布伦妥昔单抗(brentuximab)、大麻二酚(cannabidiol)、皮质类固醇(例如甲基强的松、强的松)、环孢素、达西珠单抗(dacilzumab)、去纤维苷(defribrotide)、地尼白介素(denileukin diftitox)、格拉斯地吉(glasdegib)、依鲁替尼(ibrutinib)、IL-2、英夫利昔单抗、伊他替尼(itacitinib)、LBH589、马拉维若(maraviroc)、麦考酚酸酯(mycophenolate mofetil)、那他珠单抗(natalizumab)、奈胡利珠单抗(neihulizumab)、喷司他丁(pentostatin)、派伏司他(pevonedistat)、光生物调节、光置换术、鲁索利替尼(ruxolitinib)、西罗莫司(sirolimus)、索尼德吉(sonidegib)、他克莫司(tacrolimus)、托珠单抗(tocilizumab)、和维莫地吉(Vismodegib)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗多发性硬化症(MS)的药剂/方案。非限制性实例包括阿仑珠单抗(alemtuzumab)ALKS 8700、阿米洛利(amiloride)、ATX-MS-1467、硫唑嘌呤、巴氯芬(baclofen)/>乙型干扰素(beta interferons)(例如、IFN-β-1a、IFN-β-1b)、克拉屈滨(cladribine)、皮质类固醇(例如、甲基泼尼松龙)、达珠单抗(daclizumab)、富马酸二甲酯/>芬戈莫德(fingolimod)/>氟西汀(fluoxetine)、醋酸格拉替雷(glatiramer acetate)羟氯喹(hydroxychloroquine)、异丁司特(ibudilast)、艾地苯醌(idebenone)、拉喹莫德(laquinimod)、硫辛酸(lipoic acid)、氯沙坦(losartan)、马赛替尼(masitinib)、MD1003(biotin)、米托蒽醌(mitoxantrone)、孟鲁司特(montelukast)、那他珠单抗(natalizumab)/>NeuroVaxTM、奥瑞珠单抗(ocrelizumab)、奥法木单抗(ofatumumab)、比格列酮(pioglitazone)、和RPC1063。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗移植物抗宿主病的药剂/方案。非限制性实例包括阿巴西普(abatacept)、阿仑单抗(alemtuzumab)、α1-抗胰蛋白酶、AMG592、抗胸腺细胞球蛋白、抗胸腺细胞球蛋白、巴西替尼(barcitinib)、巴利昔单抗(basiliximab)、硼替佐米(bortezomib)、布伦妥昔单抗(brentuximab)、大麻二酚(cannabidiol)、皮质类固醇(例如甲基强的松、强的松)、环孢素、达西珠单抗(dacilzumab)、去纤维苷(defribrotide)、地尼白介素(denileukin diftitox)、格拉斯地吉(glasdegib)、依鲁替尼(ibrutinib)、IL-2、伊马替尼(imatinib)、英夫利昔单抗、伊他替尼(itacitinib)、LBH589、马拉维若(maraviroc)、麦考酚酸酯(mycophenolate mofetil)、那他珠单抗(natalizumab)、奈胡利珠单抗(neihulizumab)、喷司他丁(pentostatin)、派伏司他(pevonedistat)、光生物调节、光置换术、鲁索利替尼(ruxolitinib)、西罗莫司(sirolimus)、索尼德吉(sonidegib)、他克莫司(tacrolimus)、托珠单抗(tocilizumab)、和维莫地吉(Vismodegib)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗急性移植物抗宿主病的药剂/方案。非限制性实例包括阿仑珠单抗(alemtuzumab)、α-1抗胰蛋白酶、抗胸腺细胞球蛋白、巴西利昔单抗(basiliximab)、布伦妥昔单抗(brentuximab)、皮质类固醇(例如、甲基强的松、强的松)、环孢素、达珠单抗(daclizumab)、去纤维苷(defribrotide)、登尼白介素(denileukin diftitox)、依鲁替尼(ibrutinib)、英夫利昔单抗、伊他替尼(itacitinib)、LBH589、麦考酚酸酯(mycophenolate mofetil)、那他珠单抗(natalizumab)、奈胡利珠单抗(neihulizumab)、喷司他丁(pentostatin)、光置换术、鲁索替尼(ruxolitinib)、西罗莫司(sirolimus)、他克莫司(tacrolimus)、和托珠单抗(tocilizumab)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗慢性移植物抗宿主病的药剂/方案。非限制性实例包括阿巴西普(abatacept)、阿仑珠单抗(alemtuzumab)、AMG592、抗胸腺细胞球蛋白、巴西利昔单抗(basiliximab)、硼替佐米(bortezomib)、皮质类固醇(例如、甲基强的松、强的松)、环孢素、达珠单抗(daclizumab)、登尼白介素(denileukindiftitox)、格拉吉布(glasdegib)、依鲁替尼(ibrutinib)、IL-2、伊马替尼(imatinib)、英夫利昔单抗、麦考酚酸酯(mycophenolate mofetil)、喷司他丁(pentostatin)、光生物调节、光置换术、鲁索替尼(ruxolitinib)、西罗莫司(sirolimus)、索尼德吉(sonidegib)、他克莫司(tacrolimus)、托珠单抗(tocilizumab)、和维莫德吉(vismodegib)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗乳糜泻的药剂/方案。非限制性实例包括AMG 714、AMY01、黑曲霉(Aspergillus niger)脯氨酰内切蛋白酶、BL-7010、CALY-002、GBR 830、Hu-Mik-Beta-1、IMGX003、KumaMax、醋酸拉唑肽、胰脂肪酶、TIMP-GLIA、维得利珠单抗(vedolizumab)、和ZED1227。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗银屑病的药剂/方案。非限制性实例包括外用皮质类固醇、外用克瑞沙硼(crisaborole)/AN2728、外用SNA-120、外用SAN021、外用本维莫德(tapinarof)、外用托卡非尼(tocafinib)、外用IDP-118、外用M518101、外用钙泊三醇(calcipotriene)和二丙酸倍他美松(betamethasonedipropionate)(例如、MC2-01乳膏剂和)、外用P-3073、外用LEO 90100/>外用二丙酸倍他美松(betamethasone dipropionate)/>卤代倍他索丙酸酯(halobetasol propionate)/>维生素D类似物(例如、钙泊三醇(calcipotriene)/>和骨化三醇(calcitriol)/>)、蒽林(anthralin)(例如、Dritho-/>和Dritho-/>)、外用类视黄醇(例如、他扎罗汀(tazarotene)(例如、/>和/>))、钙调神经磷酸酶(calcineurin)抑制剂(例如、他克莫司(tacrolimus)/>和匹美克莫司(pimecrolimus)/>)、水杨酸、焦油、保湿剂、光疗法(例如、暴露于阳光、UVB光疗法、窄带UVB光疗法、格克曼疗法、补骨脂素加紫外线A(PUVA)疗法、和准分子激光)、类视黄醇(例如、阿曲汀(acitretin))、甲氨蝶呤/> Apo805K1、巴瑞克替尼(baricitinib)、FP187、KD025、prurisol、VTP-43742、XP23829、ZPL-389、CF101(匹立地松(piclidenoson))、LAS41008、VPD-737(司洛匹坦(serlopitant))、乌帕替尼(upadacitinib)(ABT-494)、阿普斯特(aprmilast)、托法替尼(tofacitibin)、环孢素(/>S和/>)、生物制品(例如、依那西普(etanercept)依他西普-szzs(entanercept-szzs)/>英夫利昔单抗/>阿达木单抗(adalimumab)/>阿达木单抗(adalimumab)-adbm乌司奴单抗(ustekinumab)/>戈利木单抗(golimumab)阿普斯特(apremilast)/>苏金单抗(secukinumab)赛妥昔单抗聚乙二醇、苏金单抗(secukinumab)、替拉珠单抗(tildrakizumab)-asmn、英夫利昔单抗-dyyb、阿巴西普(abatacept)、伊克珠单抗(ixekizumab)/>ABP 710、BCD-057、BI695501、比美吉珠单抗(bimekizumab)(UCB4940)、CHS-1420、GP2017、古塞奇尤单抗(guselkumab)(CNTO 1959)、HD203、M923、MSB11022、米吉珠单抗(Mirikizumab)(LY3074828)、PF-06410293、PF-06438179、瑞莎珠单抗(risankizumab)(BI655066)、SB2、SB4、SB5、siliq(brodalumab)、那美芦单抗(namilumab)(MT203、替拉珠单抗(tildrakizumab)(MK-3222)、和伊克珠单抗(ixekizumab))、硫鸟嘌呤、和羟基脲(例如、/>和/>)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗皮肤T细胞淋巴瘤的药剂/方案。非限制性实例包括光疗法(例如、暴露于阳光、UVB光疗法、窄带UVB光疗法、格克曼疗法、补骨脂素加紫外线A(PUVA)疗法、和准分子激光)、体外光采、放疗(例如、点放射和全身皮肤电子束治疗)、干细胞移植、皮质类固醇、咪喹莫特(imiquimod)、贝沙罗汀凝胶(bexarotene gel)、外用双氯乙基硝基脲、氯乙胺凝胶、伏立诺他(vorinostat)罗米地辛(romidepsin)/>普拉曲沙(pralatrexate)生物制品(例如、阿仑珠单抗(alemtuzumab)/>布伦妥昔单抗(brentuximab)维多丁(vedotin)(SGN-35)、莫加木单抗(mogamulizumab)、和IPH4102)。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗葡萄膜炎的药剂/方案。非限制性实例包括皮质类固醇(例如、玻璃体内曲安奈德(triamcinolone)可注射混悬液)、抗生素、抗病毒药(例如、阿昔洛韦(acyclovir))、地塞米松、免疫调节剂(例如、他克莫司(tacrolimus)、来氟米特(leflunomide)、环磷酰胺(cyclophosphamide) 和环孢素/>chlorambucil、硫唑嘌呤、甲氨蝶呤、和麦考酚酸酯(mycophenolate mofetil))、生物制品(例如、英夫利昔单抗/>阿达木单抗(adalimumab)/>依那西普(etanercept)/>戈利木单抗(golimumab)/>赛妥珠单抗(certolizumab)/>利妥昔单抗(rituximab)/>阿巴西普(阿巴西普(abatacept))/>巴西利昔单抗(basiliximab)/>阿那白滞素(anakinra)/>canakinumab/>吉沃珠单抗(gevokixumab)(XOMA052)、托珠单抗(tocilizumab)/>阿仑珠单抗(alemtuzumab)efalizumab/>LFG316、西罗莫司(sirolimus)/>阿巴西普(abatacept)、沙立芦单抗(sarilumab)/>和达珠单抗(daclizumab))、细胞毒药物、手术植入物(例如、氟轻松插入物)、和玻璃体切除术。
在一些实施方式中,一种或多种其他治疗剂选自用于治疗粘膜炎的药剂/方案。非限制性实例包括AG013、SGX942(dusquetide)、氨磷汀(amifostine)冷冻疗法、思必乐锭剂(cepacol lonzenges)、辣椒素锭剂(capsaicin lozenges)、粘膜粘合剂(例如、/>)口服苯海拉明(diphenhydramine)(例如、/>elixir)、口服生物粘附剂(例如、聚乙烯吡咯烷酮-透明质酸钠凝胶/>)、口服润滑剂(例如、口服)、碳酸钾、母菊(chamomilla recutita)漱口水、食用葡萄植物外泌体、防腐漱口水(例如、葡萄糖酸氯己定(例如、/>或/>)、外用止痛药(例如、利多卡因(lidocaine)、苯佐卡因(benzocaine)、盐酸达克罗宁、木卡因(xylocaine)(例如、黏稠的木卡因(xylocaine)2%)、和/>(0.6%苯酚))、皮质类固醇(例如、强的松)、止痛药(例如、布洛芬、萘普生、对乙酰氨基酚、和阿片类(opioids))、GC4419、帕利弗明(palifermin)(角质细胞生长因子;/>)、ATL-104、可乐定月桂酸(clonidinelauriad)、IZN-6N4、SGX942、瑞巴派特(rebamipide)、神经皮素(nepidermin)、可溶性β-1,3/1,6葡聚糖、P276、LP-0004-09、CR-3294、ALD-518、IZN-6N4、槲皮素(quercetin)、含有欧洲越桔(vaccinium myrtillus)提取物的颗粒、博落回(macleaya cordata)生物碱和狭叶松果菊(echinacea angustifolia)提取物(例如、/>)、和胃肠鸡尾酒(酸还原剂such氢氧化铝和氢氧化镁(例如、Maalox)、抗真菌药(例如、制霉菌素(nystatin))、和镇痛药(例如、hurricane液))。例如、口腔粘膜炎的治疗的非限制性实例包括AG013、氨磷汀(amifostine)/>冷冻疗法、思必乐锭剂(cepacol lonzenges)、粘膜粘合剂(例如、/>)口服苯海拉明(diphenhydramine)(例如、/>elixir)、口服生物粘附剂(例如、聚乙烯吡咯烷酮-透明质酸钠凝胶/>)、口服润滑剂(例如、口服)、碳酸钾、母菊(chamomilla recutita)漱口水、食用葡萄植物外泌体、防腐漱口水(例如、葡萄糖酸氯己定(例如、/>或/>)、外用止痛药(例如、利多卡因(lidocaine)、苯佐卡因(benzocaine)、盐酸达克罗宁、木卡因(xylocaine)(例如、黏稠的木卡因(xylocaine)2%)、和/>(0.6%苯酚))、皮质类固醇(例如、强的松)、止痛药(例如、布洛芬、萘普生、对乙酰氨基酚、和阿片类(opioids))、GC4419、帕利弗明(palifermin)(角质细胞生长因子;/>)、ATL-104、可乐定月桂酸(clonidinelauriad)、IZN-6N4、SGX942、瑞巴派特(rebamipide)、神经皮素(nepidermin)、可溶性β-1,3/1,6葡聚糖、P276、LP-0004-09、CR-3294、ALD-518、IZN-6N4、槲皮素(quercetin)、和胃肠鸡尾酒(酸还原剂如氢氧化铝和氢氧化镁(例如、Maalox)、抗真菌药(例如、制霉菌素(nystatin))、和镇痛药(例如、hurricane液体))。作为另一个实例,食管粘膜炎治疗的非限制性实例包括木卡因(xylocaine)(例如,凝胶黏稠的木卡因(xylocaine)2%)。作为另一个例子,肠粘膜炎的治疗、改善肠粘膜炎的治疗以及肠粘膜炎体征和症状的治疗包括胃肠道混合物胃肠鸡尾酒(酸还原剂如氢氧化铝和氢氧化镁(例如、Maalox)、抗真菌药(例如、制霉菌素(nystatin))、和镇痛药(例如、hurricane液))。
在某些实施方式中,一种或多种其他治疗剂是化疗免疫调节剂,例如免疫检查点抑制剂,其可以如本文任何地方所定义。在其他实施方式中,第二治疗剂或方案是一种或多种在胃肠道中局部作用的抗炎剂或免疫调节剂。在其他实施方式中,第二治疗剂或方案是5-ASA(和相关的递送系统)、抗SMAD7反义物、口服配制的抗-TNF、抗整合素、柳氮磺吡啶、巴柳氮、类固醇、硫唑嘌呤、和甲氨蝶呤。在进一步的实施方式中,第二治疗剂或方案是放射或手术。
在某些实施方式中,一种或多种其他治疗剂是铂、顺铂、卡铂、奥沙利铂、甲氯乙胺、环磷酰胺、苯丁酸氮芥、硫唑嘌呤、巯基嘌呤、长春新碱、长春碱、长春瑞滨、长春地辛、依托泊苷和替尼泊苷、紫杉醇、多西他赛、伊立替康、拓扑替康、安吖啶、依托泊苷、磷酸依托泊苷、替尼泊苷、5-氟尿嘧啶、亚叶酸、甲氨蝶呤、吉西他滨、紫杉烷、亚叶酸、丝裂霉素C、优福定(tegafur-uracil)、伊达比星、氟达拉滨、米托蒽醌、异环磷酰胺和多柔比星。其他药剂包括mTOR(雷帕霉素(rapamycin)的哺乳动物靶标)抑制剂,包括但不限于雷帕霉素(rapamycin),依维莫司(everolimus),替西罗莫司(temsirolimus)和德福莫司(deforolimus)。
在某些实施方式中,一种或多种其他治疗剂可以选自以上描述的那些(参见美国专利7,927,613,其以引用方式全文纳入本文)。
在某些实施方式中,一种或多种另外的治疗剂可以选自在WO2004/006906;WO2006/120178;US 2009/0062396;WO 2012/143377;WO 2012/068274;美国专利7,132,546;美国专利7,989,498;和美国专利8,263,857的任何一项或多项中一般、亚一般和具体公开的化合物;其每个以引用方式全文纳入本文。
在某些实施方式中,一种或多种另外的治疗剂可以是选自硝唑尼特、氯生太尔(closantel)、双羟萘酸吡啶和盐霉素的驱虫剂。参见例如Senkowski,W.等,Mol.CancerTher.2015,14,1504。
在一些实施方式中,本文所述的方法还包括识别需要这种治疗的对象(例如,患者)的步骤(例如,通过活检、内窥镜检查或本领域已知的其他常规方法)。
在一些实施方式中,本文所述的化学实体、方法、和组合物可以被给予是某些难治性患者人群,例如,一种对抗TNFα治疗(例如,修美乐,恩利,类克,Cimzia,Simponi,恩利,黄嘌呤衍生物,例如,己酮可可碱和安非他酮(Bupropion);(R)-DOI,TCB-2,LSD和LA-SS-Az)无反应或耐药的人群。在某些实施方式中,患者正在经历和/或已经经历过抗TNFalpha疗法(例如,修美乐,恩利,类克,Cimzia,Simponi,恩利,黄嘌呤衍生物,例如,己酮可可碱和安非他酮(Bupropion);(R)-DOI,TCB-2,LSD和LA-SS-Az)的治疗。
为了进一步说明本发明,包括以下实施例。当然,这些实施例不应理解为对本发明构成特定限定。在权利要求范围内的这些示例的变体在本领域技术人员的范围内并且被认为落入如本文所述和要求保护的本发明的范围内。读者将认识到,具备本公开内容的本领域技术人员和本领域的技术人员能够在没有详尽示例的情况下制备和使用本发明。
实施例
实施例1.粒径对结肠暴露水平的影响。
进行了实验:(1)未研磨的氯硝柳胺API,其粒径分布D(0.9)约为30微米,和(2)喷射研磨(微粉化,以下称为“研磨”)的氯硝柳胺,其具有约5微米的减小的粒径。这些氯硝柳胺制剂配制成混悬液。用指定剂量水平的单剂量这些氯硝柳胺混悬液治疗兔子。给予后,在指定时间点获得血液样品和直肠粘膜样品。
结果总结:
在给予后1小时,与血浆浓度3.93ng/ml(标准差1.37)相比,直肠给予未研磨的氯硝柳胺(7.5mg)导致平均结肠组织氯硝柳胺浓度为22.55ng/ml(标准差14.49)。这种差异意味着在1小时时,氯硝柳胺的结肠组织浓度是血浆浓度的5倍以上。
直肠给予研磨的氯硝柳胺(7.5mg)导致给予后1小时的平均结肠组织氯硝柳胺浓度为5030ng/ml(标准差367),而1小时时氯硝柳胺的血浆浓度为6.576(标准差4.50),该时间点是在该实验中测得了氯硝柳胺的最大血浆浓度的时间点。这种差异意味着氯硝柳胺的结肠组织浓度是最大测量血浆浓度的750倍以上。
直肠给予研磨的氯硝柳胺(22.5mg)导致平均结肠组织氯硝柳胺浓度为6090ng/ml(标准差2828),而1小时时氯硝柳胺的血浆浓度为20.24(标准差21.00),这是在该实验中测得了氯硝柳胺的最大血浆浓度的时间点。这种差异意味着氯硝柳胺的结肠组织浓度是最大测量血浆浓度的300倍以上。
与未研磨的氯硝柳胺相比,经研磨的氯硝柳胺(7.5mg)直肠给予导致平均结肠组织氯硝柳胺浓度为5030ng/ml(标准差367),后者在给予后1小时导致平均直肠浓度为22.55ng/ml(标准差14.49)。这种差异意味着用研磨材料配制的氯硝柳胺的结肠组织浓度是用未研磨材料配制的氯硝柳胺的结肠组织浓度的200倍以上。
描述了本发明的许多实施方式。然而,应理解,可进行各种改进而不背离本发明的精神和范围。因此,其他实施方式包括在所附权利要求书的范围内。
Claims (222)
1.高纯度氯硝柳胺化合物、或其药学上可接受的盐。
2.如权利要求1所述的化合物,其特征在于,所述化合物具有下式:
3.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度。
4.如权利要求1-3中任一项所述的化合物,其中所述化合物具有高于约99.5%的化学纯度。
5.如权利要求1-4中任一项所述的化合物,其中所述化合物具有高于约99.7%的化学纯度。
6.如权利要求1-5中任一项所述的化合物,其中所述化合物具有高于约99.8%的化学纯度。
7.如权利要求1-6中任一项所述的化合物,其中所述化合物具有少于约45ppm的5-氯-水杨酸。
8.如权利要求1-7中任一项所述的化合物,其中所述化合物具有少于约30ppm的5-氯-水杨酸。
9.如权利要求1-8中任一项所述的化合物,其中所述化合物具有少于约50ppm的2-氯-4硝基-苯胺。
10.如权利要求1-9中任一项所述的化合物,其中所述化合物具有少于约10ppm的2-氯-4硝基-苯胺。
11.如权利要求1-6中任一项所述的化合物,其中所述化合物具有少于约45ppm的5-氯-水杨酸和少于约50ppm的2-氯-4硝基-苯胺。
12.如权利要求1-6中任一项所述的化合物,其中所述化合物具有少于约30ppm的5-氯-水杨酸和少于约10ppm的2-氯-4硝基-苯胺。
13.如权利要求1-12中任一项所述的化合物,其中所述化合物具有少于约0.05%的水。
14.如权利要求1-13中任一项所述的化合物,其中所述化合物基本上不含水和氯硝柳胺固体形式。
15.如权利要求1-14中任一项所述的化合物,其中所述化合物是无水氯硝柳胺。
16.如权利要求1-15中任一项所述的化合物,其中所述化合物是晶体。
17.如权利要求1-16中任一项所述的化合物,其中所述化合物具有减小的粒径范围。
18.如权利要求1-16中任一项所述的化合物,其中所述化合物具有约0.1μm至约30μm的粒径范围。
19.如权利要求1-18中任一项所述的化合物,其中所述化合物具有约0.1μm至约20μm的粒径范围。
20.如权利要求1-19中任一项所述的化合物,其中所述化合物具有约0.1μm至约10μm的粒径范围。
21.如权利要求1-18中任一项所述的化合物,其中所述化合物具有约1.0μm至约15.0μm的粒径分布D(0.9)。
22.如权利要求1-18和21中任一项所述的化合物,其中所述化合物具有约1.0μm至约10.0μm的粒径分布D(0.9)。
23.如权利要求1-18、21和22中任一项所述的化合物,其中所述化合物具有约6.0μm至约8.0μm的粒径分布D(0.9)。
24.如权利要求1-18和21中任一项所述的化合物,其中所述化合物具有约2.2μm至约3.2μm的粒径分布D(0.9)。
25.如权利要求1-24中任一项所述的化合物,其中所述化合物具有约0.1μm至约1.5μm的粒径分布D(0.1)。
26.如权利要求1-25中任一项所述的化合物,其中所述化合物具有约0.1μm至约1.0μm的粒径分布D(0.1)。
27.如权利要求1-25中任一项所述的化合物,其中所述化合物具有约0.3μm至约0.9μm的粒径分布D(0.1)。
28.如权利要求1-27中任一项所述的化合物,其中所述化合物具有约0.5μm至约6.0μm的粒径分布D(0.5)。
29.如权利要求1-28中任一项所述的化合物,其中所述化合物具有约1.0μm至约4.0μm的粒径分布D(0.5)。
30.如权利要求1-29中任一项所述的化合物,其中所述化合物具有约1.0μm至约2.0μm的粒径分布D(0.5)。
31.如权利要求1-29中任一项所述的化合物,其中所述化合物具有约2.5μm至约3.5μm的粒径分布D(0.5)。
32.如权利要求1或2所述的化合物,其中所述化合物具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
33.如权利要求1或2所述的化合物,其中所述化合物具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
34.如权利要求1或2所述的化合物,其中所述化合物具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
35.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
36.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
37.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
38.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
39.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
40.如权利要求1或2所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
41.如权利要求32-40中任一项所述的化合物,其中所述化合物具有约2.5μm至约3.5μm的粒径分布D(0.5)。
42.如权利要求32-40中任一项所述的化合物,其中所述化合物具有约1.0μm至约2.0μm的粒径分布D(0.5)。
43.如权利要求32-42中任一项所述的化合物,化合物具有高于约99.5%的化学纯度;或高于约99.7%的化学纯度;或高于约99.8%的化学纯度。
44.如权利要求32-43中任一项所述的化合物,其中所述化合物具有少于约45ppm的5-氯-水杨酸;或少于约30ppm的5-氯-水杨酸。
45.如权利要求32-44中任一项所述的化合物,其中所述化合物具有少于约50ppm的2-氯-4硝基-苯胺;或少于约10ppm的2-氯-4硝基-苯胺。
46.如权利要求32-45中任一项所述的化合物,化合物具有少于约45ppm的5-氯-水杨酸和少于约50ppm的2-氯-4硝基-苯胺;或少于约30ppm的5-氯-水杨酸和少于约10ppm的2-氯-4硝基-苯胺。
47.如权利要求32-46中任一项所述的化合物,其中所述化合物具有少于约0.05%的水。
48.如权利要求32-47中任一项所述的化合物,其中所述化合物基本上不含水和氯硝柳胺固体形式。
49.如权利要求32-48中任一项所述的化合物,其中所述化合物是无水氯硝柳胺。
50.如权利要求32-49中任一项所述的化合物,其中所述化合物是晶体。
51.如权利要求1-50中任一项所述的化合物,其中所述化合物具有约5m2/g至约10m2/g的比表面积。
52.一种组合物,其包含如权利要求1-51中任一项所述的氯硝柳胺化合物和一种或多种药学上可接受的赋形剂,其中所述组合物适于口服给予。
53.如权利要求52所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度的氯硝柳胺化合物的局部浓度。
54.如权利要求52或53所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约200倍的氯硝柳胺化合物的局部浓度。
55.如权利要求52-54中任一项所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约300倍的氯硝柳胺化合物的局部浓度。
56.如权利要求52-55中任一项所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约500倍的氯硝柳胺化合物的局部浓度。
57.如权利要求52-56中任一项所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约700倍的氯硝柳胺化合物的局部浓度。
58.如权利要求52-57中任一项所述的组合物,对象的胃肠道中的氯硝柳胺化合物的局部浓度高于单剂量的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
59.如权利要求52-58中任一项所述的组合物,其中对象的胃肠道中的氯硝柳胺化合物的局部浓度高于单剂量的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度至少约100倍,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
60.如权利要求52-59中任一项所述的组合物,其中对象的胃肠道中的氯硝柳胺化合物的局部浓度高于单剂量的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度至少约100倍,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
61.如权利要求52-60中任一项所述的组合物,其中第二氯硝柳胺化合物具有约25.0μm至约65.0μm的粒径分布D(0.9)。
62.如权利要求52-61中任一项所述的组合物,其中第二氯硝柳胺化合物具有约4.0μm至约10.0μm的粒径分布D(0.1)。
63.一种剂型(例如,单位剂型),其包含如权利要求52-62中任一项所述的组合物,其中所述剂型适于口服给予。
64.如权利要求63所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至升结肠的组分。
65.如权利要求63或64所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至横结肠的组分。
66.如权利要求63-65中任一项所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至远端结肠的组分。
67.如权利要求63-66中任一项所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至小肠的组分。
68.一种氯硝柳胺化合物、或其药学上可接受的盐,其具有减小的粒径。
69.如权利要求68所述的化合物,其特征在于,所述化合物具有下式:
70.如权利要求68-69中任一项所述的化合物,其中所述化合物具有约0.1μm至约30μm的粒径范围。
71.如权利要求68-70中任一项所述的化合物,其中所述化合物具有约0.1μm至约20μm的粒径范围。
72.如权利要求68-71中任一项所述的化合物,其中所述化合物具有约0.1μm至约10μm的粒径范围。
73.如权利要求68-69中任一项所述的化合物,其中所述化合物具有约1.0μm至约15.0μm的粒径分布D(0.9)。
74.如权利要求68-69和73中任一项所述的化合物,其中所述化合物具有约1.0μm至约10.0μm的粒径分布D(0.9)。
75.如权利要求68-69、73和74中任一项所述的化合物,其中所述化合物具有约6.0μm至约8.0μm的粒径分布D(0.9)。
76.如权利要求68-69和73中任一项所述的化合物,其中所述化合物具有约2.2μm至约3.2μm的粒径分布D(0.9)。
77.如权利要求68-76中任一项所述的化合物,其中所述化合物具有约0.1μm至约1.5μm的粒径分布D(0.1)。
78.如权利要求68-77中任一项所述的化合物,其中所述化合物具有约0.1μm至约1.0μm的粒径分布D(0.1)。
79.如权利要求68-77中任一项所述的化合物,其中所述化合物具有约0.3μm至约0.9μm的粒径分布D(0.1)。
80.如权利要求68-79中任一项所述的化合物,其中所述化合物具有约0.5μm至约6.0μm的粒径分布D(0.5)。
81.如权利要求68-80中任一项所述的化合物,其中所述化合物具有约1.0μm至约4.0μm的粒径分布D(0.5)。
82.如权利要求68-81中任一项所述的化合物,其中所述化合物具有约1.0μm至约2.0μm的粒径分布D(0.5)。
83.如权利要求68-81中任一项所述的化合物,其中所述化合物具有约2.5μm至约3.5μm的粒径分布D(0.5)。
84.如权利要求68或69所述的化合物,其中所述化合物具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
85.如权利要求68或69所述的化合物,其中所述化合物具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
86.如权利要求68或69所述的化合物,其中所述化合物具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
87.如权利要求68或69所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
88.如权利要求68或69所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
89.如权利要求68或69所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
90.如权利要求68或69所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
91.如权利要求68或69所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
92.如权利要求68或69所述的化合物,其中所述化合物具有高于约99.0%的化学纯度,约0.1μm至约30μm的粒径范围,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
93.如权利要求84-92中任一项所述的化合物,其中所述化合物具有约2.5μm至约3.5μm的粒径分布D(0.5);或其中所述化合物具有约1.0μm至约2.0μm的粒径分布D(0.5)。
94.如权利要求52-62中任一项所述的组合物或如权利要求63-67中任一项所述的剂型,其包含如权利要求68-94中任一项所述的化合物。
95.一种共结晶,其包含氯硝柳胺化合物、或其药学上可接受的盐和药学上可接受的共形成物。
96.如权利要求95所述的共结晶,其中氯硝柳胺化合物具有式:
97.如权利要求95-96中任一项所述的共结晶,其中所述共形成物选自下组:1-磷酸鞘氨醇(S1P)受体调节剂;甾体抗炎药;非甾体抗炎药;受体相互作用蛋白激酶1(RIPK1)抑制剂;EP4调节剂;Toll样受体(例如,TLR4、TLR9)调节剂;Janus激酶(JAK)抑制剂;羊毛硫氨酸合成酶C样2(LANCL2)调节剂;磷脂酰胆碱;整合素(例如,α4整合素)调节剂;Smad7调节剂;磷酸二酯酶4(PDE4)调节剂;肿瘤进展位点2(TPL2)抑制剂;酪氨酸激酶2(TYK2)抑制剂;和TEC激酶抑制剂。
98.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是1-磷酸鞘氨醇(S1P)受体调节剂。
99.如权利要求95-98中任一项所述的共结晶,其中所述共形成物是艾曲莫德(etrasimod)或奥扎莫德(ozanimod)。
100.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是甾体抗炎药。
101.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是倍氯米松(beclomethasone)17或布地奈德(budesonide)。
102.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是非甾体抗炎药如5-ASA。
103.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是受体相互作用蛋白激酶1(RIPK1)抑制剂如GSK2982772。
104.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是EP4调节剂如KAG-308。
105.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是Toll样受体(例如,TLR4,TLR9)调节剂。
106.如权利要求95-97和105中任一项所述的共结晶,其中所述共形成物是TLR4调节剂如JKB-122。
107.如权利要求95-97和105中任一项所述的共结晶,其中所述共形成物是TLR9调节剂如可比托莫德(cobitolimod)。
108.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是Janus激酶(JAK)抑制剂。
109.如权利要求95-97和108中任一项所述的共结晶,其中所述共形成物选自下组:TD-1473,托法替尼(tofacitinib),乌帕替尼(upadacitinib),非戈替尼(filgotinib),PF-06651600,和PF-06700841。
110.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是羊毛硫氨酸合成酶C样2(LANCL2)调节剂如BT-11。
111.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是磷脂酰胆碱如LT-02。
112.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是整合素调节剂。
113.如权利要求95-97和112中任一项所述的共结晶,其中所述共形成物是α4整合素调节剂如AJM-300(卡泰司特(carotegrast))。
114.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是Smad7反义寡核苷酸如蒙格生(mongersen)。
115.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是磷酸二酯酶4(PDE4)调节剂如阿普斯特(apremi last)。
116.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是肿瘤进展位点2(TPL2)抑制剂如GS-4875。
117.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是酪氨酸激酶2(TYK2)抑制剂。
118.如权利要求95-97和117中任一项所述的共结晶,其中所述共形成物是BMS-986165,PF-06700841,或PF-06826647。
119.如权利要求95-97中任一项所述的共结晶,其中所述共形成物是TEC激酶抑制剂如PF-06651600。
120.如权利要求95-119中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度。
121.如权利要求95-120中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.5%的化学纯度。
122.如权利要求95-121中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.7%的化学纯度。
123.如权利要求95-122中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.8%的化学纯度。
124.如权利要求95-123中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约45ppm的5-氯-水杨酸。
125.如权利要求95-124中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约30ppm的5-氯-水杨酸。
126.如权利要求95-125中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约50ppm的2-氯-4硝基-苯胺。
127.如权利要求95-126中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约10ppm的2-氯-4硝基-苯胺。
128.如权利要求95-123中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约45ppm的5-氯-水杨酸和少于约50ppm的2-氯-4硝基-苯胺。
129.如权利要求95-123中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约30ppm的5-氯-水杨酸和少于约10ppm的2-氯-4硝基-苯胺。
130.如权利要求95-129中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约0.05%的水。
131.如权利要求95-130中任一项所述的共结晶,其中所述氯硝柳胺化合物基本上不含水和氯硝柳胺固体形式。
132.如权利要求95-131中任一项所述的共结晶,其中所述氯硝柳胺化合物是无水氯硝柳胺。
133.如权利要求95-132中任一项所述的共结晶,其中所述氯硝柳胺化合物是晶体。
134.如权利要求95-133中任一项所述的共结晶,其中所述共结晶具有减小的粒径范围。
135.如权利要求95-134中任一项所述的共结晶,其中所述共结晶具有约0.1μm至约30μm的粒径范围。
136.如权利要求95-135中任一项所述的共结晶,其中所述共结晶具有约0.1μm至约20μm的粒径范围。
137.如权利要求95-136中任一项所述的共结晶,其中所述共结晶具有约0.1μm至约10μm的粒径范围。
138.如权利要求95-135中任一项所述的共结晶,其中所述共结晶具有约1.0μm至约15.0μm的粒径分布D(0.9)。
139.如权利要求95-135和138中任一项所述的共结晶,其中所述共结晶具有约1.0μm至约10.0μm的粒径分布D(0.9)。
140.如权利要求95-135和138-139中任一项所述的共结晶,其中所述共结晶具有约6.0μm至约8.0μm的粒径分布D(0.9)。
141.如权利要求95-135和138中任一项所述的共结晶,其中所述共结晶具有约2.2μm至约3.2μm的粒径分布D(0.9)。
142.如权利要求95-141中任一项所述的共结晶,其中所述共结晶具有约0.1μm至约1.5μm的粒径分布D(0.1)。
143.如权利要求95-142中任一项所述的共结晶,其中所述共结晶具有约0.1μm至约1.0μm的粒径分布D(0.1)。
144.如权利要求95-142中任一项所述的共结晶,其中所述共结晶具有约0.3μm至约0.9μm的粒径分布D(0.1)。
145.如权利要求95-144中任一项所述的共结晶,其中所述共结晶具有约0.5μm至约6.0μm的粒径分布D(0.5)。
146.如权利要求95-145中任一项所述的共结晶,其中所述共结晶具有约1.0μm至约4.0μm的粒径分布D(0.5)。
147.如权利要求95-146中任一项所述的共结晶,其中所述共结晶具有约1.0μm至约2.0μm的粒径分布D(0.5)。
148.如权利要求95-146中任一项所述的共结晶,其中所述共结晶具有约2.5μm至约3.5μm的粒径分布D(0.5)。
149.如权利要求95-133中任一项所述的共结晶,其中所述共结晶具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
150.如权利要求95-133中任一项所述的共结晶,其中所述共结晶具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
151.如权利要求95-133中任一项所述的共结晶,其中所述共结晶具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
152.如权利要求95-97中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度;并且所述共结晶具有约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
153.如权利要求95-97中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度;并且所述共结晶具有约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
154.如权利要求95-97中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度;并且所述共结晶具有约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
155.如权利要求95-97所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度;并且所述共结晶具有约0.1μm至约30μm的粒径范围,约1.0μm至约10.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.1μm至约1.0μm的粒径分布D(0.1)。
156.如权利要求95-97所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度;并且所述共结晶具有约0.1μm至约30μm的粒径范围,约6.0μm至约8.0μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
157.如权利要求95-97所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.0%的化学纯度;并且所述共结晶具有约0.1μm至约30μm的粒径范围,约2.2μm至约3.2μm的粒径分布D(0.9),约1.0μm至约4.0μm的粒径分布D(0.5),和约0.3μm至约0.9μm的粒径分布D(0.1)。
158.如权利要求149-157中任一项所述的共结晶,其中所述共结晶具有约2.5μm至约3.5μm的粒径分布D(0.5)。
159.如权利要求149-157中任一项所述的共结晶,其中所述共结晶具有约1.0μm至约2.0μm的粒径分布D(0.5)。
160.如权利要求149-159中任一项所述的共结晶,其中所述氯硝柳胺化合物具有高于约99.5%的化学纯度;或高于约99.7%的化学纯度;或高于约99.8%的化学纯度。
161.如权利要求149-160中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约45ppm的5-氯-水杨酸;或少于约30ppm的5-氯-水杨酸。
162.如权利要求149-161中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约50ppm的2-氯-4硝基-苯胺;或少于约10ppm的2-氯-4硝基-苯胺。
163.如权利要求149-162中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约45ppm的5-氯-水杨酸和少于约50ppm的2-氯-4硝基-苯胺;或少于约30ppm的5-氯-水杨酸和少于约10ppm的2-氯-4硝基-苯胺。
164.如权利要求149-163中任一项所述的共结晶,其中所述氯硝柳胺化合物具有少于约0.05%的水。
165.如权利要求149-164中任一项所述的共结晶,其中所述氯硝柳胺化合物基本上不含水和氯硝柳胺固体形式。
166.如权利要求149-165中任一项所述的共结晶,其中所述氯硝柳胺化合物是无水氯硝柳胺;和/或其中所述氯硝柳胺化合物是晶体。
167.如权利要求149-166中任一项所述的共结晶,其中所述氯硝柳胺化合物具有约5m2/g至约10m2/g的比表面积。
168.一种组合物,其包含如权利要求95-167中任一项所述的共结晶和一种或多种药学上可接受的赋形剂,其中所述组合物适于口服给予。
169.如权利要求168所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度的氯硝柳胺化合物的局部浓度。
170.如权利要求168或169所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约200倍的氯硝柳胺化合物的局部浓度。
171.如权利要求168-170中任一项所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约300倍的氯硝柳胺化合物的局部浓度。
172.如权利要求168-171中任一项所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约500倍的氯硝柳胺化合物的局部浓度。
173.如权利要求168-172中任一项所述的组合物,其中向对象给予单剂量的组合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约700倍的氯硝柳胺化合物的局部浓度。
174.如权利要求168-173中任一项所述的组合物,对象的胃肠道中的氯硝柳胺化合物的局部浓度高于单剂量的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
175.如权利要求168-174中任一项所述的组合物,其中对象的胃肠道中的氯硝柳胺化合物的局部浓度高于单剂量的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度至少约100倍,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
176.如权利要求168-175中任一项所述的组合物,其中对象的胃肠道中的氯硝柳胺化合物的局部浓度高于单剂量的包含第二氯硝柳胺化合物的第二组合物的口服给予所产生的局部浓度至少约100倍,其中第二氯硝柳胺化合物具有比氯硝柳胺化合物更高的粒径。
177.如权利要求168-176中任一项所述的组合物,其中第二氯硝柳胺化合物具有约25.0μm至约65.0μm的粒径分布D(0.9)。
178.如权利要求168-177中任一项所述的组合物,其中第二氯硝柳胺化合物具有约4.0μm至约10.0μm的粒径分布D(0.1)。
179.一种剂型(例如,单位剂型),其包含如权利要求168-178中任一项所述的组合物,其中所述剂型适于口服给予。
180.如权利要求179所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至升结肠的组分。
181.如权利要求179或180所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至横结肠的组分。
182.如权利要求179-181中任一项所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至远端结肠的组分。
183.如权利要求179-182中任一项所述的剂型,其进一步包含一种或多种在化学和/或结构上使剂型易于将化合物递送至小肠的组分。
184.一种用于治疗患有与对象胃肠道(GI)中一种或多种T细胞的不受调节的(如异常的或升高的)募集和/或滞留相关的病症的对象的方法,所述方法包括使一种或多种T细胞与有效量的如权利要求1-51和68-94中任一项所述的氯硝柳胺化合物、或其药学上可接受的盐;如权利要求52-62和168-178中任一项所述的组合物;如权利要求63-67和179-183中任一项所述的剂型;或如权利要求95-167中任一项所述的共结晶接触。
185.一种用于治疗患有与对象胃肠道(GI)中一种或多种T细胞的不受调节的(如异常的或升高的)活化相关的病症的对象的方法,所述方法包括使一种或多种T细胞与有效量的如权利要求1-51和68-94中任一项所述的氯硝柳胺化合物、或其药学上可接受的盐;如权利要求52-62和168-178中任一项所述的组合物;如权利要求63-67和179-183中任一项所述的剂型;或如权利要求95-167中任一项所述的共结晶接触。
186.一种用于治疗有需要的对象的结肠炎的方法,所述方法包括给予有效量的:如权利要求1-51和68-94中任一项所述的氯硝柳胺化合物、或其药学上可接受的盐;如权利要求52-62和168-178中任一项所述的组合物;如权利要求63-67和179-183中任一项所述的剂型;或如权利要求95-167中任一项所述的共结晶。
187.如权利要求186所述的方法,其中所述方法包含给予如权利要求1-51和68-94中任一项所述的氯硝柳胺化合物、或其药学上可接受的盐,作为适合局部递送至消化道或胃肠道的药物组合物。
188.如权利要求187所述的方法,其中所述组合物进一步包含一种或多种组分,其在化学上和/或结构上使组合物易于将氯硝柳胺化合物、或其药学上可接受的盐递送至下胃肠道。
189.如权利要求187所述的方法,其中所述组合物进一步包含一种或多种组分,其在化学上和/或结构上使组合物易于将氯硝柳胺化合物、或其药学上可接受的盐递送至升结肠和/或横结肠和/或远端结肠。
190.如权利要求188所述的方法,其中所述氯硝柳胺化合物、或其药学上可接受的盐通过片剂、丸剂或漱口水给予。
191.如权利要求186所述的方法,其中给予后,氯硝柳胺或其药学上可接受的盐在胃肠道中的局部浓度高于药剂在血浆室中的浓度。
192.如权利要求191所述的方法,其中给予后,药剂在胃肠道的局部浓度比氯硝柳胺或其药学上可接受的盐在血浆室中的浓度高约5倍。
193.如权利要求191所述的方法,其中血浆室中的氯硝柳胺或其药学上可接受的盐经历首过代谢。
194.如权利要求186所述的方法,其中至少一些药剂存在于下胃肠道中。
195.如权利要求192所述的方法,其中药剂的至少一些存在于结肠。
196.如权利要求193所述的方法,其中药剂的至少一些存在于升结肠。
197.如权利要求193所述的方法,其中药剂的至少一些存在于横结肠。
198.如权利要求193所述的方法,其中药剂的至少一些存在于远端结肠。
199.如权利要求186所述的方法,其中所述对象是人。
200.如权利要求186所述的方法,其中所述结肠炎是自身免疫性结肠炎。
201.如权利要求200所述的方法,其中所述自身免疫性结肠炎是炎症性肠病。
202.如权利要求201所述的方法,其中所述炎症性肠病是溃疡性结肠炎。
203.如权利要求201所述的方法,其中所述炎症性肠病是克罗恩病。
204.如权利要求200所述的方法,其中所述自身免疫性结肠炎是医源性自身免疫性结肠炎。
205.如权利要求204所述的方法,其中所述医源性自身免疫性结肠炎是一种或多种化疗剂诱导的结肠炎。
206.如权利要求205所述的方法,其中一种或多种化疗剂中的至少一种是化疗免疫调节剂。
207.如权利要求206所述的方法,其中所述化疗免疫调节剂是免疫检查点抑制剂。
208.如权利要求207所述的方法,其中所述免疫检查点抑制剂靶向选自下组的免疫检查点受体:CTLA-4、PD-1、PD-L1、PD-1–PD-L1、PD-1–PD-L2、白细胞介素-2(IL-2)、吲哚胺2,3-双加氧酶(IDO)、IL-10、转化生长因子-β(TGFβ)、T细胞免疫球蛋白和粘蛋白3(TIM3或HAVCR2)、半乳糖凝集素9–TIM3、磷脂酰丝氨酸–TIM3、淋巴细胞激活基因3蛋白(LAG3)、MHCII类–LAG3、4-1BB–4-1BB配体、OX40–OX40配体、GITR、GITR配体-GITR、CD27、CD70-CD27、TNFRSF25、TNFRSF25–TL1A、CD40L、CD40–CD40配体、HVEM–LIGHT–LTA、HVEM、HVEM-BTLA、HVEM-CD160、HVEM-LIGHT、HVEM–BTLA–CD160、CD80、CD80-PDL-1、PDL2-CD80、CD244、CD48-CD244、CD244、ICOS、ICOS–ICOS配体、B7-H3、B7-H4、VISTA、TMIGD2、HHLA2–TMIGD2、丁酰肌醇、包括BTNL2、Siglec家族、TIGIT和PVR家族成员、KIR、ILT和LIR、NKG2D和NKG2A、MICA和MICB、CD244、CD28、CD86-CD28、CD86-CTLA、CD80-CD28、CD39、CD73腺苷–CD39–CD73、CXCR4–CXCL12、磷脂酰丝氨酸、TIM3、磷脂酰丝氨酸–TIM3、SIRPA–CD47、VEGF、神经纤毛蛋白、CD160、CD30、和CD155。
209.如权利要求208所述的方法,其中所述免疫检查点抑制剂选自下组:乌瑞芦单抗(Urelumab)、PF-05082566、MEDI6469、TRX518、伐立鲁单抗(Varlilumab)、CP-870893、帕博利珠单抗(Pembrolizumab)(PD1)、纳武单抗(Nivolumab)(PD1)、阿替利珠单抗(Atezolizumab)(原称MPDL3280A)(PDL1)、MEDI4736(PD-L1)、阿维鲁单抗(Avelumab)(PD-L1)、PDR001(PD1)、BMS-986016、MGA271、利瑞鲁单抗(Lirilumab)、IPH2201、依米妥珠单抗(Emactuzumab)、INCB024360、Galunisertib、乌洛鲁单抗(Ulocuplumab)、BKT140、巴维妥昔单抗(Bavituximab)、CC-90002、贝伐珠单抗(Bevacizumab)、和MNRP1685A、和MGA271。
210.如权利要求208所述的方法,其中所述免疫检查点抑制剂靶向CTLA-4。
211.如权利要求210所述的方法,其中所述免疫检查点抑制剂是抗体。
212.如权利要求211所述的方法,其中所述抗体是伊皮木单抗(ipilimumab)或曲美木单抗(tremelimumab)。
213.如权利要求208所述的方法,其中所述免疫检查点抑制剂靶向PD1或PD-L1。
214.如权利要求213所述的方法,其中所述免疫检查点抑制剂选自纳武单抗(Nivolumab),兰布罗珠单抗(lambroizumab),和BMS-936559。
215.如权利要求186-214中任一项所述的方法,其中权利要求1-51和68-94中任一项所述的氯硝柳胺化合物被口服给予。
216.如权利要求69所述的化合物,化合物具有高于约99.5%的化学纯度;或高于约99.7%的化学纯度;或高于约99.8%的化学纯度。
217.如权利要求69所述的化合物,其中所述化合物具有约5m2/g至约10m2/g的比表面积。
218.一种药学组合物,其包含如权利要求69所述的化合物和一种或多种药学上可接受的赋形剂。
219.如权利要求218所述的组合物,其中所述组合物适于口服给予。
220.如权利要求218所述的组合物,其中所述组合物适于通过吸入给予。
221.如权利要求69所述的化合物,其中向对象给予单剂量的化合物在对象的胃肠道中产生高于对象的血浆室中化合物的浓度至少约300倍的化合物的局部浓度。
222.如权利要求69所述的化合物,其中向对象给予单剂量的化合物在对象的结肠组织中产生高于对象的血浆室中化合物的浓度至少约300倍的化合物的局部浓度。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962923290P | 2019-10-18 | 2019-10-18 | |
US62/923,290 | 2019-10-18 | ||
PCT/US2020/056027 WO2021076922A1 (en) | 2019-10-18 | 2020-10-16 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117597327A true CN117597327A (zh) | 2024-02-23 |
Family
ID=75492817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080088987.0A Pending CN117597327A (zh) | 2019-10-18 | 2020-10-16 | 药物制剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210114973A1 (zh) |
EP (1) | EP4045480A4 (zh) |
JP (1) | JP2022553934A (zh) |
KR (1) | KR20240039083A (zh) |
CN (1) | CN117597327A (zh) |
AR (1) | AR122323A1 (zh) |
CA (1) | CA3157861A1 (zh) |
TW (1) | TW202128610A (zh) |
WO (1) | WO2021076922A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2970434T3 (es) | 2014-09-12 | 2024-05-28 | Union Therapeutics As | Uso antibacteriano de salicilanilidas halogenadas |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
MX2018002586A (es) | 2015-09-01 | 2020-11-24 | First Wave Bio Inc | Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala. |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
WO2021174024A1 (en) * | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
CN117466786A (zh) * | 2023-12-25 | 2024-01-30 | 湖南一格制药有限公司 | 盐酸戊乙奎醚杂质及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2557615C2 (de) * | 1975-12-20 | 1985-08-14 | Bayer Ag, 5090 Leverkusen | Neue Niclosamid-Suspensionsformulierungen |
NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
WO2004006906A2 (en) * | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
CN1546919A (zh) * | 2003-07-13 | 2004-11-17 | 叶声羽 | 桑拿浴房 |
CN1626506A (zh) * | 2004-08-10 | 2005-06-15 | 李志良 | 高纯度、高收率氯硝柳胺的制备 |
EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
CN103751854B (zh) * | 2014-01-20 | 2015-08-26 | 瞿介明 | 抗菌医用导管 |
EP3168211A1 (en) * | 2015-11-10 | 2017-05-17 | Westfälische Wilhelms-Universität Münster | Pharmaceutical co-crystals of niclosamide |
-
2020
- 2020-04-07 US US16/842,695 patent/US20210114973A1/en active Pending
- 2020-10-16 JP JP2022522825A patent/JP2022553934A/ja active Pending
- 2020-10-16 WO PCT/US2020/056027 patent/WO2021076922A1/en active Application Filing
- 2020-10-16 EP EP20877454.7A patent/EP4045480A4/en active Pending
- 2020-10-16 CN CN202080088987.0A patent/CN117597327A/zh active Pending
- 2020-10-16 CA CA3157861A patent/CA3157861A1/en active Pending
- 2020-10-16 TW TW109136022A patent/TW202128610A/zh unknown
- 2020-10-16 KR KR1020227016634A patent/KR20240039083A/ko unknown
- 2020-10-19 AR ARP200102884A patent/AR122323A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021076922A1 (en) | 2021-04-22 |
TW202128610A (zh) | 2021-08-01 |
JP2022553934A (ja) | 2022-12-27 |
KR20240039083A (ko) | 2024-03-26 |
AR122323A1 (es) | 2022-08-31 |
CA3157861A1 (en) | 2021-04-22 |
EP4045480A4 (en) | 2023-11-22 |
US20210114973A1 (en) | 2021-04-22 |
EP4045480A1 (en) | 2022-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN117597327A (zh) | 药物制剂 | |
JP7189983B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
US10844080B2 (en) | Compositions and methods for inhibiting arginase activity | |
ES2881395T3 (es) | Composiciones y métodos para inhibir la actividad de la arginasa | |
ES2820827T3 (es) | Formas sólidas de un compuesto modulador de quinasas | |
US10570152B2 (en) | Antibacterial therapeutics and prophylactics | |
JP2018172397A (ja) | シスタチオニン−γ−リアーゼ(CSE)阻害剤 | |
US10100023B2 (en) | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | |
JP2009040767A5 (zh) | ||
US20230102999A1 (en) | Deuterated niclosamide | |
WO2020081723A1 (en) | Carbon monoxide prodrugs for the treatment of medical disorders | |
EP3110800A1 (en) | Novel compounds having anti-allodynic and antihyperalgesic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |